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3Abstract
1H magnetic resonance spectroscopy (MRS) is a technique that 
allow s the in vivo and non-invasive q uantificatio n  of 
metabolites from the human brain. MRS was used in the study 
of patients with multiple sclerosis (MS) to determ ine the 
metabolic profile of acute MS lesions and areas of normal 
apearing w hite m atter (NAWM). Abnorm ally elevated
m etabolite peaks attributable to mobile lipids and cytosolic 
proteins indicative of myelin breakdown were found in all 
acute lesions studied. A study of chronic MS lesions and 
NAWM was perform ed in patients in the four clin ical 
subgroups of MS - benign, relapsing/rem itting, primary and 
secondary progressive disease to evaluate mechanisms of 
disability in MS. This study showed a correlation between 
reduction of NAA - a neuronal marker and disability in the 
different clinical subgroups of MS.
To test the hypothesis that a reduction in NAA may occur as a 
consequence of axonal loss, a group of patients were studied 
with hereditary autosomal dominant cerebellar ataxia (ADCA) 
a condition in which axonal loss is known to be a striking 
pathological feature. This study supported the relationship  
between axonal loss and reduction of NAA by showing a 
sign ifican t reduction in the concentration of NAA from  
cerebellar white matter. To provide a more rigorous test of 
the hypothesis that axonal loss is an important determinant in 
the development of disability, an MRS study was performed in 
two groups of MS patients - a group with severe cerebellar 
deficit and a group with no clinical evidence of cerebellar
involvement in these two conditions. Again, this study 
showed a strong correla tion  between the presence of 
persistent functional deficit and axonal loss as evidenced by 
a reduction of N acetyl aspartate only in the group of MS 
patients with severe cerebellar deficit.
MRS was also perform ed in a group of patients with  
n e u ro p s y c h ia tr ic  m a n ife s ta tio n s  of s y s te m ic  lupus  
erythematosus (SLE) to determine whether MRS is useful in 
d ifferen tia ting  this condition from MS. The pattern of 
abnormality did not allow differentiation of SLE lesions from 
the chronic plaques occurring in MS. Finally, MRS was carried 
out in a group of adult patients with phenylketonuria (PKU) 
who had abnorm alities v is ib le  with m agnetic resonance  
imaging (MRI) to show that MRS is able to d ifferentiate  
between the pathological processes that produce MRI 
abnormalities in MS and those occurring in PKU. Patients 
with PKU showed a normal metabolite profile from MRI visible 
lesions and NAWM indicating axonal preservation from lesions 
which on conventional MRI resemble lesions seen in MS.
These studies have shown that 1H MRS is a useful non- 
invasive technique which can help, not only in understanding 
the pathophysiology of MS, but may also help in differential 
diagnosis.
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CHAPTER 1
Introduction
1.1 HISTORY
Magnetic Resonance Imaging (MRI) is a technique that has shown itself 
to be particularly valuable in the study of the multiple sclerosis (MS) 
lesion. Although the principles of nuclear magnetic resonance (NMR) 
were established as early as 1946, it was only with the first 
demonstration of the MS lesion by Young et al (1981), that MRI began 
to realise its potential as an important tool in the diagnosis of MS 
(Ormerod et al.,1987; Paty et al.,1988; Fazekas et al.,1988; Offenbacher 
et al.,1993 ) and as a non-invasive means in studying the evolution of 
the MS plaque ( Lukes et al.,1983; Miller et al.,1988a; Kermode et al., 
1990; Kidd et al., 1993; Katz et al., 1993). Prior to this time NMR had 
been used almost exclusively as a spectroscopic technique for chemical 
analysis. Initially the role of magnetic resonance spectroscopy (MRS) 
was restricted to in-vitro analysis. Later, the technique was applied to 
in-vivo experiments in animals (Ackerman et al., 1980) and studies of 
plant systems (Schaeffer et al., 1975). Since then MRS has become an 
established means of non-invasively investigating cellular metabolism 
within the healthy human brain (Cady et al., 1980; Frahm et al.,1989a; 
Van Rijen et al 1989; Beckman et al., 1991) and in several disease 
states (Arnold et al., 1990a, b; Matthews et al., 1991b; Gideon et al., 
1992; Shino et al., 1993; Davie et al., 1995)(Vion-Dury et al., 1994).
1.2 NUCLEI AND METABOLITES VISIBLE WITH MRS
In contrast to conventional MRI which exploits the NMR properties of 
the Hydrogen nucleus, MRS is able to use other nuclei which possess a 
property known as spin. These include phosphorus, Lithium, Carbon,
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Fluorine, Sodium and Nitrogen. The potential value of these various 
nuclei with MRS is dependent on their natural abundance and NMR 
sensitivity. A wide range of metabolites can be identified using these 
various nuclei (table 1.1). Hydrogen pH) and Phosphorus (31P) have been 
the two main nuclei used for clinical studies in humans and MRS is now 
routinely used to provide information from localised areas within the 
human brain concerning metabolite concentrations, the mobility (or 
relaxation properties) of various substances as well as the metabolic 
exchange rates occurring between metabolites.
1.3 31 p MRS studies
Studies using 3ip MRS have been particularly useful in the investigation
of oxidative metabolism in cells (Moon and Richards, 1973), animals
(Ackerman et al., 1980) and humans ( Chance et al., 1980; Arnold et al., 
1984; Hayes et al., 1985) 3 ip  MRS is able to detect signals from the 
molecules containing high energy-phosphate bonds which include the 
three phosphates of adenosine triphosphate (ATP), phospocreatine 
(PCr), inorganic phosphate and phosphomonoesters. Changes in the 
signal from these metabolites allows evaluation of the energy balance 
occurring in a wide range of physiological and non-physiological 
conditions. In addition, 3 ip  MRS can provide information about 
intracellular pH and, indirectly from changes in the three ATP
resonances, allow measurement of free and bound magnesium 
concentration in the brain thus giving some insight into glycolytic
pathways.
1.4 RECENT ADVANCES IN THE STUDY OF THE 1H NUCLEUS
MRS studies using the hydrogen nucleus were slower to develop, 
mainly for reasons of greater technical difficulty. The hydrogen
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nucleus has a concentration in the human brain of approximately 91 
Molar in grey matter and 80 Molar in white matter (Norton et al., 1966) 
which is predominantly in the form of water. Although such a 
concentration makes water ideal for imaging of the brain by NMR, other 
mobile metabolites containing hydrogen are present in the human brain 
in millimolar concentrations. The majority of these metabolites 
resonate at frequencies close to that of water and therefore the signals 
they produce are swamped by the water signal in conventional imaging. 
An important advancement in proton MRS has been the development of 
techniques which allow adequate suppression of the water signal and as 
a result, identification and quantitation of other compounds which 
contain hydrogen. Other important advances have gone hand in hand 
with this, including the introduction of more effective sequences for 
localisation, improved resolution allowing the study of smaller 
volumes in vivo and, more recently, methods which allow absolute 
metabolite quantitation. These developments will be discussed in the 
methods section. With such technical progress, it is now possible using 
proton MRS to identify and quantify, non-invasively, a large number of 
metabolites in the human brain from volumes as small as 1ml ( Frahm 
et al., 1990). Table 1.1 shows some of the metabolites that have been 
assigned in the proton spectrum. The ability to identify a particular 
metabolite is dependent on a number of factors. These include its 
concentration, the proximity to the remaining suppressed water peak, 
the presence of other metabolites that produce signal at similar 
frequencies within the spectrum and, its mobility within different 
tissues which influences the amount of signal produced in any given 
MRS experiment. For these reasons, it is a rather small number of 
metabolites which are are particularly well visualised by proton MRS.
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1.5 METABOLITES VISIBLE WITH 1H MRS
Until recently the four main peaks visible with proton MRS were N- 
acetyl containing compounds (NA) - the largest contribution coming 
from N-acetyl aspartate (NAA), choline containing compounds (Cho), 
creatine / phosphocreatine and lactate (lac) (Figure 1.1). Again with 
technical advances, which allow the collection of short echo-time 
spectra, it is possible to visualise routinely, signal from other 
substances including glutamate and glutamine, GABA, myo-inositol, 
and broad resonances from lipids and macromolecules (Figure 1.2). In 
order to use proton MRS to evaluate the metabolic changes occurring in 
the healthy and diseased brain, it is important to have a clear 
understanding about what is known regarding the chemical function and 
properties of some of these substances and whether any of them may 
be used as markers for particular cell types. The chemical structure 
(Figure 1.3a,b) and chemical shift frequencies for the 1H spectrum are 
given in table form (Table 1.2).
1.5.1 N-acetyl containing compounds
NAA is an amino-acid which was first described by Tallan et al (1956) 
(Figure 1.3a). It is the second most abundant amino-acid in the human 
brain, second only to glutamate. Despite this, the precise role of NAA in 
the central nervous system is unknown. Studies by Patel and Clark 
(1979) and later reproduced by Brenner et al (1993b) showed that NAA 
was synthesised within mitochondria from aspartate and acetyl- 
coenzyme A and is then exported to the cytosol. NAA also arises as a 
breakdown product of N-acetyl-aspartyl-glutamate (NAAG) (Blakely et 
al., 1988). NAAG is present in mammalian brain at about one tenth of 
the concentration of NAA and contributes to the NA resonance on MRS 
seen at 2.02 parts per million (ppm) (Birken and Oldendorf, 1989). More
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recently Urenjak et al (1992, 1993) have shown in cultured neural cells 
from rats that NAA is specifically expressed in neurones, 
oligodendrocyte -type2 astrocyte (02A ) progenitors and immature 
oligodendrocytes. It is undetectable in cortical astrocytes, meningeal 
cells and mature oligodendrocytes. The presence of NAA within 02A  
progenitor cells is of interest. These cells act as precursors in the 
development of oligodendrocytes and type 2 astrocytes. Although 02A  
progenitor cells have recently been demonstrated within adult brain 
(Scolding et al., 1994). they are present in very small numbers 
(approximately 1% of oligodendroglial lineage cells) and therefore, in 
adults at least, are unlikely to contribute significantly to the total 
concentration of NAA. Similarly, immature oligodendrocytes are 
infrequent within the mature adult brain. These observations then, 
indicate that in the adult brain at least the vast majority of NAA is 
contained within neurones. Thus analysis of NAA concentration within 
different regions of the brain may provide specific information 
concerning neuronal dysfunction and loss. The neuronal localisation of 
NAA has also been shown with immunocytochemical techniques- 
Simmons et al.(1991) have shown that NAA is present not only within 
the cell body but distributed throughout the axon and proximal
dendrites. The predominant localisation of NAA to neurones is also
supported by clinical MRS studies of disease processes in which
neuronal loss is a prominent pathological feature. Examples of these 
include stroke (Gideon et al., 1992), HIV (Chong et al., 1993) and 
degenerative disorders (Van der knaap et al., 1992) in which a
reduction of NAA has been demonstrated. Additionally, MRS studies 
from non-neuronal tumours of human brain such as meningiomas and 
astrocytomas (Demaerel et al., 1991b; Frahm et al., 1992) show marked 
reduction or complete loss of NAA.
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Several theories have been advanced to explain the function of NAA. A 
number of lines of evidence have suggested that NAA acts as a donor of 
acetyl groups for lipid synthesis, particularly in myelination (D’Adamo 
et al., 1966; Burri et al., 1991) since the acetyl group of NAA is 
incorporated into brain lipids far more effectively than acetate alone. 
It has been proposed by Patel and Clark (1980) that NAA acts as a 
carrier for carbon moieties from the mitochondria to lipogenic enzymes 
in the cytosol . If this theory is correct, it may perhaps explain why 
02A  progenitor cells express NAA, since these precursor cells are 
important in the process of myelination occurring during development. 
NAA is found in very small concentrations outside the central nervous 
system being present in other organs in quantities less than 1% of that 
seen in brain. Furthermore, NAA shows regional variation in 
concentration within the brain with a number of biochemical studies 
showing that its concentration increases rostrally in the central 
nervous system (CNS) (Tallan, 1957; Curatola et al., 1965). MRS studies 
have shown an approximately 25% higher concentration of NAA in grey 
matter than white matter with Michaelis et al (1993) finding a 
concentration of 8.8 and 11.7mmol/kg for cerebral white and grey 
matter respectively in healthy young adults. NAAG on the other hand 
increases caudally in concentration and is undetectable in grey matter 
with MRS (Michaelis et al., 1993).
There is some disparity between in vitro measurements of NAA and 
those calculated from in vivo MRS studies. Post mortem biochemical 
studies suggest an NAA concentration of approximately 6mM (Tallan, 
1956; Petroff et al 1988) in mammalian brain. Lower in vitro values 
may be the result of autolysis of NAA after death and higher MRS values 
may arise because of overlap of the aspartyl resonances at 2.02 ppm 
with other compounds such as macromolecules (Rothman et al 1994)-
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1.5.2 Choline containing compounds (Cho)
The resonance observed at 3.2 ppm in the spectrum In MRS is not one 
compound but the combination of signal from a number of metabolites. 
These include free choline, phosphocholine, glycerophosphocholine, 
acetylcholine, phosphatidylcholine and sphingomyelin (Miller BL, 1991). 
Other metabolites including carnitine containing compounds (Miller BL. 
1991) and betaine (Brenner et al., 1993a) have also been shown to be 
present in this resonance. The contribution to this peak from free 
choline (which is present in human brain at a concentration of less than 
0.08mM) is small and it has been suggested that the Cho resonance is 
more likely to reflect total brain choline stores (Miller BL, 1991). In 
contrast to NAA, the concentration of Cho as detected by MRS is greater
in white matter than grey matter with approximate concentrations of
1.8mM and 1.4mM respectively (Michaelis et al., 1993). There is quite 
marked regional variation of concentration within the brain of Cho with 
particularly high levels seen in the pons (Michaelis et al., 1993). An 
elevation of Cho has been observed in a number of conditions producing 
inflammation and it seems likely from experimental studies carried out 
on animals with acute experimental allergic encephalomyelitis (EAE) 
that this is the result of increased membrane turnover during the 
inflammatory response (Brenner et al., 1993a).
1.5.3 Creatine and Phosphocreatine
W hereas 3 ip  MRS produces a signal specifically from creatine
phosphate, the creatine signals at 3.02 and 3.9 ppm in the proton
spectrum is a combination of creatine (Cr) and phosphocreatine (PCr) . 
These metabolites are present in high concentration in the brain acting 
as as a reserve for high energy phosphates in the processes of oxidative 
metabolism. Creatine kinase converts creatine to phosphocreatine by
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utilising ATP. These chemicals are in equilibrium with each other by 
the following equation,
phosphocreatine + ADP = creatine + ATP 
Since they are in equilibrium, the total concentration of the two should 
accordingly remain constant in the brain. For this reason the Cr peak is 
often used as an internal standard of reference with the relative 
concentration of the other metabolites being expressed as a ratio to 
creatine. Using absolute quantitation,the estimated concentration of Cr 
from recently published studies has been estimated at 6.7mM and 8.4mM 
in cerebral grey and white matter respectively (Kreiss et al., 1994). 
These metabolites also show regional variation in the brain, with in one 
study, concentrations being as high as 9.1 mM in the cerebellum and as 
low as 6.0 mM in the pons (Michaelis et al., 1993).
1.5.4 Lactate (lac)
Lactate, when present, produces a double resonance or doublet at 1.33 
ppm in the proton spectrum. Under normal physiological circumstances 
a small signal from lac, can occasionally be detected in the human brain 
during rest. For example, lac has been observed in the visual cortex 
during the resting state at a concentration of 0.5-1 .OmM (Merboldt et 
al., 1992). Furthermore, an increase in lactate concentration has been 
detected from the visual cortex (Prichard et al., 1991) and basal 
ganglia (Kuwabara et al., 1994) after functional activation studies in 
healthy controls. Such observations are in keeping with a study using 
positron emission tomography (PET) which showed that normal neuronal 
activity may produce a temporary, localised, anaerobic environment ( 
Fox et al., 1988).
An increased concentration of cerebral lactate has been reported in 
several disease states which produce an increase in glycolytic activity. 
These include stroke (Bruhn et al., 1989), glial tumours (Demaerel et
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al., 1991b), mitochondrial disease (Matthews et al., 1991b, 1993) and 
acute MS lesions (Miller et al., 1991). It has been proposed that 
persistent lactate production in stroke is the result of macrophage
activation (Petroff et al., 1992).
1.5.5 Glutamate, glutamine and gamma-amino-butyric acid (GABA) 
Glutamate, glutamine and gamma-amino-butyric acid (GABA) are all 
detectable by 1H MRS in the human brain. Unlike the well defined 
resonances produced by the metabolites discussed above, glutamate 
produces a more complex signal which is present in the in the NMR
spectrum between 2.1-2.5 ppm and 3.5-3.9ppm. Glutamate acts as an
excitatory neurotransmitter in the brain and, as a component of the 
Kreb’s cycle, plays an important role in oxidative metabolism. The 
concentration of glutamate estimated by 1H MRS is 8.1 mmol/kg in 
cerebral white matter and 12.5mmol/kg in cerebral grey matter 
(Michaelis et al., 1993). These values are 20-35% less than the values 
for glutamate which have been assayed biochemically (Kauppinen RA 
and Williams SR, 1991) and it has been suggested that a proportion of 
glutamate is located in a non-cytoplasmic intracellular compartment 
which is not visible with NMR (Kauppinen et al., 1993). It has been 
postulated that many of the degenerative neurological disorders are, at 
least in part, caused by an excitotoxic effect of increased glutamate 
release and recently there have been reports of an observed increase in 
glutamate and glutamine in patients with Huntington’s disease (HD) 
studied by 1H MRS (Taylor-Robinson et al., 1994; Davie et al., 1994a). 
Glutamine is detectable in far smaller concentrations in the brain by 
MRS, being present at approximately 20% of the concentration of 
glutamate in grey matter (Michaelis et al., 1993). Glutamine plays an 
important role in the metabolism of ammonia and it is therefore not
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suprising that the concentration of glutamine is markedly elevated in 
patients with chronic hepatic encephalopathy (CHE) secondary to 
increased levels of ammonia (Kreiss et al., 1992). Elevated levels of 
glutamine have also been observed in MRS studies at an echo time of 
135ms in children with ornithine transcarbamylase deficiency (Gadian 
et al., 1991).
The resonances of GABA, an inhibitory neurotransmitter, overlap with 
those of glutamate and glutamine in the NMR spectrum. It is possible 
however,with specialised editing techniques, to identify specifically 
the signal from GABA under physiological conditions (Rothman et al.,
1993) and to observe an increase in concentration after anticonvulsant 
administration (Preece et al., 1991).
1.5.6 Myo-lnositol
Myo-lnositol (In) is an osmolyte that produces a resonance in the proton 
spectrum at 3.54 ppm. It has an approximate concentration of 
6 .0 mmol/kg and 6 .6 mmol/kg from cerebral white and grey matter 
respectively (Kreiss, 1994). There is likely to be a minor contribution 
to this signal from glycine which resonates at 3.55ppm and has an 
approximate brain concentration of less than 0.7mmol/kg (Perry et al 
1971). It has been suggested that In may act as a marker for 
astrocytes. This seems unlikely since experimental studies in cultured 
cells from rats has shown expression of In from both neurones as well 
as cortical astrocytes (Urenjak et al., 1993). In has been shown to be 
elevated after prolonged cocaine and polysubstance abuse (Chang et al.,
1994) and in patients with Alzheimer’s disease (Miller BL et al., 1993). 
Kreiss et al (1992) have reported decreased levels of In, in patients 
with CHE. The significance of alterations of In in these various 
disease states remains unclear.
30
1.5.7 Lipids and macromolecules
It has become apparent with the use of short echo-time MRS, that broad 
resonances occur in the human spectrum of healthy controls between 
0.9 and 1.3 ppm (Davie et al., 1992) and that these signals are not the 
result of contamination from subcutaneous scalp fat. Studies by Behar 
et al (1994) have shown similar resonances arising from 
macromolecules in the cytosol in rat and human brain. Kauppinen et al 
(1992) have shown that thymosin I34, a macromolecule, produces a 
resonance at 1.4ppm in a cerebral cortex preparation from the guinea 
pig. Further experimental studies by Callies et al (1993) have shown 
the appearance of resonances at 0.9 and 1.3 ppm after the induced 
formation of lipid droplets in myeloma cells. These studies, then, 
provide evidence that the resonances between 0 and 2 ppm in the NMR 
spectrum represent signal from lipids and cytosolic proteins.
1.6 MAGNETIC RESONANCE AND MULTIPLE SCLEROSIS
1.6.1 The role of MRI in understanding MS
MRI studies have demonstrated important differences between the four 
main subpopulations of MS patients (Thompson et al., 1990a; 1991; 
1992; Kidd et al., 1994) in relation to lesion size, the frequency at 
which new lesions appear and enhance after Gadolinium (Gd-DTPA) 
administration and lesion volume. In patients with primary progressive 
MS (patients in whom the disease course has been progressive from 
onset) , MRI tends to show fewer and smaller cerebral lesions than 
patients with secondary progressive MS in whom the illness initially 
has a relapsing remitting pattern and then becomes progressive 
(Thompson et al., 1991). Additionally, in the patients with primary 
progressive disease, new lesions tend to develop less often and rarely 
exhibit Gd-DTPA enhancement. In patients with the relapsing/remitting
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form of MS, conventional MRI studies tend to show a high incidence of 
lesion development Thompson et al., 1992). However, only a weak 
relationship has emerged between MRI lesion load and clinical 
disability (Li et al., 1984; Filippi et al., 1994). There is a number of 
factors contributing to this. First, the site of lesions may be 
important; many lesions occur in areas of the brain which are clinically 
‘silent’ (Phadke and Best 1983) and would not be expected to greatly 
influence disability which, on current grading systems (Kurtzke, 1983), 
is heavily weighted towards locomotor function. Secondly, the degree 
of disability may be influenced by the extent of spinal cord involvement 
as suggested by a modest though significant correlation between 
clinical disability and cord atrophy (Kidd et al., 1994). And finally, 
there is considerable pathological heterogeneity between lesions 
(Dawson, 1916; Allen, 1991; Barnes et al 1991): some MS plaques may 
show very marked axonal loss (Allen, 1991; Lassmann et al 1994) which 
may contribute to functional impairment while in others there may 
simply be demyelination which may be compatible with normal function 
(Halliday et al., 1972). Conventional MRI cannot identify myelin
breakdown products and is not able to differentiate between the 
various pathological processes occurring within an MS lesion which 
include inflammation, oedema, demyelination, remyelination and axonal 
loss (Allen, 1991; Prineas, 1993). By virtue of its ability to identify 
myelin breakdown products and measure levels of NAA, a neuronal 
marker, MRS has the potential to differentiate some of the 
pathological events occurring within the MS lesion and thus help to 
understand the mechanisms that produce disability.
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1.6.2 MRS studies in MS
MRS provides a non-invasive means of monitoring metabolic changes 
within the MS plaque and from areas of normal appearing white matter 
(NAWM). Technical advances in MRS now permit the study of volumes as 
small as 1ml (Frahm et al., 1990), the size of many MS lesions. The 
first studies of MRS in MS were carried out at long-echo times (TE) and 
were able to provide information concerning NAA, Cho, Cr and lac. In 
these studies, Cr was used as an internal standard of reference. Arnold 
et al (1990b) carried out MRS from the cerebral hemispheres in seven 
MS patients using, in six of them, large volumes of between 1 2 0  and 
160 mis. In four of the patients they observed a reduction of the 
NAA/Cr ratio compared to controls. They also studied one acute lesion 
which was clinically symptomatic. This lesion showed no abnormality 
of the metabolite ratios compared to controls. Although this study was 
carried out on large volumes of interest and performed on a small 
number of patients, the finding of a reduced NAA/creatine ratio from 
chronic plaques was of interest since it suggested that MRS may be 
able to differentiate between old and new lesions. Furthermore, given 
that NAA is predominantly found within neurones, the authors 
speculated that a reduction of NAA within plaques could be used as an 
index of axonal damage.
In a larger study of 16 MS patients, Wolinsky et al (1990) were able to 
carry out short echo-time MRS at a TE of 30ms on 25 plaque containing 
volumes of interest. The advantage of using a short TE was the ability 
to visualise lipid and protein signal in the region of the spectrum 
between 0 and 2 ppm. In this study, eight of the spectra showed changes 
consistent with the presence of free lipids. The increased lipid signal 
in some patients (though not all) correlated with recent clinical 
activity. The authors felt that these lipid peaks represented myelin
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breakdown products and that MRS may be useful in determining whether 
recent demyelination had occurred within an MS lesion. Gadolinium (Gd) 
was not used in this study and it was not possible therefore to date 
accurately the lesions though in a subsequent report by the same 
group, there was a greater tendency for lipid peaks to be seen from 
lesions that demonstrated Gd enhancement (Narayana et al., 1992) 
indicating that demyelination may occur early in the development of the 
MS lesion. Other groups have also observed increased lipid peaks in MS 
lesions. Larsson et al. (1991) performed MRS at an echo-time of 30ms 
in 15 patients with MS. They observed resonances corresponding to free 
lipids in six lesions. These signals were visible as early as 10 days in 
lesions which were clinically symptomatic and were present in one 
lesion judged on clinical grounds to be eight months old. The authors 
were able to carry out repeat studies in four patients and in one of 
these, the intensity of signal in the lipid region of the spectrum 
increased from the first study at day 10 to the follow up at day 70. 
However there was no systematic follow up of the patient group and Gd 
was not given. It was therefore not possible to characterise the 
temporal course of the elevated lipid peaks or their relationship to 
blood brain barrier impairment. A study by Koopmans et al (1993) has 
also found elevated resonances at 0.9 and 1.3ppm in MS lesions. This 
group also observed an increase in the In/Cr ratio in lesions. The 
significance of this latter finding is uncertain though it was speculated 
by the authors that an increase in In may also act as a marker for 
demyelination.
The finding of increased lipid and protein signals in MS lesions has 
however not been universal. A number of investigators have been unable 
to confirm this finding. Bruhn et al (Bruhn et al., 1992) in an MRS study 
of eight children with established MS failed to observe elevated lipid
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peaks either within chronic lesions or from two enhancing plaques 
using a TE of 2 0 ms. It is of course possible that the pathophysiology of 
MS lesions in childhood differs from that of adults. This to some extent 
is supported by neurophysiological studies of optic neuritis in 
childhood (Kriss et al., 1988) where recovery is far more complete 
than in adults. It is also notable that the two acute lesions (as 
evidenced by Gd enhancement) that were looked at in this study were 
rather small and did not fill the volume of interest. It is possible 
therefore that failure to detect elevated signal in the lipid/protein 
region of the spectrum may have been the result of a partial volume 
effect. The same group (Poser et al., 1992) have also reported short- 
echo time MRS in one patient from a large, acute demyelinating lesion 
detecting only small resonances at 0.9 and 1.3 ppm which they 
attributed to mobile aliphatic hydrocarbons such as cholesterol esters 
and lac respectively. Grossman and co-workers (1992) studied 16 
patients with clinically definite MS. They performed MRS at a TE of 
19ms in 21 lesions, seven of which enhanced after Gd. They did not 
detect lipid signals at 0.9 and 1.3 ppm from any of the lesions studied. 
They did however detect elevated peaks between 2.1 and 2.6ppm in five 
of the seven enhancing lesions and five of the 14 lesions which showed 
no enhancement. The authors felt that these elevated peaks were 
possible markers for demyelination. As with other groups, this study 
also reported decreased levels of NAA with a reduction seen in 17 of 
21 lesions. There was no correlation between decreased NAA and the 
presence of Gd enhancement.
There has been, therefore, some conflict in the published literature 
about the presence of elevated lipid/protein resonances in MS lesions 
and, if present, whether they represent markers of myelin breakdown. 
It has been argued that these peaks may represent contamination of the
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spectroscopic volume of interest from subcutaneous scalp fat. To date 
there have been no serial MRS studies which would help to resolve this 
issue. It is known from post-mortem studies of MS brains that myelin
breakdown products in the form of cholesterol ester are present for
over six months in lesions which had been symptomatic. If lipid 
resonances occur in the acute lesion it should be possible to follow 
them serially and document their gradual resolution. Such a study would 
also provide serial information regarding changes in the other 
spectroscopically visible metabolites. In particular, this may be of 
particular interest in the case of NAA. Arnold (1992) has reported 
reversibility of the NAA/Cr ratio from an acute MS lesion raising the 
posibility that at least in some cases, NAA may act as a marker of 
neuronal dysfunction rather than loss. This hypothesis is supported by 
the work of Brenner et al (1993b) who have shown a reduction of the 
NAA/Cr ratio despite structurally intact neurones in the brains of 
guinea pigs with chronic EAE. A serial study of acute MS lesions may
therefore provide confirmation of this finding by Arnold and if so, give
a clearer time-scale of how long such recovery takes.
MRS may also be a useful means of observing metabolic changes within 
areas of NAWM (Husted et al., 1994). It is known from pathological 
studies that small foci of myelin breakdown products or cuffs of 
inflammatory cells may be seen in NAWM and this is consistent with MR 
studies which have shown changes in the relaxation values of water 
from such areas (Miller et al., 1989). It is conceivable that subtle 
histological changes within NAWM are at least in part responsible for 
the development of disability in MS.
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1.7 THE USE OF MR IN THE DIFFERENTIAL DIAGNOSIS OF MS
The diagnosis of MS remains a clinical one, it being necessary to 
demonstrate a dissemination of lesions in the central nervous system 
within time and space (Poser et al., 1983). In this regard, conventional 
MRI may be invaluable in providing support for diagnosis with new 
lesions developing on MRI more frequently than the occurrence of 
clinical relapse (Thompson et al., 1991, 1992). MRI of the brain is 
abnormal in over 95% of patients with clinically definite MS (Ormerod 
et al., 1987) and this figure increases if taken in conjunction with 
imaging of the spinal cord (Kidd et al., 1993). However, high signal 
lesions seen with MRI are by no means specific to MS. Similar changes 
can be observed in healthy controls, being particularly common in 
individuals over the age of 50 (Gerard and Weisberg, 1986;Fazekas, 
1989). Furthermore, a wide variety of other neurological conditions 
may also cause white matter abnormalities detectable on brain MRI. 
These include among others systemic lupus erythematosus (SLE) (Miller 
et al.,1992a), sarcoidosis (Miller et al.,1988b), Behget’s disease 
(Morrissey et al 1993), acute disseminated encephalomyelitis 
(Kesselring et al 1990), phenylketonuria (PKU) (Thompson et al, 1993), 
the leukodystrophies (Demaerel et a l., 1991 a) and the acquired 
immunodefficiency syndrome (AIDS) (Olsen et al 1988). The differential 
diagnosis of neurological disorders producing white matter 
abnormalities on MRI is extensively covered by Thorpe and Miller 
(1994). Of these conditions, neurosarcoidosis and SLE are particularly 
important since, they may also produce a clinical picture which is 
indistinguishable from that of MS. In other conditions such as PKU, it 
is unclear whether the signal change that may occur on brain MRI arises 
from the same pathological processes that contribute to the lesions in 
MS. MRS has the potential to improve diagnostic specificity in these
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conditions and furthermore provide information regarding metabolic 
heterogeneity between them.
1.8 UNRESOLVED ISSUES
There is then, a number of unresolved questions, regarding the 
pathophysiology and differential diagnosis of MS. The aim of this 
thesis is to determine whether the application of MRS is useful in 
addressing such issues. They include:
(1 ) The mechanisms that produce disability in MS.
(2) The time course of demyelination in the acute MS lesion.
(3) The time course of changes in NAA in the acute MS lesion.
(4) The identification of pathological and metabolic heterogeneity in MS 
lesions and NAWM.
(5) The role of MRS in evaluating other neurological conditions which 
may radiologically and/or clinically mimic MS?
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Table 1.1 
Some examples of metabolites identified 
by MRS in human and animal tissues
Nucleus Metabolites
1H alanine aspartate glutamate glutamine
glycine
choline
GABA
acetate
taurine
lactate
glucose
creatine
scylloinositol
phenylalanine
phosphorylcholine
m yo-inositol lipids 
phosphocreatine glucose
N-acetylaspartate
31P  adenosine triphosphate phosphomonoesters
phosphodiesters inorganic phosphate
phosphocreatine glucose-6 -phosphate
1 3 C  glucose lactate glutamate glycogen c itra te
1 5N  urea glutamine glutamate c itru llin e  GABA
aspartate ammonia alaninne N-acetylaspartate
19F halothane 5 Fluoro-uracil and its metabolites
Figure 1.1
Proton MRS from healthy control 
periventricular white matter TE 135ms TR 2.2secs
N-acetyl groups
Cho
Cr/PCr
3.0
ppm chemical shift
Figure 1.2
Proton MRS from healthy control 
Periventricular white matter TE 10ms TR 2 secs
N-acetyl groups
Cr/PCr
Cr/PCr 9 h 0
cytosolic proteins/ 
lipids
Tau NAA-CH2
.GAB,
3.0 2.0 0.01.0
ppm chemical shift
Figure 1.3 a Chemical structures of some 
metabolites visible with Proton MRS
Compound Structure
O
N-acetylaspartate ' CH2-CH-C
O
NH
C = <
CH3
° \  + 
Creatine / Phosphocreatine (2-CH.2- N - C-NH3
°  CH3 NH
Choline
CH3
+  l
HO-CH2-CH2- N -CH3
I
CH3
Figure 1.3b Chemical structures of some 
metabolites visible with Proton MRS
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Compound Structure
Glutamate .C-CH2-CH2-CH-CI \NH3 u
N il2  n
\  /  
Glutamine .C-CH2-CH2-CH-C
Lactate
O wNH3 0
H
° \  I
C-C-CH3
^  IO
OH
OH OH 
OH I I H
l / J - f x l
Myo-inositol f x ?  °‘H/ f
c —  c  
H V i OH
OH H
Table 1.2
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CHEMICAL SHIFTS OF METABOLITES IN IH SPECTRUM
COMPOUND CHEMICAL COMPOUND CHEMICAL
SHIFT (PPM) SHIFT (PPM)
L a c ta te CH 4 .1 2 In o s ito l CH 3.54
CH3 1 .3 3
C re a tin e CH2 3 .9 3 G lutam ine CH 3 .7 6
CH3 3 .0 4 gamma CH2 2 .4 6
NAA BCH2 2 .7 0 G lu tam ate BCH 2 .0 6
CH3 2 .0 2 gamma CH2 2.36
alpha CH 4 .4 0 BCH 2 .1 0
GABA BCH2 1.91 Taurine SCH2 3 .4 4
alpha CH2 2.31 NCH2 3 .2 7
gamma CH2 2 .3 6
Aspartate BCH 2 .6 9 A lan ine CH 3 .7 8
13 CH 2 .8 2 BCH3 1 .4 8
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CHAPTER 2
Methods
2.1 THE NMR EXPERIMENT
2.1.1 Precession
NMR is dependent on the observation that the nuclei of atoms with odd 
atomic numbers possess a property known as spin or precession. This 
can be visualised as a spinning motion of the nucleus about its axis. In 
keeping with the theories of classical electromagnetism this spin 
endows such nuclei with a magnetic charge or “moment”. Only those 
nuclei that possess spin give rise to NMR signals. Each species of 
nucleus possessing an odd atomic number has a nuclear magnetic 
moment which is specific to that particular nucleus. When an 
appropriate nucleus is placed in a magnetic field, it will absorb energy 
at a specific frequency. The possible orientations of the nucleus within 
the magnetic field are dependent on the type of spin they possess. 1H 
has a spin quantum number of 1= 1 / 2  and can have one of two possible 
orientations within the magnetic field. These two orientations have
slightly different energy levels-the energy difference between them
being proportional to the magnitude of the magnetic field. In a
spectroscopy experiment it is possible to ‘tune’ in to different nuclei 
by applying a short-wave radiofrequency pulse which will specifically 
excite one type of nucleus and not the others. A particular advantage of 
this type of stimulation compared to other spectroscopic techniques 
(such as infrared for example) is that radiofrequency penetration into 
tissue is very effective and therefore ail material within a volume is 
examined. Following the radiofrequency pulse, the nuclei absorb energy 
and ‘resonate’ for a fraction of a second. This resonance induces an 
oscillating voltage in the NMR coil which is detectable by the
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spectrometer. Another name for this oscillating voltage is the free 
induction decay (FID). The FID then undergoes Fourier transformation 
(FT). This is a mathematical procedure performed by a computer which 
separates out the frequency components of a signal from its amplitudes 
as a function of time. This converts the FID to a spectrum.
The resonance frequency for a particular nucleus, for example 1H, is 
directly proportional to the local magnetic magnetic field experienced 
by the nucleus. If this field were simply the applied magnetic field 
which was perfectly uniform over the entire sample, all protons would 
absorb energy at the same frequency and thus one could not 
differentiate between protons in different chemical environments. In 
imaging, this problem is overcome by applying gradients to the 
magnetic field. This modifies the resonant frequency in such a way that 
the precise frequency is dependent on the spatial position of a nucleus 
within the gradient. In spectroscopy this is not necessary because of an 
intrinsic property known as chemical shift.
2.1.2 Chemical shift
When a nucleus is placed in an external field, the actual magnetic field 
experienced by each individual nucleus is very slightly different from 
the applied field. This is because the external field induces electronic 
currents in atoms and molecules which produces a further small field 
at the nucleus. The size of this small field (known as Boo) is dependent 
not only on the size of the external field (Bo), but also on the degree of 
shielding produced by surrounding electrons. Since the electron 
environment of each nucleus will depend on its chemical environment, 
the effective magnetic field (Betf) is slightly different and therefore 
nuclei in different environments give rise to signals at different 
frequencies. The separation of resonance fequencies from an 
arbitrarily chosen reference frequency is known as chemical shift.
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Chemical shift is expressed in dimensionless units known as parts per 
million (ppm).
The different protons within a chemical give rise to separate signals or 
resonances. The intensities of the signals as measured by their areas 
are proportional to the number of nuclei that contribute to them. To 
illustrate this, the spectum of ethanol (CH3 -C H 2 -OH) is shown in Figure
2.1 Three different resonant frequencies are shown which from left to 
right represent the H in the OH group, the H2 in the CH2 group and the H3  
in the CH 3 group. Some of the resonances in Figure 2.1 split into 
multiple lines or multiplets. This splitting is a manifestation of J- 
coupling which is discussed more fully in section 2 .6 . 1  of this chapter. 
In theory the ratios of the three peak areas from ethanol should be 
1:2:3, reflecting the different number of protons in each environment. 
The amount of signal however is also dependent on other factors 
including the relaxation times which are now discussed.
2.1.3 Relaxation within tissues
When a nucleus is exposed to a an appropriate radio-frequency (RF) 
pulse it gains energy along the direction of the applied magnetic field. 
When the RF pulse is removed, the nucleus subsequently returns to its 
initial state of equilibrium. It does this via two relaxation processes: 
longitudinal or spin-lattice relaxation (T 1 ) and transverse or spin-spin 
relaxation (T 2 ). T 1 describes the return to equilibrium along the 
direction of the magnetic field whereas T2 represents the return of 
magnetisation in the plane perpendicular to the field. In most 
instances the T-i times are much longer than those of T2 . For instance 
NAA in the occipital white matter of healthy controls has a T 1 of 
approximately 1.5 secs and a T2 of 450ms (Table 2.1).
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2.1.4 Relaxation properties and echo-time.
The various metabolites discussed in Chapter 1 all exhibit different 
relaxation times. The values for these are dependent on magnetic field 
strength. Approximate values (Frahm et al., 1989b) for the relaxation 
times of the main metabolites are shown in Table 2.1. The Ti and T 2  
values for other metabolites including proteins and lipids are far 
shorter. These substances only produce a visible signal in the proton 
spectrum when a short T 2 weighting is used (e.g. 10-50ms). The effect 
of increased T 2 weighting on protein and lipid signal in the human brain 
is shown in Figure 3.6. As the TE is increased, the signal from the lipid 
and protein moieties to the right of NAA gradually disappear so that by 
a TE of 135ms no signal is seen in this region. If one is specifically 
interested in lactate, NAA, creatine or Cho all of which have a 
relatively long T 2 value (Table 2.1) , a long T2 weighting such as 135 or 
270ms is often employed since this will improve water and fat 
suppression.
2.2 VOLUME LOCALISATION
Perhaps one of the most important advances in MRS in the last few 
years has been the development of NMR sequences which allow accurate 
localisation of a volume of interest (voxel) within the human brain. 
Ideally a sequence should allow collection of an undistorted spectrum 
from a well defined volume without contamination from signal outside 
the voxel. For a localisation sequence to be useful in a clinical setting 
it must be easy to use as well as providing reliable and consistent 
results.
2.2.1 Surface Coil Methods
This was the earliest localisation method suggested (Haase et al.,
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1983) and relies on a flat circular coil to excite a limited volume. The 
coil transmits radio-frequency pulses and receives the NMR signal. 
Although this system has the advantages of being easy and providing 
very good signal to noise ratio (SNR), the volume is neither well defined 
nor restricted (Haase et al., 1983)
2.2.2 Volume selection by frequency selective RF pulses 
Most spectroscopic localisation methods currently employed select 
planes in an object by applying frequency selective pulses in the 
presence of linear gradients. These can be split into two groups; those 
involving a combination of several acquisitions known as multishot and 
those achieving localisation of a volume in a single shot.
The most frequently used multishot method is the so called ISIS or 
Image Selected In vivo Spectroscopy technique devised by Ordidge et al 
(1986). This technique selects a cube by the combination of a minimum 
of eight acquisitions. As with the singleshot sequences, this method 
has the advantage of being able to define a freely selectable volume in 
terms of size and position. The ISIS technique however also has the 
advantage of very small Ti relaxation losses and no T 2 losses. This has 
made it particularly useful in 3 ip  NMR where the T2 values are very 
short in vivo. A major disadvantage of this sequence is the limited 
ability to suppress signal from outside the voxel. This has limited its 
use in 1 H MRS where extra-voxel contamination from subcutaneous lipid 
may be a problem.
2.2.3. Single-shot methods of volume selection.
PRESS
The PRESS method ( Point REsolved Spectroscopy) (Ordidge et al., 1985)
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excites only those magnetisations that contain the desired voxel as 
part of an excited slice. The three slices required stem from a 900 
excitation pulse and two 1800 refocussing pulses. The voxel is defined 
by the intersection of the three planes. For use in proton spectroscopy, 
the sequence is preceded by one or more chemical-shift selective water 
suppression pulses. Although PRESS has the advantages of good SNR and 
being easy to use it has the drawback of requiring 180° refocussing 
pulses which means that it is not possible to optimise the SNR with 
short repetition times. PRESS also has greater T2 relaxation losses than 
the Stimulated Echo Acquisition Mode (STEAM) sequence and therefore 
may be less useful in studying highly bound metabolites with short spin- 
spin relaxation times (T2 )
STEAM
The STEAM sequence (Granot et al., 1986; Frahm et al., 1987) is the
method used in the clinical MRS studies described in this thesis. It is
similar to the PRESS technique but instead defines the voxel by the
intersection of three slices selectively excited by three successive 900
pulses. The STEAM sequence can be written in the abbreviated form as
900 -TE/2 - 900 - TM - 900 -JE/2  -Acq
This is illustrated diagramatically in Figure 2.2
The STEAM sequence has a number of advantages over other singleshot 
localisation methods such as PRESS. Although the STEAM sequence does 
produce some T2 relaxation loss this can be reduced to a minimum since 
there is no T 2 I0 SS between the the second and third RF pulse -the so 
called mixing time (TM). This has allowed, when appropriate, the
collection of spectra at an echo time as short as 10ms. The
implementation of such a short echo-time is particularly useful when 
trying to visualise highly bound metabolites such as lipids and
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macromolecules which have very short T2 relaxation times . The 
STEAM sequence also provides a better resolution of signal from 
glutamine and glutamate in the 2 .0 -2 .5 region of the spectrum 
compared to PRESS. This sequence is easy to use thus allowing the 
author to acquire spectra from patients and controls in the various 
clinical studies described in the following chapters. This sequence has 
become established as a reliable means of volume localisation in proton 
M R S (Frahm et al.,1987, 1989a, 1990) and one that is now routinely 
used in clinical MRS studies of the brain (Arnold et al., 1990; Gideon 
and Henriksen, 1992; Chong et al., 1993). As with nearly all 
spectroscopy sequences, several acquisitions have to be collected to 
produce a good signal to noise ratio (SNR). SNR is dependent on several 
factors including the size of the volume of interest and echo-time
collected. In the current studies, volumes ranging from 3-12 ml have 
been collected with echo-times of 10ms,135ms and 270 ms. It has 
therefore proved necessary to acquire between 128 and 512 averages to 
collect one spectrum for each volume of interest.
Before collection of the spectroscopic data there are two further
procedures that must be carried out. These are shimming and water 
suppression.
2.3 SHIMMING
Following on from the earlier description of the NMR experiment as 
applied to spectroscopy, it is important that the magnetic field over 
the volume of interest is as uniform as possible to allow maximum 
advantage of the chemical shift that results from nuclei being in 
different chemical environments. Improving the homogeneity of the 
magnetic field results in the protons within a particular chemical
group resonating at the same frequency and therefore producing a
narrower line-width in the spectrum. This is important for two
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reasons. First, it allows differentiation of signals from different 
chemical groups that resonate at similar frequencies in the spectrum. 
Conversely, with poor field homogeneity, the peaks from different 
chemicals merge making quantitation less accurate. This can be a 
particular problem with the resonances from creatine at 3.02 ppm and 
choline containing substances at 3.2ppm. The homogeneity of the 
magnetic field is also important in allowing optimal water suppression. 
By producing narrow line-widths it is possible to suppress most of 
the signal fom the water resonance without distorting the resonances 
from the remaining chemical groups.
Correction of the magnetic field is carried out with the use of 
supplemental coils- known as shim coils. By adjusting the current in 
the three shim coils x,y and z, one is able to correct for 
inhomogeneities in the magnetic field. Although magnetic field 
inhomogeneity may result from external factors such as pieces of ferro­
magnetic material becoming inadvertently attached to the magnet, the 
uniformity of the field may also be altered by particular susceptibility 
effects from the area of the brain being studied. For example it is more 
difficult to produce narrow line-widths from spectra acquired in the 
basal ganglia. Figure 2.3 is a T2 weighted spin-echo sequence (TR 
2000ms TE 80ms) showing the basal ganglia from a healthy control. 
The low signal visible in the basal ganglia is the result of iron 
deposition within the globus pallidus. This is a normal finding in 
healthy individuals, though more extensive iron deposition extending 
laterally into the putamen may be of pathological significance. Iron 
deposition within the basal ganglia produces susceptibility effects 
(hence the signal loss on imaging) which are reflected by broadening of 
the line-widths in spectra collected from the basal ganglia compared to 
areas of the brain where iron deposition is not a feature (Figure 2.4.)
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such as the cerebral hemispheres.
2 .4  WATER SUPPRESSION
The concentration of water in the healthy human brain is approximately 
79.5molar (M) in white matter and 91M in grey matter (Norton et al., 
1966) making it an ideal molecule to use when imaging the brain. In 
contrast, the metabolites which are visible with MRS have 
concentrations within the millimolar range. One of the major 
difficulties with proton MRS has been the accurate detection of signal 
from these substances in the presence of a water concentration which 
is approximately 10,000 times greater. There have been great advances 
in methods that allow selective suppression of the water signal from 
the spectrum. The most widely used technique and the one adopted in 
the following studies is the use of presaturation pulses. With this 
method, one applies a pulse sequence over a particular frequency range 
to selectively excite and then dephase the signal from that part of the 
spectrum. This occurs prior to the STEAM sequence. In the case of 
water, this produces a 1000 fold reduction in signal. The presaturation 
method that has been adopted is the CHEmical Shift Selective method 
(CHESS) (Haase et al., 1985; Doddrell et al., 1986). This is a sequence of 
three RF pulses each followed by a spoiler gradient. The first two RF 
pulses are 90°. The third pulse which tends to range between 1 1 0 0  and 
1400 depending on factors such as the echo-time, can be modified by 
the operator to optimise water suppresion. The saturation pulses are 
specifically designed to excite only a 50 Hz range of frequencies 
centred around the water signal which resonates at 4.7ppm. The effect 
of water supression on the resulting spectrum is shown in Figure 2.5.
2 .5 POST PROCESSING
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2.5.1 Fourier Transformation
The spectroscopic data is acquired as an oscillating signal - known as 
the FID which represents an amalgamation of signal from all the 
resonating nuclei of the various metabolites. To resolve out the 
different frequencies and characteristics of individual metabolites the 
data undergoes FT. This mathematical procedure is, as mentioned 
earlier, a means of separating out the frequency components of a signal 
from its amplitude and is performed by computer.
2.5.2 Apodisation
After FT has been performed, the spectroscopic data is ready for 
display. In practice however the FID usually undergoes a small amount 
of filtering in order to improve signal-to-noise. This is another 
mathematical procedure known as apodisation whereby all the 
datapoints are multiplied by a set function. This has the effect of 
smoothing out the FID throughout its signal. The effect of this after 
fourier transformation is to produce broadening of the peak line- 
widths. The advantage of this (illustrated in Figure 2.6) is to smooth 
out the resonances and produce a less ‘noisy’ baseline. If however too 
much apodisation is applied to the FID then, after FT, the resonances 
from different metabolites may merge making quantification difficult 
(figure 2.7). The amount of apodisation which is necessary may vary 
depending on SNR and the line-widths of the metabolites. In the studies 
described in the following chapters, a 1- 1.5 Hertz (Hz) apodisation or 
line-broadening function has been applied.
2.5.3 Phase correction
After the NMR signal has undergone FT, a spectrum is produced similar 
to that shown in Figure 2.8. The peaks of the main metabolites are 
visible but they are not pointing in an an upright direction. This is due 
to the arbitrary phase relationship between the collected signal and
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the reference RF frequency. Phasing can be performed manually to 
adjust the peaks till they are all upright as illustrated in Figure 2.8. 
This process is often carried out automatically by applying the phase 
information in the water reference signal to that of the water 
suppressed spectrum. Phasing may be performed in two steps. In the 
first step (or zero- order phasing) all the peaks are adjusted by the 
same amount. In the second step (or first-order phasing) the amount of 
correction increases linearly across the spectrum. In practice first- 
order phasing is seldom necessary.
2.5.4 Baseline correction
This is a post processing technique which allows for correction of the 
baseline which may be distorted by residual signal from what remains 
of the water peak. In the studies described in this thesis it was 
possible to quantify the data without applying baseline correction.
2.6 PEAK ASSIGNMENTS
The assignment of resonances to specific metabolites in the 1H NMR 
spectrum of the human brain in-vivo can be determined in a number of 
ways.
2.6.1 Extract identification
The tissue of interest can be removed from the body and a tissue 
extract made. Making extracts allows narrower line widths to be 
obtained with in-vitro MRS (using higher field strengths ) than is 
possible in vivo thus helping to separate out resonances from 
metabolites with a similar chemical shift. Furthermore, resonance 
assignments can be confirmed by adding quantities of the pure 
compound and observing an increase in intensity of the appropriate 
metabolite. It is also possible to use two dimensional NMR methods 
(for example 2 D-COSY) to visualise coupling patterns between different 
Hydrogen groups within a given compound (Behar et al., 1991).
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Editing techniques 
J modulation
It is also possible to use ‘editing’ techniques in-vivo to identify or null 
particular metabolites. An example of this is the inversion of signal 
from a number of metabolites. This occurs as a result of J- coupling. J- 
coupling is the term used to describe any interaction which occurs 
between the magnetic fields of the nuclei themselves. Each nuclear 
magnetic moment has its own magnetic field which adds to or 
subtracts from the field of neighbouring nuclei. This produces a slight 
change in the chemical shift thus producing multiplet patterns from CH 
groups in the same molecule. Other manifestations of J-coupling 
include modulation of peak intensities and in some cases peak inversion 
in a spin-echo experiment. For example, lac produces a double 
resonance -or doublet- which are 7 Hz apart at 1.33 ppm in the 1 H NMR 
spectrum. The two resonances come from the CH and CH 3  groups which 
are adjacent within the lactate molecule (Figure 1.3b). When the lac 
signal is exposed to a spin-echo sequence, the doublet undergoes 
marked changes in phase and amplitude. At an echo-time of 270ms the 
lactate doublet demonstrates an in-phase signal and is therefore 
upright in the spectrum. However at 135ms, the doublet is out of phase 
and appears inverted (Figure 2.9). Other metabolites which possess 
this property include alanine GABA, glutamate and glutamine and J 
modulation can be used to highlight or suppress their signals.
2.7 METABOLITE QUANTITATION
2.7.1 Determination of peak areas
Peak integration is normally carried out by software provided with the 
MRS instrument. In this study peak areas were determined using a 
commercial package (“SA / GE”, G.E. Milwaukee W.I.). The peak areas
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were fitted to a gaussian line shape using a Marquardt fitting 
procedure. Although theoretically the resonances should have a 
Lorentzian line-shape, in practice, the peaks do not conform to this 
ideal shape. The fitting produced from a gaussian line shape proved 
more accurate and reproducible and was therefore used in the studies 
described in this thesis.
2.7.2 Relative quantitation
The majority of MRS studies have, to date, relied on an internal 
standard of reference for quantitation. The resonance from 
creatine/phosphocreatine at 3.2 ppm has been most frequently used in 
this role since theoretically these two compounds are in chemical 
equilibrium and would therefore be expected to remain constant in 
concentration. With this method, the data is converted into 
concentration units by calculating the area of signal produced from the 
creatine/phosphocreatine resonance and relating this to the other 
metabolites by simple proportion. This method was employed in 
chapters 3 and 6  of this thesis prior to the development of methods 
which allowed the application of absolute quantitation described below.
2.7.2 Absolute quantitation
More recently, it has proved possible to accurately quantitate the 
millimolar concentration of metabolites in vivo by MRS (Tofts and Wray 
1988; Michaelis et al., 1993; Christiansen et al., 1993). The method of 
quantitation employed in chapters four, five and seven of this thesis is 
that described by Christiansen et al (1993). Metabolite concentrations 
are calculated by using the fully relaxed and unsupressed water 
spectrum as an internal standard of reference. A number of correction 
factors are necessary. These take into account the concentration of 
water in the spectroscopic volume of interest, the number of protons in
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each metabolite, Ti and T 2 correction values and the difference in 
receive attenuator settings. These can all be expressed in the following 
equation,
Met = [H20] X PI x T i c<)rr *  T 2 Corr x  So Met !  So H20 x ^ 2 R
where So Met and So H 2 0  denote the signal intensities for metabolites 
and water respectively, [ H 2 0 ]  is the brain water concentration from the 
volume of interest. In the MS patients, the water concentration from 
the voxel of interest was calculated by comparing the signal intensity 
from the PD images in the basal ganglia (where no lesions were visible) 
with the signal intensity from the region of interest. The putamen was 
chosen since this region of the basal ganglia is not affected by heavy 
metal deposition in healthy controls (Olanow, 1 9 9 2 ) .  Furthermore a 
recent study by Grimaud and colleagues (1 9 9 5 )  has shown no evidence 
of hypointensity on T 2 -weighted images to suggest increased heavy 
metal deposition in the putamen of MS patients. The water 
concentration of normal appearing grey matter has been taken as 4 5 .5 M  
(Norton et al., 1 9 6 6 ) .  In the control groups the concentration of water 
in white matter has been taken as 3 9 .7 5 M  (Norton et al., 1 9 6 6 ) .  T 1 COrr 
and T 2  Corr are T1 and T 2  correction values based on published values 
for the metabolites studied (Frahm et al, 1 9 8 9 ) .  T 1 and T2 relaxation 
times were not measured in the following studies because of the 
prohibitively long examination times required. A T 1 or T 2 effect canot 
therefore be excluded and for this reason the term apparent 
concentrations are usedPI is the proton index and R =  ((R 1  + R 2 )  
metabolite - ( R 1 + R 2 )  water) accounts for different receive attenuator 
settings. For further theoretical discussion of this method see 
Appendix A.
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Figure 2.1
1H NMR spectrum of ethanolol (CH3-CH2-OH)
CH3
OH
5.0 4.0 3.0 2.0 0.0
Table 2.1
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Spin-lattice relaxation times (Ti) and spin-spin (T2) 
relaxation times at 1.5 tesla of the major 
metabolites in the 1H NMR spectrum from occipital 
white matter
(Frahm et al., 1989b)
Compound ppm I i 12
NAA 2.02 1450 ms 450 ms
Cr and PCr 3.04 1550 ms 240 ms
Cho 3.2 1150 ms 330 ms
Lactate 1.33 1550 ms 1200 ms
Myo-lnositol 3.54 900 ms 110 ms
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Figure 2.3 61
T2 weighted coronal MRI 
with volume of interest 
localised to the lentiform 
nucleus
Figure 2.4
NA
Cho
parietal 
white matter
basal ganglia
Comparison of spectra from the basal ganglia and the cerebral hemisphere. 
The broader line-widths in the basal ganglia are the result of greater 
magnetic field inhomogeneity due to iron deposition in this region of the brain.
62
Figure 2.5A
H20
magnified 200 times
6.0 5.0 4.0 3.0 2.0 1.0 0.0
Unsuppressed water spectrum. While some metabolites are visible 
in the blownup spectrum, these are grossly distorted by the tail of 
the water peak.
Figure 2.5B
NA
ChoCr
H 2 0
6.0 5.0 4.0 3.0 2.0 1.0 0.0
Spectrum from Figure 2.5A after water suppression showing 
remaining water signal and metabolites. TE 135ms
63
Figure 2.6 
Effect of line broadening on NMR spectrum
NA
ChoCr
1.5 Hz line broadening
1 Hz line broadening
0.5 Hz line broadening
0 Hz line broadening
0.03.0
ppm
Figure 2.7
Merging of Cho and Cr with a line-broadening of 4 Hz
NA
1.02.0
nnm
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Figure 2.8
The effect of phasing on the 1H NMR spectrum
Upper spectrum -  no phase correction 
Lower spectrum manual phase correction applied
Figure 2.9
The effect of J modulation on the lactate signal
Cho
lacNAA
lac
Upper spectrum TE 270ms with upright lactate doublet
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CHAPTER 3
SERIAL PROTON MAGNETIC RESONANCE SPECTROSCOPY 
IN ACUTE MULTIPLE SCLEROSIS LESIONS
3.1 SUMMARY
Serial 1 H MRS, was carried out at one to two monthly intervals on 8  
patients with MS who presented with evidence of a large acute 
cerebral white matter lesion. MRS was obtained from acute lesions 
(volumes of interest 4 to 12 mis), which at presentation showed Gd- 
DTPA enhancement, and from similar volumes of NAWM lateral to the 
lesion and nearer the scalp. Follow up ranged from 4 to 9 months 
(mean 6  months). Short echo spectra from acute enhancing lesions 
invariably showed the presence of large resonances at 0.9 and 1.3 ppm 
compared to NAWM and white matter from healthy age matched 
controls, indicating that these peaks were not the result of voxel 
contamination from scalp fat. These resonances, which probably 
represent lipid products of myelin breakdown, were detected in lesions 
which had been enhancing for less than one month and remained 
elevated for a mean of 5 months (range 4-8 months). The results 
provide evidence that short echo 1 H MRS can detect myelin breakdown 
products and that myelin breakdown occurs during the initial 
inflammatory stage of lesion development. The ratio of NAA - a 
neuronal marker- relative to Cr was reduced in acute lesions and in 
NAWM. In 6  of the lesions studied there was however a subsequent rise 
in the NAA/Cr ratio indicating that axonal loss is not the only 
mechanism of reduction in the NAA/Cr ratio.
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3.2 INTRODUCTION
An important unresolved question about the pathogenesis of MS is when 
does demyelination occur ? Though it has long been known that both 
inflammation and demyelination can be present in the same lesion 
(Dawson 1916; Lumsden 1970; Allen 1991), the temporal pattern of 
evolution of each of these processes has not been elucidated by 
pathological studies which provide information only at a single time 
point. Serial Magnetic resonance imaging (MRI) studies (Kermode et al 
., 1990) have shown that the earliest detectable event in the 
development of a new lesion is a breakdown of the blood brain barrier; 
there is experimental (Hawkins et al ., 1990) and post mortem evidence 
(Katz et al .,1993) that this indicates the presence of inflammation. 
However, conventional MRI has not yielded information about the time 
course of demyelination since it does not reveal normal myelin or 
myelin breakdown products.
MRS at long echo times of 135 and 270 ms detects metabolites with 
long T 2 relaxation times such as NAA, Cho, Cr/PCr and lac. MRS at short 
TEs of 10-30ms detects additional metabolites with short T 2 
relaxation times. These include mobile lipids, proteins, inositol, and a 
number of the neurotransmitters such as glu and GABA. The ability to 
detect mobile lipid resonances within MS lesions using proton MRS 
would provide, for the first time, a non-invasive tool with which to 
monitor myelin breakdown and to study the temporal relationship of 
inflammation and demyelination in vivo.
It has also been suggested that proton MRS may have a role in 
monitoring axonal loss (probably an important factor in the 
development of persistent disability in MS) since NAA, an amino acid 
clearly visible on proton MRS, is largely confined to neurones and their 
processes.
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Recent technical advances in proton spectroscopy have improved its 
spatial resolution, allowing the study of volumes as small as 1 ml 
(Frahm et al., 1990)- a common size for multiple sclerosis lesions. 
Serial long-and short- TE proton MRS has therefore been performed on 
patients with MRI or symptomatic evidence of acute cerebral lesions. 
The aim was (1) to determine whether myelin breakdown products are 
spectroscopically detectable at short echo times within the acute 
lesion; (2 ) if they are, to determine whether they are the result of 
voxel contamination from overlying scalp; (3) to establish at what 
phase in the evolution of the lesion demyelination occurs; and (4) to 
elucidate the time course of changes in NAA.
3.3 MATERIALS AND METHODS
3.3.1 Subjects
Eight patients (age range, 20-48; mean age 28) were studied.
6  patients had clinically definite MS and two had laboratory supported 
definite MS (Poser CM et al ., 1983). The disease severity ranged from 
mild to severe as measured on the expanded disability status scale 
(Kurtzke 1983). Two patients had undergone treatment with intravenous 
methylprednisone one day prior to the first spectroscopic examination. 
Nevertheless, these lesions still enhanced after administration of Gd- 
DTPA, (Miller et al ., 1992b). The patients were followed at one to two 
monthly intervals. Follow up ranged from 4 to 9 months (mean 6  
months). The patients were examined neurologically by the author at 
entry into the study and at each follow up session. The patients then 
underwent unenhanced MRI, localised proton MRS and finally Gd-DTPA 
enhanced MRI.
The study was approved by the Joint Ethics Committee at the Institute 
of Neurology and the National Hospital for Neurology and Neurosurgery,
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London. Informed consent was obtained from all patients prior to each 
study. The patients were judged to have an acute lesion if 1) there 
was an area of increased signal intensity within white matter on MRI 
which displayed Gd-DTPA enhancement and which had not been present 
on MRI carried out in the previous month (4 patients). These patients 
had undergone monthly unenhanced and enhanced brain scans over the 
previous year as part of other longitudinal studies.
2 ) There had been an acute clinical relapse within the previous two 
weeks and there was an appropriately placed new lesion on MR imaging 
which enhanced after Gd-DTPA administration (4 patients).
Eight healthy age matched controls underwent MRI and localised proton 
MRS without administration of Gd-DTPA. A 17-year-old female with a 
lipoma in the quadrigeminal cistern was also studied.
3.3.2 Magnetic resonance imaging and spectroscopy 
MRI and MRS were performed on a 1.5 T. G.E. signa whole body scanner 
using a standard quadrature head coil. The study commenced with a T 2 
weighted fast spin echo imaging sequence (TR 3000 ms, TEf80 ms) 
(5mm slices with 2.5 mm gap, 256x256 matrix, echo train length 8  ). 
After imaging, a volume of interest ranging between 3.5 ml and 12ml 
was prescribed which in the patient group incorporated a new high 
signal lesion. Large lesions were chosen in order to minimise partial 
volume effects. An MR image of the voxel was then obtained to ensure 
accurate localisation. Water suppressed 1H spectra were obtained using 
a STEAM sequence (Frahm et al ., 1987 and1989a). Acquisition 
parameters were TR 2000 ms, TM 12ms, TE 10 and 135ms. 256
averages were collected using an 8  step phase cycle in ~ 9 minutes. 
1024 points were collected, with a spectral width of 750 Hz. 
Shimming to a line width of ~3Hz. and water suppression were re­
optimised for each new location. In the control group, spectra were
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collected from an area of periventricular white matter.
In the patient group, long and short TE spectra were acquired from 
acute lesions on the first study and at all subsequent examinations. At 
the first study only, a separate location containing NAWM was also 
examined which was lateral to the lesion and closer to the scalp. After 
collection of the spectroscopic data, Gd-DTPA, 0.1 mM./kg. was 
injected intravenously and Ti-weighted Gd-DTPA-enhanced images 
were obtained (TR 500 ms, TE 40ms).
Data processing included 1.5 Hz. line broadening for filtering, Fourier 
transformation, and zero order phase correction. No baseline correction 
was applied. Resonance areas were calculated by manual integration. 
Ratios for the various metabolites are expressed relative to creatine. 
NAA and choline ratios were calculated from the spectra collected at 
135ms. Inositol ratios were calculated from spectra collected at 
10ms. Statistical analysis was performed using Student’s t test. 
Values are expressed ± 1 SD together with a level of significance (p).
3.4 RESULTS
3.4.1 Controls
Representative short echo and long echo spectra from a healthy 28-year- 
old female control are shown in Figure 3.1 A. All spectra collected at a 
short echo time from controls showed small resonances at 1.3 and 0.9 
ppm (Davie et al., 1992) which have been assigned to macromolecules 
(Behar et al., 1994) and lipid (May et al., 1986; Callies et al 1993). The 
lipid assignments are corroborated by an experimental model, showing 
that signals appear at 0.9 and 1.3 ppm in the proton spectrum after the 
induced formation of lipid droplets in myeloma cells (Callies et al., 
1993). In vivo confirmation of these assignments were obtained from
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the 17-year-old female patient with a lipoma situated in the 
quadrigeminal plate (Figure 3.1 B); large resonances were seen only at 
0.9 and 1.3 ppm (Figure 3.1 C).
A Spectrum at an echo time of 135ms confirmed that there was no 
contribution from lactate in the resonance at 1.3 ppm in healthy 
controls (Figure 3.1 A ). Lipid resonances were not observed at this 
longer echo time.
Resonances from the other metabolites have been assigned as follows 
(Behar and Ogino 1991, Frahm et al., 1989b); NAA at 2.02 ppm and 
2 .6 ppm, Cr/PCr at 3.04 ppm. Cho at 3.2 ppm, In at 3.54 ppm, glu , gin 
and GABA between 2.1 and 2.45 ppm.
3.4.2 Short echo time spectra: patients
Short echo spectra in the patient group showed large resonances at 0.9 
and 1.3 ppm from Gd-DTPA enhancing lesions (Figure 3.2), when 
compared to the small resonances seen in the regions of normal 
appearing white matter lateral to the lesion and in white matter from 
healthy controls. In one 36-year-old female with clinically definite MS 
it was possible to study a number of volumes from the lesion and 
surrounding normal appearing white matter. A spectrum (Figure 3.4 
Spectrum A ) was collected from a 12ml volume which included most of 
a region of high signal as shown on a T 2 weighted scan (Figure 3.3 
image A). When the voxel was reduced to a volume of 4 ml and taken 
from the centre of the lesion (Figure 3.3 image B) , the changes were 
far more striking (Figure 3.4 Spectrum B); this region was subsequently 
shown to enhance (Figure 3.3 image D). A spectrum obtained from a 4ml 
volume incorporating part of the lesion lateral to the region of 
enhancement and including normal appearing white matter (Figure 3.4 
spectra C and 3.3 image C) showed only small lipid resonances, 
consistent with the evidence that these non-enhancing areas
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surrounding enhancing active lesions are the result of oedema (Larsson 
et al 1988; McDonald et al., 1992 ). In addition, the small size of 
these lipid signals (which are at control levels) from a volume nearer 
the scalp makes it highly unlikely that the large resonances from the 
centre of the lesion are due to contamination from scalp fat.
In 7 patients, these abnormal lipid signals gradually resolved to control 
levels in from 4 to 8  months (mean ~ 5 months) (Figure 3.5), whereas 
Gd-DTPA enhancement had ceased in all patients by 2 months. One
patient followed to date, for only four months, still has increased lipid
resonances.
In 3 of the patients there was the suggestion of a separate resonance 
seen at 1.4 ppm (Figure 3.6). This resonance was only visible at 
relatively short echo times reflecting the short T2 of its components. 
In/Creatine ratios were elevated within acute enhancing lesions (0.95 ± 
0.16) compared to areas of NAWM (0.7 ± 0 . 1  p<0.01) and white matter 
from healthy age matched controls (0.62 ± 0.2 p<0.003). The 
In/Creatine ratio in the lesion group remained elevated throughout 
followup. There was no significant difference between In/Creatine 
ratios in the control group and NAWM (p<0 .2 )
3.4.3 Long echo time spectra: patients
There was a reduction of NAA/Cr ratios in acute enhancing lesions 
(1.35 ± 0.27 p=0.001) and NAWM (1.6 ± 0.22 p<0.02 ), compared to 
controls (1.84 ± 0.2 ). In 5 of these lesions there was a subsequent 
further reduction in NAA/Cr ratios (mean 1.16 ± 0.15) with maximum 
reduction seen between land 4 months (mean 2.2 months). In 6  of the
lesions, there was a later rise in the NAA/Cr ratio which began
between 4 and 6  months (Figure 3.7). The mean NAA/Cr ratio at 
presentation in these 6  lesions was 1.41 ± 0.27 falling to 1.1 ± 0.15, 
(p= 0.006) between 1 and 4 months and rising to 1.57 ± 0.22,( p= 0.001)
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between 4 and 8  months. The mean NAA/Cr ratio in all 8  lesions over 
time is shown in Figure 3.8.
The mean Cho/Cr ratio in the lesions when first studied was elevated 
(1.26 ± 0.26). This was significantly greater than in NAWM, (0.82 ± 
0.13, p=0.006) and controls,( 0.92 ±0.08, p=0.01). With follow up, the
Cho/Cr ratio returned to control levels in 5 out of 8  lesions over 2-6 
months. Although the mean Cho/Cr ratio was lower in NAWM compared 
to controls, this was not statistically significant (p<0.09).
Two of the lesions showed evidence of lac production. In one, lactate 
was visible at the first study, 3 weeks after symptom onset (Figure 
3.9). MRS one month later after Gd-DTPA enhancement had ceased 
showed resolution of the lac peak. In the second patient, spectra 
acquired from a large enhancing lesion 1 0  days after symptom onset 
showed no lac signal. However lactate was visible 1 month later when 
Gd-DTPA enhancement had ceased. The lac signal was no longer visible 
on spectroscopy 1 0  weeks after symptom onset.
3.5 DISCUSSION
The outstanding findings in this study are the regular detection of 
small lipid resonances in normal white matter using short echo time 
proton spectroscopy, the marked increase in lipid and protein 
resonances in association with the inflammatory phase of the new MS 
lesion and the partially reversible reduction in the NAA/creatine ratio 
in new MS lesions.
3.5.1 Increased lipid and protein resonances and the course of 
demyelination
This study has shown that small resonances at 0.9 and 1.3 ppm are a 
consistent finding in normal white matter of healthy individuals and MS
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patients. However, in large acute MS lesions, there was a marked 
increase in these resonances which have been assigned to lipid and 
macromolecules (Callies et al ., 1993; Behar et al., 1994).
When lipid peaks have been described in previous MRS studies in MS, no 
consistent relationship has hitherto emerged, either with the apparent 
age of the lesion or the presence of Gd-DTPA enhancement (Narayana et 
al ., 1992). Systematic serial observations have not however been 
performed. Moreover doubts have arisen as to whether the lipid peaks 
described have been due to extravoxel contamination from scalp. In the 
present study, two observations strongly suggest that these elevated 
peaks are not the result of scalp contamination: first, they were 
consistently and markedly higher in the acute lesions than from an area 
of NAWM closer to the scalp; and secondly they consistently decreased 
towards normal levels over several months.
There are a number of possible reasons why previous studies have not 
revealed increased lipid resonances in MS lesions. First, the lesions 
studied were often small and the voxels could have included a 
considerable proportion of NAWM resulting in partial volume effects. In 
the present study, large lesions were studied to avoid this problem. 
Secondly, a number of the non-enhancing lesions may have been chronic 
and the present study shows that abnormal lipid peaks will have 
disappeared in most lesions older than six months. Thirdly, a number 
of published studies have used echo times of 20 to 30 msecs. Lipid has 
a very short T 2 (Figure 4) and the increased signal may therefore not be 
as obvious at these slightly longer echo times especially if the lesions 
are several months old.
In the present study, increased lipid/protein resonances were seen in 
all lesions which displayed Gd-DTPA enchancement. Indeed, when 
lesion size allowed more precise resolution this increase was maximal
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in areas of enhancement (Figure 3.4 Spectrum B, Figure 3.3 Image B). 
Four lesions had not been apparent with or without enhancement on 
scans in the previous four weeks . Since in MS, enhancement indicates 
an increase in permeability of the blood-brain barrier in association 
with inflammation, ( Katz et al.,1993; Kermode et al., 1990) it can be 
inferred that demyelination occurs during the inflammatory phase of 
lesion development. Just how early in this phase it occurs, or whether 
it might precede it, is unknown, though recent observations on acute 
optic neuritis have shown that delayed evoked potentials (indicating 
the presence of demyelination) can be seen in enhancing lesions within 
48 hours of the onset of symptoms (S. Jones, R Kapoor, W.l. McDonald, 
unpublished observations). Since enhancement is the earliest
detectable event in the evolution of a new lesion and may precede the 
onset of symptoms (Barrat et al., 1988). it may be concluded that 
demyelination occurs early in its development.
Increased lipid/protein peaks were detectable in new lesions for 4 to 8  
months. Histopathological studies of demyelination (Adams et al., 
1 989 )  have shown lipid, in the form of triglyceride and cholesterol
ester, in lesions (which were originally symptomatic) symptomatic for 
up to twenty-six weeks. Similar observations in cerebral infarction 
(Stehbens 1972) show lipid laden macrophages which are detectable for 
a minimum of 3 months and in larger lesions for several years. The 
time course of increased lipid signal detected by proton MRS is thus 
compatible with the histologically determined time course of 
disappearance of lipid laden macrophages from areas of acute myelin
destruction. Such destruction is, of course, not peculiar to MS and it is
likely that abnormal lipid resonances will be found in a wide range of 
pathological conditions, including vascular and granulomatous 
disorders. Whether a pattern of spectral changes will emerge which is
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characteristic of Multiple Sclerosis remains to be seen.
A number of the acute lesions studied showed a resonance at 1.4 ppm. 
This resonance was more prominent at echo times of 20 and 30 msecs 
(Figure 3.4) indicating that it either has a longer T2 than the resonance 
at 1.3 ppm or is subject to J modulation (see Chapter 2 ). It is at present 
uncertain which metabolite this signal is due to, though the polypeptide 
thymosin 34, found in macrophages and in a subset of oligodendrocytes, 
produces resonances at this region of the spectrum (Kauppinen et al.,
1992). There is also some preliminary evidence that other 
macromolecules such as myelin basic protein may also produce 
resonances in this part of the spectrum (S. Davies, unpublished 
observations).
3.5.2 Reversible reduction in the NAA/Cr ratio
Previous studies have reported a reduction in the NAA/Cr ratio both in 
acute (Arnold et al ., 1992 a , Bruhn et al ., 1992, Miller et al ., 1991).) 
and chronic lesions (Matthews et al ., 1991, Van Hecke et al., 1991) in 
MS. In this study a reduction in NAA/Cr ratios was observed from 
acute lesions which was partially reversible over four to eight months 
(Arnold 1992). A simple loss of axons cannot account for these 
reversible changes. A number of factors may be involved. First, 
alterations in the chemical environment of the lesion could alter the 
relaxation times of NAA thus affecting signal intensity. This however 
is unlikely. If one assumes an approximate T 1 value of 1500 ms for 
normal cerebral white matter (Frahm et al., 1989b), it would require a 
75% increase in the T 1 of a lesion to explain the reduction in NAA signal 
observed in the current study. Such a change is improbable and 
spectroscopy of animals with acute EAE has shown no changes in the T 1 
or T2 values of NAA (Inglis et al., 1992).
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Secondly, Cr/PCr has been used in this study as an internal standard of 
reference since these two compounds are in chemical equilibrium and 
their total concentration should accordingly remain constant. Frahm et 
al(1989b) have calculated the cerebral concentration of total creatine 
as between 10 and 11 mM. If there were a reduction in the total Cr/PCr 
concentration which continued to fall after stabilisation of NAA levels, 
the NAA/Cr ratio would rise. This hypothesis is not however in keeping 
with a study using 3 ip  MRS in which there was an increase in PCr levels 
in MS lesions compared to healthy controls (Minderhoud et al., 1992). 
Furthermore a recent study by Husted et al (1994) using spectroscopic 
imaging has shown an increase in the levels of Cr from MS lesions and 
NAWM.
Thirdly, oedema is a prominent feature of the acute Multiple Sclerosis 
lesion (McDonald et al., 1992) and it is possible that the relative 
number of axons per unit volume in the white matter affected by the 
lesion is at first reduced and later increases as the oedema is absorbed. 
Another possibility which is testable experimentally, is that the 
function of the mitochondria (where NAA is formed ) (Patel and Clark 
1979) is reversibly impaired during inflammation (Brenner et al., 
1993b). Finally there is the possibility that adult 02A  progenitor cells 
containing NAA proliferate locally or migrate into the lesion in order to 
promote remyelination. Though the latter is extensive in some lesions 
(Prineas et a l ., 1993), it is not in others, and whether the magnitude of 
the change in NAA can be accounted for in this way is unknown.
3.5.3 Other observations.
The increase in Cho/Cr has previously been interpreted as evidence for 
demyelination because of the abundance of choline containing 
compounds in myelin. They are, however, abundant in all cell
membranes (Mcllwain and Bachelard 1985) and as the study of EAE (in
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which there is inflammation, but no demyelination) shows (Brenner at 
al., 1993), a large increase in the Cho/Cr ratio can be produced by the 
increased membrane turnover associated with inflammatory cellular
infiltration. This is likely to contribute to the changes in the Cho/Cr 
observed in this study and others (Matthews et al., 1991).
The elevation in the In/Cr ratio in the lesion group is in agreement with
previous studies (Bruhn et al .,1992; Koopmans et al.,1993). The 
function of In (an osmolyte) is uncertain and it is not yet clear why the 
In/Cr ratio is increased in MS.
3.5.4 Implications for monitoring therapy
The reliable detection of lipid breakdown by spectroscopy has 
implications for monitoring treatment in MS. Beta interferon reduces 
the frequency of evidence of new disease activity as judged by 
unenhanced MRI (IFNB Multiple Sclerosis Study Group 1993, Paty et al.,
1993), but its mechanism of action is uncertain. It will be important 
to determine whether it (and future putative therapeutic agents) have 
differential effects on inflammation and demyelination. The former 
can be assessed by Gd-DTPA enhanced MRI. the results of this study 
would indicate that it may be possible to monitor demyelination by 
short echo time proton MRS. The observation of abnormalities in NAWM 
may be due to the presence of microscopic demyelination (Allen 1991) 
and is thus a potential measure of the extent of the disease process and 
possibly a prognostic indicator. Accordingly, it will be important in 
future studies to monitor not only the visible lesions, but the 
apparently uninvolved white matter as well.
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LEGENDS 
Figure 3.1 A
Proton spectra from a healthy 28 year old female control taken from 
periventricular white matter. The upper spectrum is at an echo time (TE) of 10 
ms. The lower spectrum is at a TE of 135 ms.
Figure 3.1 B,C
T2 weighted NMR scan (TR 3000 ms, TEf 80ms) and short echo spectrum (Tr 
2secs, TE 10ms.) from a 17 year old female with a lipoma in the quadrigeminal 
cistern. The spectrum taken from a voxel centred on the lipoma shows 
resonances from the methyl lipid group at 0.9 ppm and from the methylene group 
at 1.3 ppm.
Figure 3.2
Short echo time spectra (TR 2 secs, TE 10 ms ) from a 48 year old female with 
clinically definite, relapsing remitting, Multiple Sclerosis. The upper spectrum is from 
a large gadolinium enhancing lesion which had been clinically symptomatic for 10 
days. The lower spectrum is from an area of normal appearing white matter 
lateral to the lesion and nearer the scalp.
Figure 3.3 Images A,B,C and D.
Magnetic resonance images and spectra fom a 36 year old female with clinically 
definite, secondary progressive, Multiple Sclerosis. Images A, B and C are T2 
weighted scans (TR 3000 ms, TEf 80ms) which show the respective volumes of 
interest from which spectra A, B and C were obtained (see main text). Image D is 
a Ti  weighted scan (TR 500 ms, TE 40ms) showing the area of Gd-DTPA 
enhancement within the lesion from which Spectrum B was obtained. The increased 
lipid resonances are maximal in the area of Gd-DTPA enhancement.
Figure 3.4
Magnetic resonance spectra from an acute enhancing lesion. Spectra A is from a 
voxel encompassing the majority of the lesion. Spectra B is from the centre of the 
lesion as shown in Figure 3.3B showing marked evidence of myelin breakdown 
products. Spectra C is fro the non-enhancing area shown in Figure 3.3 C showing 
normal resonances at 0.9 and 1.3ppm.
Figure 3.5
Serial short echo time spectra (TR 2secs, TE 10ms) at two monthly intervals 
taken from an acute lesion showing gradual resolution of lipid resonances over 
time. The lower spectrum is from an area of normal appearing white matter 
lateral to the lesion collected at the time of the first study - 10 days after 
symptom onset.
Figure 3.6
Proton spectra from the same lesion as Figure 3.2. These spectra were obtained 
at progressively increasing echo times from 10ms to 135ms and show the 
resultant decrease in lipid signal at 0.9 and 1.3 ppm as the echo time increases. 
They also show a resonance at 1.4 ppm at shorter echo times.
Figure 3.7
Serial long echo spectra (TR 2 secs, TE 135ms) taken at 1-2 monthly intervals 
from an acute lesion showing a fall in the NAA signal relative to creatine and then a 
subsequent rise over time. . The lower spectrum is from a healthy age matched 
control.
Figure 3.8
Mean NAA relative to creatine ratio of the 8 acute lesions studied over time.
Figure 3.9
Proton MRS (TE 270ms,TR 2000ms) from the centre of an acute lesion showing 
evidence of increased lactate at 1.3ppm.
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Serial MRS of acute MS lesion
Voxel 8 mis TR 2secs. TE 10msecs.
NAA
Cho
Ins
CH3
lipid
CH2
lipid
8 months
6 months
4 months
2 months
10 days
NAWM
3.0 2.0
ppm / chemical shift
87
Figure 3.6
MRS of acute lesion at increasing echo times 
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Figure 3.8
mean NAA / Cr ratio
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CHAPTER 4
PERSISTENT FUNCTIONAL DEFICIT IS ASSOCIATED WITH AXONAL
LOSS IN MULTIPLE SCLEROSIS AND AUTOSOMAL DOMINANT 
CEREBELLAR ATAXIA
4.1 SUMMARY
Proton MRS and MRI were carried out in eleven patients with multiple 
sclerosis (MS) who had clinical evidence of severe cerebellar deficit, 
eleven MS patients (of similar age and disease duration) who had 
minimal or no signs of cerebellar involvement, eight patients with 
autosomal dominant cerebellar ataxia (ADCA) and in 11 healthy 
controls. In all subjects MRS was localised to cerebellar white matter 
(volumes of interest 3 - 6ml). Metabolite concentrations were 
calculated using the fully relaxed water spectrum as an internal 
standard of reference. The patients also underwent MR imaging to 
assess cerebellar volume and (in the two MS groups) lesion volume 
within the posterior fossa. MRS from cerebellar white matter showed a 
highly significant reduction in the concentration of N -acetylaspartate 
(NAA) (a neuronal marker) in the MS group with cerebellar deficit 
compared to the MS group with minimal or no signs of cerebellar 
involvement and healthy controls. Follow-up MRS performed in six of 
the MS patients nine months later showed no change in the [NAA]. The 
ADCA group showed a significant reduction of NAA from a region of 
cerebellar white matter and also a reduction in the concentration of 
Cho. The MS group with severe cerebellar deficit and the ADCA group 
both had significant cerebellar atrophy (suggesting axonal loss) 
compared to the MS patients with minimal or no signs of cerebellar 
deficit and the healthy controls. The MS patients with cerebellar 
deficit had a significantly greater lesion volume in the posterior fossa
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although the proportion of the spectroscopic voxel occupied by lesion 
was small suggesting that the observed reduction in NAA is also due to 
axonal loss from NAWM.
These results support the hypothesis that axonal loss is important in 
the development of clinical disability in MS.
4.2 INTRODUCTION
The mechanisms producing permanent disability in MS are poorly 
understood. Although conventional MRI has provided a sensitive means 
of following the evolving pathological process, studies using MRI have 
shown only a weak relationship between brain MRI lesion load and 
clinical disability (Li et al 1984). This discordance may be due to 
several factors ( Kermode et al., 1990, McDonald et al 1992). First, the 
location of lesions is likely to be important since many lesions occur in 
areas of the brain which are not clinically eloquent (Phadke and Best., 
1983). Secondly, there may be inaccuracies in the measurement of 
lesion load. Thirdly the degree of disability may also be influenced by 
spinal cord involvement - as shown by the modest though significant 
correlation between clinical disability and cord atrophy (Kidd., et al 
1993). Finally, there is considerable pathological heterogeneity 
between lesions (Dawson, 1916; Allen, 1991; Barnes., et al 1991). 
Conventional MRI does not differentiate between the various
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pathological processes occurring within an MS lesion which may include 
inflammation, oedema, demyelination, remyelination, gliosis and axonal 
loss. Of these, demyelination and axonal loss have been suggested as 
the main factors responsible for the development of disability. There 
is however electrophysiological evidence to suggest that demyelination 
may not contribute much to permanent loss of function; MS patients 
with optic neuritis may show marked prolongation in the visual evoked 
potential (indicating demyelination) despite normal visual acuity in the 
affected eye (Halliday et al., 1972). It is not yet proven whether 
axonal loss is the key pathological event which determines the 
development of disability in MS.
The aim of the present study is to determine using proton MRS whether 
the concentration of NAA in the cerebellum can differentiate between 
MS patients with signs of severe cerebellar deficit and those patients 
with little or no clinical evidence of cerebellar involvement. As a 
pathological control group in which cerebellar neurones are known to be 
lost (Schut and Haymaker 1951; Hoffmann et al., 1971) a number of 
patients with ADCA have also studied.
4.3 MATERIALS AND METHODS
4.3.1 Patients
Patients with clinically definite MS (Poser 1983) and ADCA (Harding 
1982) were recruited from the National Hospital for Neurology and 
Neurosurgery . The study was approved by the Joint Ethics Committee 
at the Institute of Neurology and the National Hospital for Neurology 
and Neurosurgery, London. Informed consent was obtained from all 
patients prior to each study.
The patient groups were defined as follows:
(1) 11 MS patients with marked upper limb cerebellar incoordination 
and/or gait ataxia. These patients were classified on the Kurtzke 
(Kurtzke, 1983) functional cerebellar scale between 3-5. All patients 
in this group had evidence of marked cerebellar deficit for one year or 
more. These patients had a median age of 37 years (range 25 - 44) and 
a median disease duration of 6 years (range 2- 34 years).
(2) 11 MS patients with minimal or no signs of cerebellar deficit. These 
patients were classified on the Kurtzke functional cerebellar scale as 0 
or 1. These patients had a median age of 32 years (range 22 - 56) and a 
median disease duration of 6 years (range 3 - 20 years).
(3) 8 patients with ADCA. These patients had type 1 ADCA (n=5), two
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with the SCA 1 mutation (Giunti et al., 1994), two with the SCA 3 
mutation (Kawaguchi et al., 1994), one with no known mutation and 
three patients with the pure form of cerebllar degeneration (type 3) 
using the classification devised by Harding (1982). The median age in 
this group was 46.5 years (range 25 -65 years) with a median disease 
duration of 6 years (range 3 years - 22 years)
In addition 11 healthy controls with a median age of 31 years (range 24- 
48 years) were studied. Each patient underwent a full neurological 
examination and in the MS patients a kurtzke cerebellar functional 
system and EDDS score were obtained.
4.3.2 Magnetic resonance imaging and spectroscopy
Both MRI and MRS were were carried out on a Signa 1.5 Tesla system
(General Electric, Milwaukee, Wl) without contrast enhancement.
Sagittal images:
T-j weighted 3mm contiguous slices covering the posterior fossa were 
collected [repetition time (TR) 640ms, echo-time (TE) 11ms].
Axial images:
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A proton density weighted scan [TR 5000ms, effective TE (TEef) 
18/78ms] (5mm slices, 2.5mm interspace, 256x256 matrix, echo train 
length 8) was collected. Finally, contiguous axial slices were collected 
through the posterior fossa [TR 2000ms TEef17m s] (3mm, 256x256 
matrix, echo train length 8). The axial posterior fossa scans of the 
two MS groups were analysed while unaware of the clinical details. 
All intrinsic lesions in the posterior fossa were documented. These 
were divided into anatomical site: cerebellar hemispheres and 
peduncles, medulla and pons and midbrain. Lesions that fell within the 
spectroscopic volume of interest were also recorded. A lesion load for 
the individual sites and total posterior fossa lesion load were then 
determined using a semi-automated contouring programme which 
segmented lesions (“Dispimage”, DL Plummer, UCL, London, UK). The 
same contouring programme which allowed exclusion of cerebrospinal 
fluid (CSF) between the folia was then used on the Ti weighted sagittal 
slices through the posterior fossa to determine the cerebellar volume. 
This was carried out by the authors who was unaware of patient 
identity at the time of analysis.
MRS
After imaging, a volume of interest localised to the cerebellar white 
matter was prescribed ranging in size from 3.5 to 6ml (Figure 4.1). In
the patient groups the cerebellar hemisphere ipsilateral to the more 
ataxic side was chosen. The size and shape of each volume was 
adjusted to avoid inclusion of grey matter and cerebrospinal fluid. In 
both MS groups the region of interest included lesions (when present) 
and NAWM. An MRI of the voxel was then obtained to ensure accurate 
localisation. Water suppressed 1H spectra were obtained using a STEAM 
sequence. Acquisition parameters were TR 2000 ms, TM 12ms, TE 
135ms. 384 averages were collected using an 8 step phase cycle in ~
12 minutes. 1024 points were collected, with a spectral width of 750 
Hz. Data processing included 1 Hz. line broadening for filtering, 
Fourier transformation, and zero order phase correction. Peak areas 
were determined using a line-fitting programme (“SA / GE”, G.E. 
Milwaukee W.I.). Peaks were fitted to a Gaussian line shape using a 
Marquardt fitting procedure. Absolute concentrations for the 
metabolites were calculated using the fully relaxed water signal as an 
internal standard of reference (Christiansen et al 1993)- Metabolite 
concentrations [met] were calculated as described in Chapter 2 and 
appendix A
Statistical analysis was performed with a Mann-Whitney confidence 
interval and test. Results are expressed as a median value together 
with the range and p value. A Spearman’s rank correlation test was 
also used and results are expressed as an r value together with levels
of significance.
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4.4 RESULTS
4.4.1 MRS
In the MS patients with severe ataxia, there was a highly significant 
reduction in the median concentration of N-acetylaspartate (NAA) 
(6.7mM, range 4.58 - 8.93mM) in the cerebellar white matter compared 
to the controls (9.6mM, range 8.3 - 10.8mM, p=0.0002) (Figure 4.2 and 
Table 4.1). In contrast, the concentration of NAA in the MS patients 
without cerebellar deficit (median 9.74mM, range 9.25mM - 11mM) 
showed no significant difference from the control group (p>0.4) (Figure 
4.3 and Table 4.2). The patients with hereditary ataxia also showed a 
significant reduction in the median [NAA] from cerebellar white 
matter (6.82mM, range 3.55 - 7.96mM, p=0.0003) compared to the 
control group (Figure 4.4). The NAA values for the four groups are 
shown as a scatter graph (Figure 4.5). The Cho concentration showed no 
significant change in either MS group compared to the controls. The 
ADCA group, however, showed a significant median reduction in the Cho 
concentration (median 1.0mM, range 0.44 - 1.86mM) compared to the 
control group (median 1.56mM range 1.2 - 3.15mM, p=0.04) (Figure 4.4 
and Table 4.3). There was no significant correlation between [Cho], and
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[NAA], cerebellar volume or disease duration.
There was no significant difference between the median concentration 
of creatine in the cerebellar white matter from the control group 
(9.05mM, range 7.8 - 11.6mM) compared to the MS patients with 
cerebellar deficit (median 9.82mM, range 7.65 - 11.7mM, p.0.2) nor 
indeed the MS group without cerebellar deficit ( median 9.8, range 7,98 - 
11.0mM, p.0.2). The ADCA group also showed no significant difference 
in the median concentration of creatine (9.76mM, range 8.6 - 11.8mM) 
compared to the healthy controls.
Follow up MRS at nine months was carried out in 6 of the 11 clinically 
affected MS patients. The median concentration of NAA at follow up 
(median 7.42mM, range 5.04 - 8.73mM) showed no significant difference 
from the first study (median 7.45mM, range 5.88 - 8.93mM, p >0.4) 
(Table 4.1).
4.4.2 MSI
The cerebellar volumes for the MS patient groups are shown in Table 1 
and 2. In the ataxic MS group, there was a highly significant reduction 
in the median cerebellar volume ( 107, 865 sq mm, range 101, 574 sq 
mm - 131, 421 sq mm) compared to the control group (132, 003 sq mm, 
range 121, 278 - 143, 778 sq mm, p=0.0005). In contrast, the median 
cerebellar volume of MS patients who were clinically unaffected (
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median 128, 037 sq mm, range 112, 008 sq mm - 135, 750 sq mm ) 
showed no significant difference from the control group (p>0.05). The 
patients with ADCA also showed a significant reduction in the median 
cerebellar volume (94, 137 sq mm, range 61, 596 sq mm - 115, 434 sq 
mm, p=0.0003) compared to the control group (Table 4.3).
The posterior fossa lesion loads in the two MS groups are shown in 
Table 4.1 and 4.2. The median voxel lesion load in the MS group with 
cerebellar deficit (median 157sq mm, range 74 - 260 sq mm) was 
increased compared to the MS group without cerebellar deficit (median 
117 sq mm, range 0 - 263 sq mm, p>0.03) though this did not achieve 
statistical significance. When corrected for voxel size, the percentage 
of voxel occupied by abnormal signal was found to be moderately 
higher in the MS roup with cerebellar deficit (median 9%, range 5.2 - 
15.7%) compared the patient group with no cerebellar deficit (median 
5.9%, range 0 - 15.3%, p<0.05). There was also a significantly greater 
lesion volume in the total ipsilateral cerebellar hemisphere (p<0.008) 
and within the brainstem (p<0.009) in the MS patients with cerebellar 
deficit compared to the MS patients with no clinical cerebellar 
involvement.
Taking all MS patients together, there was a modest though significant 
negative rank correlation between the concentration of NAA from the 
cerebellum and both the Kurtzke extended disability status score
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(EDSS) (r -0.517, 0.02> p >0.01) (Figure 4.6) and the Kurtzke functional 
cerebellar score ( r -0.49, 0.05> p >0.02) (Figure 4.7). There was also a 
negative correlation between the concentration of NAA and lesion 
volume within the voxel (r -0.527, 0.02> p >0.01). Additionally, there 
was a positive correlation between [NAA} and cerebellar volume (r
0.438, 0.05> p >0.02). There was no rank correlation between lesion 
volume in the posterior fossa and kurtzke score though there was a
significant correlation between the total posterior fossa lesion volume
and the cerebellar functional score ( r 0.536, 0.02> p >0.01).
4.5 DISCUSSION
The outstanding findings in this study are the persistent reduction of 
[NAA] from cerebellar white matter together with cerebellar atrophy in 
the MS patients with severe cerebellar deficit.
4.5.1 Decreased [NAA] and cerebellar atrophy in the MS group with 
cerebellar deficit
This study has shown a significant reduction of [NAA] from cerebellar 
white matter and cerebellar atrophy in a group of patients with ADCA, a 
syndrome in which neuronal loss is known to occur within the
cerebellum, either as a result of pure cerebellar atrophy or as part of
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olivopontocerebellar atrophy (Schut and Haymaker, 1951; Hoffmann et 
al., 1971). The finding therefore of reduced cerebellar [NAA] together 
with cerebellar atrophy in the ataxic MS group is perhaps the most 
convincing evidence to date that neuronal loss has occurred primarily in 
those MS patients with irreversible disability.
It has been established that there is a persistent reduction of NAA in 
chronic MS lesions (Arnold et al., 1994). However the serial studies of 
acute MS lesions described in the preceding chapter has shown partial 
reversibility of the NAA/Cr ratio over four to eight months suggesting 
that at least in the inflammatory phase of the disease, factors other 
than axonal loss are partly responsible for the observed reduction of 
NAA (Brenner et al., 1993b).
Previous MRS studies have failed to show a correlation between the 
reduction of NAA within a volume of interest and the degree of clinical 
disability (Arnold et al., 1994). One explanation for this may be that 
studies to date have concentrated primarily on lesions and NAWM 
within the periventricular white matter of the cerebral hemispheres. 
Lesions in this part of the brain are often ‘clinically silent’ (Phadke et 
al., 1983) and therefore of less importance in the development of 
disability, as measured by the Kurtzke EDSS score which is strongly 
influenced by locomotor function.
In the present study, a reduction of [NAA] has been observed from
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cerebellar white matter in a group of 11 patients with severe 
cerebellar deficit, which in the six patients restudied after nine 
months was shown to be persistent. Such a persistent reduction makes 
axonal loss the most likely explanation for the low [NAA] observed in 
this group, supporting the hypothesis that axonal loss is an important 
mechanism in the development of irreversible clinical deficit in MS, a 
conclusion further supported by the observation of cerebellar atrophy 
in the MS group with cerebellar deficit.
An important issue to address is whether the MRS findings in this study 
are simply due to lesions within the region studied. This is unlikely for 
two reasons. First, only a modest increase in voxel lesion load was 
detected in the MS group with cerebellar deficit compared to the non- 
ataxic group and secondly, the median percentage of voxel occupied by 
abnormal signal in the ataxic patients was only 9%, compared with a 
median reduction in [NAA] of 30%. Such a disproportionate reduction of 
NAA may reflect axonal loss within the NAWM in the ataxic group. 
There was a significantly greater lesion volume in adjacent regions of 
the cerebellum and brainstem in these patients and therefore the 
decrease in NAA may in part arise from axonal damage by lesions 
located outside the spectroscopic volume of interest.
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4.5.2 Other findings
An unexpected finding in this study was the reduction of [Cho] from 
cerebellar white matter in patients with ADCA. [Cho] was below the 
control range in four of the eight patients. This was not associated 
specifically with any mutation or type of ADCA or clearly correlated 
with [NAA], disease duration or cerebellar volume. However, although 
the patient group was small there was a tendency for the patients with 
the longest disease duration and greatest degree of cerebellar atrophy 
to have the lowest values of [Cho] (Table 4.3).
As discussed earlier, the resonance observed at 3.2 ppm in the proton 
spectrum is not one compound but the combination of signal from a 
number of metabolites. These include free choline, phosphocholine, 
glycerophosphocholine, acetylcholine,
phosphatidylcholine sphingomyelin and betaine (Miller BL, 1991; 
Brenner et al., 1993a). Immunocytochemical studies have provided 
evidence for the existence of cholinergic transmission in the human 
cerebellum, with the detection of muscarinic receptors in the mossy 
fibres that terminate in the granular layer (Casanova et al., 1990). 
Mossy fibres account for about two thirds of the myelinated axons 
underlying the cerebellar cortex. It is conceivable that degeneration of 
these axons may explain the reduction of [Cho] that was observed in a 
number of patients with ADCA. Kish et al (1986) have shown a
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significant reduction of choline acetyltransferase from the cerebral 
cortex in patients with ADCA, suggesting a loss of cholinergic neurones 
projecting from the nucleus basalis. It is not yet known whether 
cholinergic neurones are lost from the cerebellum in ADCA.
The reduction in [NAA] from a clinically eloquent location and its 
correlation with disability suggest that spectroscopy may emerge as a 
relevant tool for monitoring axonal loss in MS, particularly in the 
context of treatment trials. In order to do this effectively it would be 
desirable to survey the whole brain rather than a small localised 
volume. Spectroscopic imaging techniques are now able to achieve this 
and are already being used in the study of MS (Arnold et al., 1992; 
Husted et al., 1994).
LEGENDS
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Figure 4.1
A proton density weighted scan [TR 5000ms TE 78ms] showing a volume 
of interest localised to the cerebellar white matter in an MS patient 
with no cerebellar deficit.
Figure 4.2
Magnetic resonance spectroscopy from cerebellar white matter in MS 
patient with severe cerebellar deficit (top spectrum) compared with 
healthy age-matched control.
Figure 4.3
Magnetic resonance spectroscopy from cerebellar white matter in MS 
patient with no cerebellar deficit (top spectrum) compared to healthy 
age-matched control.
Figure 4.4
Magnetic resonance spectroscopy from cerebellar white matter in 
patient with Autosomal dominant cerebellar ataxia (upper spectrum) 
compared to healthy control.
Figure 4.5
Scattergraph of apparent concentration of NA (mM) in multiple 
sclerosis patients, hereditary ataxia patients and controls.
Figure 4.6
Scattergraph of apparent concentration of NA (mM) compared to Kurtzke 
EDSS score in MS patients.
Figure 4.7
Scattergraph of apparent NA concentration (mM) compared to Kurtzke 
cerebellar functional score in MS patients
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Figure 4.1
An axial MRI scan (TR 5000ms, TE 78ms) through the posterior fossa, 
showing a spectroscopic volume of interest localised to the cerebellar 
white matter in an MS patient with no cerebellar deficit.
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Figure 4.2
MRS of cerebellar white matter in an ataxic MS patient 
v control. Volume 3.5ml TE 135ms TR 2.135secs
Cho
NA
MS patient with
cerebellar deficit
control
1.0
ppm chemical shift
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Figure 4.3
MRS of cerebellar white matter in MS patient (no ataxia) v control 
Volume 3.5 mis TE 135 ms TR 2.135 secs
Cho NA
MS patient no cerebellar signs
3.0 2.0 1.0 0.0
ppm chemical shift
Figure 4.4
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MRS in patient with ADCA Type 1 v control 
cerebellar white matter TE 135ms TR 2.135 secs. Volume 3mls
Cho
Autosomal dominant 
cerebellar ataxia
control
1.0
ppm chemical shift
115
Figure 4.5
[NAA] values in patients and controls
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Scattergraph of [NAA] 
v kurtzke score
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Figure 4.7
scattergraph of [NAA] 
v cerebellar functional score
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cerebellar functional score
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CHAPTER 5
1H MAGNETIC RESONANCE SPECTROSCOPY OF CHRONIC CEREBRAL 
WHITE MATTER LESIONS AND NORMAL APPEARING WHITE MATTER IN 
MULTIPLE SCLEROSIS
5 .1  SUMMARY
In order to explore further the hypothesis presented in the previous 
chapter that irrecoverable neurological deficit in MS is associated with 
axon loss, the apparent concentration of NAA (a neuronal marker) from 
cerebral white matter has been compared in four groups of MS patients 
classified as relapsing/remitting, secondary progressive, primary 
progressive, benign and a control group. In the MS patients with
relapsing/remitting disease (n=9) there was a highly significant
reduction of apparent NA (median 8.73mM, range 6.86mM - 10.74mM, 
p=0.0008) from an area of high signal compared to the control group
(median 11.97mM, range 10.55-14.5mM). In the MS patients with
secondary progressive disease (n=10),there was again a highly 
significant reduction of apparent NA (median 7.82mM, range 3.5mM - 
10.3mM, p=0.0003) from an area of high signal compared to the control 
group. In the MS patients with primary progressive disease (n=6) there 
was once again a highly significant reduction of apparent NA (median 
8.83mM, range 6.95mM - 9.89mM, p<0.002) from an area of high signal 
compared to the control group. In the MS patients with benign disease 
(n=6) however, there was no significant difference in the apparent NA 
(median 10.5mM, range 8.53mM - 12.8mM, p>0.05) from an area of high 
signal compared to the control group.
In the MS patients with benign disease (n=5) there was also no 
significant difference in the apparent NA (median 10.74mM, range
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8.58mM - 13.4mM, p>0.3) from an area of NAWM compared to the control 
group. In the MS patients with primary progrsessive patients however, 
there was a significant reduction of apparent NA from an area of NAWM 
(median 8.78mM, range 8.7mM - 12.38mM, p< 0.025) compared to the 
control group
There was a statistically significant inverse correlation between [NA] 
from lesions in the MS patients and disability as measured on the 
Kurtzke EDSS score r= -0.364, 0.05< p > 0.02
These findings support the hypothesis that axonal loss is important in 
the development of disability in multiple sclerosis. They also provide 
evidence for axonal loss in NAWM in patients with primary progressive 
disease
5 .2  INTRODUCTION
It is well recognised that the clinical course of multiple sclerosis (MS) 
may follow a number of patterns. The majority of patients have a 
relapsing, remitting course at onset though after a variable interval 
many will develop progressive disability on a background of superadded 
relapses(Thompson et al., 1992). In approximately 30% of patients 
however, the disease adopts a benign course where minimal disability 
is observed after 10 years from symptom onset (McAlpine., 196, Kidd et 
al., 1994a). In 10 to 15% of MS patients the disease process is 
progressive from onset (1y progressive disease) (Thompson et al., 
1991). These patients tend to be male, are older at the onset of 
symptoms and frequently present with a spastic paraparesis. Magnetic 
resonance imaging (MRI) studies in these patient groups have 
demonstrated important differences in the distribution, size and 
frequency of lesion development in these groups (Thompson et al., 1990, 
1991, Kidd et al., 1994a) together with differing degrees of blood brain
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barrier breakdown as evidenced by the presence of enhancement after 
the administration of gadolinium-DTPA (Kermode et al., 1990). 
However, to date there has been poor correlation between the degree of 
disability in the various MS patient subgroups and lesion load measured 
from conventional MR imaging (Li et al., 1984). From the results of the 
previous study (Chapter 4) it is possible to hypothesise that a 
sustained neurological deficit occurs in patients with primary and 
secondary progressive disease as a consequence of axonal loss 
occurring within lesions and also in areas of NAWM. A loss of neurones 
(cell bodies and axons) would be predicted to cause a persistent 
reduction in the concentration of NA in those patients with greatest 
disability. In order to test the hypothesis that irrecoverable 
neurological deficit in MS is associated with axon loss, the apparent 
concentration of NA has been compared in four groups of patients with 
differing degrees of disability classified as relapsing/remitting, 
secondary progressive, primary progressive and benign.
5 .3  Materials and Methods
5.3.1 Patients
Patients with clinically definite MS (Poser 1983) were recruited from 
the National Hospital for Neurology and Neurosurgery. The study was 
approved by the Joint Ethics Committee at the Institute of Neurology 
and the National Hospital for Neurology and Neurosurgery, London. 
Informed consent was obtained from all patients prior to each study.
The patient groups were defined as follows:
1. Relapsing-remitting (n=9): a history of relapses and remission 
without gradual deterioration, excluding benign cases. The patients had 
a median age of 31 (range 26 - 49 years) and a median disease duration 
of 3 years (range 1 -1 2  years). The median Kurtzke EDSS score was 3.5
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(range 2.0 - 5.5)
2. Benign (n=9): relapsing-remitting disease of at least 10 years 
disease duration with a disability scoring on the Kurtzke Expanded 
Disability Status Score (EDSS) of less than or equal to 3.0. The patients 
had a median age of 45 (range 39 - 63 years) and a median disease 
duration of 20 years (range 10 years -35 years). The median Kurtzke 
EDSS score was 2.5 (range 1.0 - 3.0)
3. Secondary progressive (n=10): patients presenting with a relapsing- 
remitting course with evidence of progressive deterioration for at 
least six months with or without superimposed relapses. The patients 
had a median age of 46 years (range 21 - 55 years) and a median 
disease duration of 13.5 years (range 5- 25 years). The median Kurtzke 
EDSS score was 7.0 (range 4.0 - 8.0)
4. Primary progressive (n=8): patients with progressive deterioration 
from symptom onset without any relapses or remissions. The patients 
had a median age of 42 years (range 37 - 47 years) and a median 
disease duration of 4.5 years (range 1.5 - 19 years). The median 
Kurtzke EDSS score was 6.0 (range 5.0 - 7.5)
Nine healthy controls were also studied.
5.3.2 Magnetic resonance imaging and spectroscopy
MRI and MRS were performed on a 1.5 T. G.E. signa whole body scanner 
using a standard quadrature head coil. The study commenced with a T2 
weighted fast spin echo imaging sequence (TR 3000 ms, TEf80 ms)
(5mm slices with 2.5 mm gap, 256x256 matrix, echo train length 8 ).
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After imaging, a volume of interest ranging between 3.5 ml and 6ml 
was prescribed which in the patient group incorporated a chronic high 
signal lesion and or an area of normal appearing white matter (NAWM). 
Lesions were determined to be chronic if they were unchanged on 
imaging over a period of six months or greater. Large lesions were 
chosen in order to minimise partial volume effects. If a sufficiently 
large enough lesion could not be identified on imaging then spectra 
were collected from NAWM alone. In several of the patients it was not 
possible to collect spectra from an area of high signal and NAWM 
because of time constraints and patient compliance. An MR image of 
the voxel was then obtained to ensure accurate localisation. Water 
suppressed 1H spectra were obtained using a STEAM sequence (Frahm et  
al  ., 1987 and1989a). Acquisition parameters were TR 2000 ms, TM 
12ms, TE 135ms. 256 averages were collected using an 8 step phase
cycle in ~ 9 minutes. 1024 points were collected, with a spectral 
width of 750 Hz. Shimming to a line width of ~1.5Hz. and water 
suppression were re-optimised for each new location. In the control 
group, spectra were collected from an area of periventricular white 
matter.
Data processing included 1.5 Hz. line broadening for filtering, Fourier 
transformation, and zero order phase correction. No baseline correction 
was applied. Peak areas were determined using a line-fitting 
programme (“SA / GE”, G.E. Milwaukee W.I.). Peaks were fitted to a 
Gaussian line shape using a Marquardt fitting procedure. Absolute 
concentrations for the metabolites were calculated using the fully 
relaxed water signal as an internal standard of reference (Christiansen 
et al 1993) as outlined in Chapter 2 and Appendix A.
Statistical analysis was performed with a Mann-Whitney confidence 
interval and test. Results are expressed as a median value together
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with the range and p value. A Spearman’s rank correlation test was 
also used and results are expressed as an r value together with levels 
of significance.
5 .4  RESULTS
5.4.1 MRS Lesions.
A spectrum from a healthy control is shown in Figure 1.
All patients in the relapsing-remitting and secondary progressive 
groups had lesions large enough to be studied with single voxel 
spectroscopy. In the benign group six patients had lesions large enough 
to study with MRS. Similarly in the primary progressive group, six 
patients had at least one lesion of sufficient size to study with 
spectroscopy.
Relapsing-remitting patients.
In the MS patients with relapsing remitting disease (n=9) there was a 
highly significant reduction of apparent NA (median 8.73mM, range 
6.86mM - 10.74mM, p=0.0008) from an area of high signal compared to 
the control group (median 11.97mM, range 10.55-14.5mM). The apparent 
creatine concentration in the same group from an area of high signal 
was reduced (median 8.3mM, range 7.0mM - 12.1mM, p=0.29) compared 
to controls (median 9.05mM, range 8.1 mM - 11.7mM) though this did not 
achieve statistical significance. There was no significant difference in 
the apparent choline concentration between the relapsing-remitting 
lesion group (median 1.73mM, range 1.27mM - 2.5mM, p=1) and controls 
(median 1.66mM, range 1.29mM - 1.91mM). (Figure 2).
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Secondary progressive patients.
In the MS patients with secondary progressive disease (n=10),there was 
again a highly significant reduction of apparent NA (median 7.82mM, 
range 3.5mM - 10.3mM, p=0.0003) from an area of high signal compared 
to the control group. The apparent creatine concentration in the same 
group from an area of high signal was reduced (median 7.89mM, range 
4.83mM - 10.3mM, p=0.1) though again this did not achieve statistical 
significance. There was no significant difference in the apparent 
choline concentration between the secondary progressive lesion group 
(median 1.78mM, range 1.36mM - 2.18mM, p.0.48) and controls. (Figure 
3 )
Primary progressive patients.
In the MS patients with primary progressive disease (n=6) there was 
once again a highly significant reduction of apparent NA (median 
8.83mM, range 6.95mM - 9.89mM, p<0.002) from an area of high signal 
compared to the control group. The apparent creatine concentration in 
the same group from an area of high signal was reduced (median 
7.39mM, range 6.47mM - 12.4mM, p>0.08) though again this did not 
achieve statistical significance. There was no significant difference 
in the apparent choline concentration between the primary progressive 
lesion group (median 2.0mM, range 1.3mM - 2.28mM, p>0.20) and 
controls. (Figure 4)
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Benign patients
In the MS patients with benign disease however there was no 
significant difference in the apparent NA (median 10.5mM, range 
8.53mM - 12.8mM, p>0.05) from an area of high signal compared to the 
control group. The apparent creatine concentration in the same group 
from an area of high signal was reduced (median 7.7mM, range 5.96mM - 
11mM, p>0.4) though again this did not achieve statistical significance. 
There was no significant difference in the apparent choline 
concentration between the benign lesion group (median 1.75mM, range 
1.08mM - 2.25mM, p>0.34) and controls. (Figure 5).
5.4.2 MRS normal appearing white matter 
Benign patients.
In the MS patients with benign disease (n=5) there was again no 
significant difference in the apparent NA (median 10.74mM, range 
8.58mM - 13.4mM, p>0.3) from an area of NAWM compared to the control 
group. The apparent creatine concentration in the benign group from an 
area of NAWM (median 9.15mM, range 8.68mM - 9.76mM, p>0.9)did not 
differ from the control group. There was no significant difference in 
the apparent choline concentration between the benign lesion group 
(median 1.82mM, range 1.72mM - 2.28mM, p>0.12) and controls.
Primary progressive patients.
In the MS patients with primary progrsessive patients however, there 
was a significant reduction of apparent NA from an area of NAWM 
(median 8.78mM, range 8.7mM - 12.38mM, p< 0.025) compared to the 
control group (Figure 6). The apparent creatine concentration in the 
primary progressive group from an area of NAWM (median 8.9mM, range
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6.46mM - 9.49mM, p>0.5)did not differ from the control group. There 
was no significant difference in the apparent choline concentration 
from NAWM in the primary progressive lesion group (median 1.44mM, 
range 0.96mM - 2.53mM, p>0.14) and controls.
Due to time constraints, it was not possible to collect spectroscopic 
data from NAWM in the relapsing-remitting and secondary progressive 
patients.
There was a small but nevertheless significant inverse correlation 
between [NA] from lesions in the MS patients and disability as 
measured on the Kurtzke EDSS score r= -0.364, 0.05< p > 0.02
5 .5  DISCUSSION
There are three findings of note in this study. The first is the relative 
preservation of [NA] from lesions in the benign MS patients compared to 
[NA] from lesions in the primary progressive, secondary progressive, 
relapsing remitting patients and NAWM from the control group. The 
second finding of note is small but nevertheless significant correlation 
between the reduction of [NA] from an MS lesion and the degree of 
disability measured on the Kurtzke score. Finally, this study has shown 
a reduction of [NA] from NAWM in the primary progressive group of MS 
patients compared to the preservation of [NA] from NAWM in the benign 
group of MS patients and healthy controls. These findings will now be 
discussed.
5.5.1 [NA] in MS lesions
Lesions from the patient groups with progressive and 
relapsing/remitting MS showed a significant reduction in the median
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[NA]. The demonstration of a reduced [NA] from MS lesions in these 
patient groups is in keeping with the observations in Chapters 3 and 4 
and is consistent with other reported studies (Arnold et al, 1990b, 
1992a; Miller et al, 1991; Husted et al, 1994).
However an original observation in the present study is the relative 
preservation of [NA] from lesions in MS patients with benign disease. 
The incidence of benign MS varies in different series from between 15 
and 40% (McAlpine., 1961, Confraveux et al., 1980, Thompson et al., 
1986). The pathophysiological mechanisms that lead to a benign
course are not fully understood. MRI studies in brain (Thompson et al., 
1990) or spinal cord (Kidd et al., 1993) have shown little or no relation 
between disability and lesion load. It does seem however that new or 
enlarging MS lesions show significantly less gadolinium enhancement 
in MS patients with benign disease compared to relapsing remitting 
patients (Kidd et al., 1994a) suggesting a less marked inflammatory 
process in the evolution of the developing lesion in the benign group. 
Given that the principal component of NA is N acetyl aspartate, an 
amino acid almost exclusively localised within neurones and their 
processes, the relative preservation of [NA] from lesions in the benign 
group may reflect a relative preservation of axons in these lesions. It 
may be that the less marked initiating inflammatory event in benign MS 
produces less axonal disruption and a preserved capacity for axonal 
repair.
The patients in the primary progressive and secondary progressive 
groups had a significantly higher median Kurtzke score compared to the 
patients in the benign group. Although the relapsing/remitting group 
showed a reduction in the median concentration of NA, three of these 
patients had a preserved concentration of NA (Figure 5.7) with minimal 
disability on the EDSS score. It is intriguing to speculate that these
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patients may in fact have a benign form of the disease over time and 
thus would be expected to have a preservation of NA in lesions. An 
alternative explanation for this finding is that the patients in the 
relapsing/remitting group who had higher levels of NA tended towards 
a shorter disease duration, though not invaraiably so (Table 1, patient 
10). Nevertheless, this observation at least raises the possibility that 
MRS may have some predictive role in determining disability in MS.
5.5.2 Correlation between the reduction of [NA] from an MS lesion and 
the degree of disability measured on the Kurtzke score
This study has also shown a weak correlation between the reduction of 
[NA] from MS lesions and increased disability as measured on the 
Kurtzke EDSS score (Figure 8). That such a modest correlation was 
found is not suprising. Previous investigators have failed to show a 
correlation between a reduction in NAA from chronic lesions and 
disability (Arnold 1994), probably because, as in the present study, 
lesions and NAWM in the periventricular areas were examined which are 
not clinically eloquent (Phadke and Best, 1983) except in relation to 
cognitive function (Rao et al., 1989 Feinstein et al., 1993). The study 
described in the previous chapter concentrated on an area of the brain 
that was clinically eloquent and showed a stronger correlation 
between a reduction of NAA and the Kurtzke EDSS score. Furthermore a 
spectroscopic study of acute symptomatic lesions showed a strong 
negative correlation between reduction of NAA and disability (De 
Stefano et al., 1995)
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5.5.3 reduction of [NA] from NAWM in the primary progressive MS 
patients
The other finding of note in this study was the significant reduction of 
[NA] in NAWM in patients with primary progressive MS patients 
compared to NAWM from benign MS patients and white matter from 
healthy controls (Figure 6). In the study of acute lesions (Chapter 3) a 
reduction in the NAA/creatine ratio from normal appearing white 
matter was observed in patients with relapsing remitting MS. Such a 
reduction is likely to reflect microscopic abnormalities which have 
been documented in pathological studies (Allen, 1991). A diffuse 
pathological process in primary progressive MS may explain the 
tendency towards increased disability in these patients despite the 
relative lack of visible lesions observed with MRI (Thompson et al., 
1991, Revescz et al., 1994).
5.5.4 Other findings
A post-mortem study by Davies and colleagues (1995) showed an 
absolute reduction of NA and creatine from MS lesions studied 48 hours 
after death whereas areas of NAWM studied showed normal metabolite 
levels. In the present study there was a tendency for the creatine 
concentration to be reduced in lesions from all MS groups though this 
did not achieve statistical significance. There was no significant 
difference between the creatine concentration from NAWM in the benign 
and primary progressive patients compared to controls.
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LEGENDS
Figure 5.1
Magnetic resonance spectroscopy (TR 2000ms, TE 135ms) from parietal 
white matter in healthy control.
Figure 5.2
Magnetic resonance spectroscopy (TR 2000ms, TE 135ms) from a 
chronic parietal white matter lesion in a patient with relapsing 
remitting MS (disease duration 12 years, Kurtzke EDSS 5.0, [NA] 
8.14mM).
Figure 5.3
Magnetic resonance spectroscopy (TR 2000ms, TE 135ms) from a 
chronic parietal white matter lesion in a patient with secondary 
progressive disease (disease duration 20 years, Kurtzke EDSS 7.5, [NA] 
6.97mM).
Figure 5.4
Magnetic resonance spectroscopy (TR 2000ms, TE 135ms) from a
chronic parietal white matter lesion in a patient with primary 
progressive disease (disease duration 4 years Kurtzke EDSS 6.0, [NA] 
7.37mM ).
Figure 5.5
Magnetic resonance spectroscopy (TR 2000ms, TE 135ms) from a
chronic parietal white matter lesion in a patient with benign disease
(disease duration 20 years, Kurtzke EDSS 3.0, [NA] 11.45mM).
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Figure 5.6
Magnetic resonance spectroscopy (TR 2000ms, TE 135ms) from an area 
of normal appearing parietal white matter in a patient with primary 
progressive disease (disease duration 4 years Kurtzke EDSS 6.0, [NA] 
9.9 mM).
Figure 5.7
Scattergraph of apparent [NA] compared to Kurtzke EDSS in MS patients 
with relapsing remitting disease.
Figure 5.8
Scattergraph of apparent [NA] from lesions compared to Kurtzke EDSS in 
MS patients from all subgroups.
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Disease duration,
Benign
Patients
1
2
3
4
5
6
Relapsing
Remitting
7
8
9
10 
1 1 
12
13
14  
1 5
Table 5.1
Kurtzke EDSS and [NA] in the MS lesion subgroups
disease duration EDSS [NA]
20 years 3.0 11.45
19 years 2.0 12.8
14 years 2.0 9.01
25 years 2.5 9.9
15 years 2.5 8.53
29 years 3.0 10.5
4 years 5.0 9.67
1 year 2.0 10.74
1.5 years 3.0 7.12
5 years 2.5 10.14
12 years 5.0 8.14
3 years 3.5 8.4
1.5 years 2.0 10.25
1 year 2.0 6.9
1 year 3.5 8.73
133
Disease duration, 
2y
progressive 
patients  
1 6
1 7
18
1 9
20
21
22
23
24
25
iy
progressive
patients
26
27
28
29
30
31
Table 5.1 (continued)
Kurtzke EDSS and [NA] in the MS lesion subgroups
disease duration EDSS [NA]
14 years 4.0 10.3
7 years 5.5 3.5
20 years 7.5 9.97
20 years 7.5 6.97
13 years 8.0 5.4
25 years 7.0 7.22
7 years 4.5 8.47
24 years 4.0 7.43
7 years 7.5 10.07
5 years 7.5 8.2
8 years 7.5 9.89
3 years 6.0 9.02
4 years 5.0 9.84
1.5 years 5.5 6.95
4 years 6.0 7.37
9 years 6.0 8.64
Figure 5.1
MRS from NAWM parietal lobe healthy control 
Volume 4mls TE 135ms TR 2000ms
NA
Cho
0.0
ppm chemical shift
Figure 5.2
MRS from a white matter lesion in a relapsing-remitting MS patient
Cho NA
2.0
ppm chemical shift
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Figure 5.3
MRS from a chronic WM lesion in a patient with 2y progressive MS
Cho
NA
3.0 2.0 1.0 0.0
ppm chemical shift
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Figure 5.4
MRS from a chronic WM lesion in a primary progressive MS patient
Cho
NA
3.0
ppm chemical shift
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Figure 5.5
MRS from a lesion in a patient with benign MS
NA
1.03.0 2.0
ppm chemical shift
Figure 5.6
MRS from NAWM in a primary progressive MS patient
NA
Cho
t -
3.7
i '  _  i • i
2.7 1.7 0.7
ppm chemical shift
[N
A
]
Figure 5.7
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Figure 5.8 141
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CHAPTER 6
1H MAGNETIC RESONANCE SPECTROSCOPY OF SYSTEMIC LUPUS 
ERYTHEMATOSUS INVOLVING THE CENTRAL NERVOUS SYSTEM 
6.1 SUMMARY
In this study 13 patients with neurological manifestations of SLE with 
previous and/or current neurological or psychotic episodes were 
studied by MRI and 1H MRS together with psychiatric and cognitive 
assessment. MRI was abnormal in 7 patients, showing high signal 
lesions in the white matter and/or cerebral atrophy. Proton MRS 
centred on white matter lesions in 5 patients showed a reduction in 
the (NAA)/creatine ratio compared to NAWM in the SLE group and in 10 
healthy controls. This pattern of abnormality does not allow 
differentiation of SLE lesions from the chronic plaques occurring in MS. 
There was a very high frequency of current psychiatric morbidity in the 
SLE group: occurring in 12 of the 13 patients. There was no correlation 
between the presence of current psychiatric involvement and/or 
cognitive dysfunction and abnormalities detected with MRI or MRS.
6.2 INTRODUCTION
SLE is an autoimmune disease which frequently involves the nervous 
system (Johnson and Richardson; 1968 Harris and Hughes, 1985). 
Neurological manifestations include seizures, strokes or transient 
ischaemic attacks, cranial neuropathies, depression, psychosis and 
cognitive impairment (Baker, 1973). Some manifestations (e.g. optic 
neuropathy, transverse myelopathy) resemble those of MS. Brain MRI 
may show a variety of abnormalities including large infarcts or
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multifocal grey and/or white matter lesions, most commonly 
multifocal white matter lesions. This appearance is not specific (Miller 
et al., 1992) and similar lesions may be seen in MS, arteriosclerotic 
cerebrovascular disease and granulomatous disease.
A conservative estimate suggests that cognitive dysfunction occurs in 
approximately a quarter of patients with SLE attending an out-patient 
clinic (Hanly et al., 1992). This figure rises to 40% when active brain 
involvement is present and significantly exceeds that for related 
disorders without cerebral involvement, such as rheumatoid arthritis 
(Hanly et al., 1992). Similar prevalence figures have been found in 
children with SLE (Papero et al., 1990) suggesting that the degree of 
cognitive dysfunction is not age related. A wide array of cognitive 
abnormalities are found, but the most noticeable deficits are seen with 
tests of attention (Ginsburg et al., 1992).
In addition to the cognitive changes, psychiatric abnormalities 
frequently occur in SLE. Point prevalence has ranged from 21% (Hay et 
al., 1992) to approximately 60% (Lim et al., 1988) with both studies 
showing a firm correlation between the presence of more minor 
psychiatric disturbance (anxiety and depression) and social stress. An 
earlier study (Lim et al., 1988) failed to find a correlation between 
affective and anxiety symptoms and the presence of cerebral pathology 
as demonstrated by MRI.
1H MRS has been carried out in a group of SLE patients with 
neurological involvement. The aims of the study were:
(i) to assess the value of MRS in the differential diagnosis of MS and 
SLE and
(ii) to determine if there was a correlation between spectral 
abnormalities on the one hand and neuropsychiatric manifestations on 
the other.
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6.3 PATIENTS AND METHODS
6.3.1 Patients
13 patients (10 women and 3 men) aged 22 - 58 (median 43 years) and 
10 healthy controls aged 20-55 years (median 38 years) were studied. 
SLE was diagnosed using the 1982 American Rheumatism Association 
criteria (Tan et al., 1982). Patients were recruited from two hospital 
departments of rheumatology on the basis of a past and/or current 
neurological or psychotic episode (see Table 1). In 12 there was a 
history of neurological symptoms in keeping with a diagnosis of 
cerebral SLE. These included acute episodes of ataxia and diplopia, 
dysphasia, hemiparesis or sensory disturbance and episodes of altered 
behaviour in keeping with complex partial seizures. Patient 12 had a 
history of psychotic illness without any definite neurological signs or 
symptoms attributable to SLE although there was a history of late 
onset migraine. In 10 patients there was evidence of neurological 
deficit at entry into the study. These included hemiparesis, 
myelopathy and brain stem involvement. Time since onset of 
neurological symptoms ranged from 6 months to 30 years (median 6.5 
years). Patients underwent formal neuropsychological, psychiatric and 
neurological examination. Three patients exhibited a parkinsonian 
syndrome, something not hitherto associated with SLE. In one this was 
possibly attributable to neuroleptic treatment. In the other two it was 
felt possible that it was either due to to coincidental idiopathic 
Parkinson’s disease or an unusual manifestation of cerebral lupus. The 
latter may be more likely since one of these patients exhibited signal 
change in both basal ganglia and Gd-DTPA enhancement in the right 
caudate nucleus on MRI (Figure 6.2), abnormalities which are not seen in 
idiopathic Parkinson’s disease.
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6.3.2 Magnetic resonance imaging and spectroscopy 
MRI and MRS were performed on a 1.5 T. whole body imager using a 
standard quadrature head coil. The study commenced with a T 2 - 
weighted fast spin-echo imaging sequence (TR 3000 ms, TEf80 ms) 
(5mm slices with 2.5 mm gap, 256x256 matrix, echo train length 8 ). 
In the patient group, spectra were then acquired from a volume of 
interest (3.5 - 6ml) centred on a white matter lesion if present and if 
not, from an area of normal appearing frontal white matter. On each 
occasion an MR image of the voxel was obtained to ensure accurate 
localisation. Water suppressed 1H spectra were obtained using a STEAM 
sequence. Acquisition parameters were, TR 2000 ms, TM 12ms, TE 10 
and 135ms. 256 averages were acquired using an 8 step phase cycle in
~ 9 minutes; 1024 points were collected, with a spectral width of 750 
Hz. Shimming to a line width of ~3Hz. and water suppression were re­
optimised for each new location. In the control group, spectra were 
collected from an area of frontal white matter. After collection of the 
spectroscopic data, in the patient group only, Gd-DTPA 0.1 mM./kg. was 
injected intravenously and T 1 -weighted Gd-DTPA-enhanced images 
were obtained (TR 500 ms, TE 20ms). The MRI and MRS examination 
took approximately 90 minutes.
Data processing included 1.5 Hz. line broadening for filtering, Fourier 
transformation, and zero order phase correction. No baseline correction 
was applied. Resonance areas were calculated by manual integration. 
Ratios for the various metabolites are expressed relative to Cr. NAA 
and Cho ratios relative to creatine  w ere calcu lated  
from the spectra collected at 135ms. Inositol ratios were calculated 
from spectra collected at 10ms. Statistical analysis was performed 
using a Mann-Whitney test. Values are expressed as a median together 
with the range.
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6.3.3 Psychiatric assessment
All 13 patients underwent psychiatric evaluation. Prior to undergoing 
psychiatric assessment, demographic data was collected on all 
subjects. This included marital and employment status, a family 
history of mental illness and previous or family history of psychiatric 
illness and/or substance abuse.
Subjects were then interviewed using the Present State Examination 
(PSE) and symptoms present only during the past month were noted. 
The 140 items of the PSE embrace both neurotic and psychotic 
psychopathology with the first 107 questions devoted to assessing 
subjective complaints and the remainder assessing objective evidence 
of mental state disturbance. The data generated by the PSE was then 
analysed using the CATEGO software programme (Wing et al., 1974)
6.3.4 Neuropsychological assessment
Cognitive assessment was carried out by a psychologist on 11 patients 
using measures of general intellectual ability and focal cognitive tests. 
Evidence of general intellectual deterioration was obtained by 
analysing discrepancies between estimates of optimal levels of 
general ability (premorbid I.Q.) and measures of general ability at the 
time of assessment (current I.Q.). Estimates of optimal levels of 
general ability were based on the patients’ reading vocabulary using the 
National Adult Reading Test (Nelson, 1971) and/or the Schonell Reading 
Test (Schonell 1942).
Focal cognitive deficits were defined on the basis of tests of memory, 
language, visual perception and “executive skills”. In addition, tests of 
speed and attention and tests considered to be sensitive to frontal lobe 
dysfunction were used i.e. word fluency tests (Benton, 1968) and a
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modified version of the Wisconsin Card Sorting Test (Nelson, 1976). 
Patients who scored below the 10th percentile for their age group or 
showed a significant discrepancy between their performance on focal 
tests and measures of general intelligence (I.Q.) were considered to 
have specific focal cognitive deficits.
6.4 RESULTS
6.4.1 MB1
MRI was performed In 13 patients and reported by a senior neuro­
radiologist . In seven patients, there were abnormalities on T2 weighted 
scans. In six of these patients there were discrete periventricular 
and/or subcortical white matter high signal lesions (Figure 6.1). 
Patient 10 also showed evidence of patchy high signal in the basal 
ganglia on T2 weighted imaging which enhanced after Gadolinium on T 1 
weighted imaging (Figure 6.2). In four patients (three of whom also had 
white matter lesions) there was evidence of mild generalised cerebral 
atrophy.
6.4.2 MRS
Spectroscopic data was collected from 12 patients, one patient being 
unable to remain in the scanner for the length of the spectroscopic 
examination. In five of the patients studied, MRS was localised to focal 
lesions seen on MRI and in the other seven from an area of NAWM. The 
lesions studied occupied 40-60% of the spectroscopic volume.
There was no significant difference in the mean inositol/creatine ratio 
from the spectra collected at 10ms in SLE lesions (median 0.59, range 
0.3-0.78) compared to NAWM in the SLE group (median 0.64, range 0.30- 
0.99, p>0.6) and NAWM from healthy controls (median 0.65, range 0.45-
1.01 p>0.8) (see Figure 3).
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The median Cho/Cr ratio was also normal in the SLE lesions (median 
1.08, range 0.97-1.17) compared to frontal NAWM in the SLE group 
(median1.06, range 0.76-1.4, p>0.8) and control NAWM (median 1.00, 
range 0.77-1.22, p>0.6). There was however a significant reduction in 
the NAA/Cr ratio in lesions (median 1.3, range 1.12-1.68,) compared to 
NAWM in the SLE group (median 1.74, range 1.6-2.08, p=0.01) and 
control NAWM (median 1.76, rangel .49-2.06, p<0.03) (see Figure 6.4). 
Only two patients had evidence of frontal lobe dysfunction on 
neuropsychological testing. These patients showed no evidence of 
frontal lobe lesions or atrophy on MRI and no reduction of the NAA/Cr 
ratio from an area of frontal NAWM compared to controls. Neither lac 
nor abnormally elevated lipid/protein peaks were observed in lesions or 
NAWM in the SLE patients or in the control group.
6.4.3 Psychiatric assessment
A family history of psychiatric illness was present in the first degree 
relatives of four subjects and second degree relatives of one more. No 
patients had a history of substance abuse, though 10 had a past history 
of psychiatric problems necessitating consultation with a psychiatrist 
in all but one case. At the time of the study only one had insufficient 
psychopathology to warrant a psychiatric diagnosis. Of the remainder, 
four had had a psychotic illness within the past month (schizophrenia 
{1}; mania {1}; paranoid psychosis {1}; and psychotic depression {1}. 
While 8 subjects had experienced non psychotic disordrers (anxiety 
states {2}; neurotic depression {2} and retarded depression {4} ) during 
this period.
A closer look at the nature of the psychopathology was undertaken by 
collapsing the 140 individual PSE items into discrete categories such 
as anxiety (PSE items 11-18), concentration difficulties (19-22),
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depression (23-27), perceptual disorders (49-54). The symptoms which 
occurred most frequently are shown in Table 6.2.
Overall, there was no correlation between the presence of a psychiatric 
disorder (psychotic or neurotic) and abnormalities on MRI or MRS. Too 
few MRI lesions were present to allow any meaningful correlations 
between specific psychiatric symptoms and the location of brain 
lesions.
Of the four patients with a history of psychotic illness, three had 
normal imaging and one mild generalised atrophy. The one subject with
normal PSE had no lesions on MRI and normal spectroscopy.
Significantly, 3 of the 4 psychotic patients as opposed to 1 of 8
neurotic patients had a positive history of psychiatric illness in a first 
degree relative.
6.4.4 Neuropsychological assessment (Table 6.3)
In four of the 10 patients who underwent cognitive assessment there 
was a significant degree of deterioration on measures of general 
intellectual ability. Most of the patients with focal cognitive deficits 
showed a degree of general intellectual deterioration. However in one 
patient with evidence of visual memory impairment there was no 
observed deterioration in her general level of functioning. Patients 
who failed on one or more of the speed tests also showed impairment 
on general ability or focal cognitive testing. In five patients there was 
no evidence of deficit on any of the neuropsychological tests. In two 
patients with evidence of neuropsychological deficit MRI revealed high 
signal abnormalities on imaging. In two of the five patients with 
completely normal cognitive testing there were also discrete white
matter lesions on imaging. There was no correlation between 
neuropsychological deficit and the NAA/Cr ratio of lesions or of NAWM. 
Of two patients who showed impairment on tests sensitive to frontal
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lobe dysfunction, one had generalised cerebral atrophy with no white 
matter lesions present in the brain. The other patient had a normal MRI.
6.5 DISCUSSION
In this study of 13 patients with SLE and neuropsychiatric involvement 
it was found that:
(i) MRS showed a reduction of the NAA/Cr ratio in white matter 
lesions. There were no metabolic differences on MRS between NAWM in 
SLE and white matter from healthy controls.
(ii) There was no correlation between neurological, psychiatric or 
cognitive involvement and MRI or MRS abnormalities. These findings 
are now dicussed in turn.
6.5.1 Spectroscopy findings in SLE
In SLE, the areas of signal change observed on MRI probably represent 
areas of ischaemic infarction secondary to vasculopathy, the most 
frequent pathological finding at post mortem (Johnson and Richardson, 
1968; Hume-Adams and Duchen, 1992). A number of mechanisms are 
likely to contribute to the vascular changes seen in cerebral SLE, 
including hypertension, coagulopathy, embolism from cardiac 
vegetations and immune complex vasculitis (Berry and Hodges, 1965). 
The reduction of the NAA/Cr ratio observed in this study from areas of 
signal change may be the result of axonal dysfunction or more likely 
axonal loss in these regions given that the pathological basis of these 
lesions is probable infarction. Conversely, the normal NAA/Cr ratio 
from frontal NAWM in the SLE patients suggests that there is unlikely 
to be a substantial degree of axonal dysfunction or loss in these 
regions.
In contrast to an earlier report (Haseler et al., 1991), there was no
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elevation of lac or lipids in any of the lesions studied, nor were
significant changes seen in the ratio of Cho/Cr in either lesions or in
NAWM. The lack of elevation of the Cho/Cr ratio in the SLE lesions 
suggests that they were not inflammatory or that cellularity was not
increased at the time they were studied. This is in contrast to the
elevation of Cho/Cr ratio observed in acute MS lesions (Chapter 3). It 
is likely, however, that most of the SLE white matter lesions observed 
in the present study were longstanding, since only one patient showed 
evidence of contrast enhancement on imaging. It is not possible from 
this study therefore to exclude an increase in Cho during the early 
stage of lesion development in SLE.
A low NAA/Cr ratio is very non specific and has been reported in a large 
number of neurological disorders including acute and chronic MS lesions 
(see Chapters 3,4 and 5). It would seem that MRS has little diagnostic 
value in evaluating chronic lesions in SLE. In MS, acute lesions may be 
associated with increases in choline, inositol, lipids and lactate. A 
study of similarly aged lesions in SLE is needed.
6.5.2 Lack of correlation between spectroscopic.
neuropsychological and neuropsychiatric features 
The fact that the majority of patients had recent or current evidence of 
psychiatric involvement suggests that psychiatric phenomena in SLE 
cannot, at least in most instances, be ascribed to structural brain 
disease detectable on MRI or MRS. This is in keeping with the findings 
of a previous study of 40 patients with SLE and psychiatric and 
neurological manifestations (Lim et al.. 1988) which also found no 
correlation between abnormalities on MRI and the presence of 
psychiatric symptoms. In the same study by Lim et al, a weak 
correlation was found between the presence of neurological disease and
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abnormalities on imaging. In the present study, no association was 
found between neurological involvement and the presence of 
abnormalities on MRI. This may reflect a smaller patient group or that 
the neurological disease in the patients in the present study was 
quiescent. Nevertheless, it is recognised that there may be marked 
discordance between the clinical findings in SLE and the 
neuropathological changes. As Berry (Berry, 1971) has observed 
“despite neurologic involvement clinically, there is often a 
disconcerting lack of gross and even microscopic findings in the 
nervous system on post mortem examination.” The pathogenesis of 
many of the cognitive, neurological and psychiatric syndromes in SLE 
remains poorly understood. It may be that other factors including 
genetic predisposition and the degree of perceived social and personal 
stress are of relevance.
In summary, proton MRS has shown a non-specific reduction in the 
NAA/Cr ratio within brain lesions in patients with neuropsychiatric 
SLE probably indicating axonal loss or dysfunction due to ischaemia or 
infarction. This pattern of abnormality does not allow differentiation 
of SLE lesions from the chronic plaques occurring in MS, a condition 
with which it may be confused clinically. It remains to be determined 
whether MRS can help differentiate lesions in these two conditions 
when they present acutely.
Legends
Figure 6.1
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T 2 -weighted MRI in a patient with SLE (patient 2), showing mild 
cerebral atrophy and high signal lesions in the periventricular and 
subcortical white matter.
Figure 6.2
T-i-weighted MRI of a patient with active neurological SLE (patient 11) 
showing patchy gadolinium enhancement centred on the right caudate 
nucleus.
Figure 6.3
Short echo time (TE 10ms) spectrum from patient 11 showing no change 
in the inositol/creatine and choline/creatine ratios in a periventricular 
white matter lesion compared to an area of NAWM in the same patient 
and from an age matched control. There is also no elevation of signal in 
the lipid region.
Figure 6.4
Long echo time (TE 135ms) spectrum from patient 12 showing a low 
NAA/creatine ratio from a volume centred on a white matter lesion 
compared to NAWM in the same patient and an area of white matter 
from an age-matched control.
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Table 6.2
Commonest occurring psychiatric symptomatology. 
symptom No. of subjects
(13)
1. w orry 13
2. anxiety 11
3. concentration difficulties 1 1
4. vegetative depressive features 10
(ie. sleep, appetite disturbance)
5. ir r ita b ility 6
6. obsessive-compulsive symptoms 5
7. perceptual abnormalities 5
8. depersonalisation 4
9. auditory hallucinations 3
10. visual hallucinations 3
11. olfactory hallucinations 2
12. delusions of reference 1
13. persecutory delusions 1
Ta
bl
e 
6.
3
Ne
ur
op
sy
ch
ol
og
ica
l 
De
fic
it 
in 
SL
E 
pa
tie
nt
s
0 4—> (0 
CD4—>
c
o
4->c0 4—< 4—«
CO
0
0
04—*
CO
CO
-a0
'0
Q.
E
O)c'■e
o
0
_C0 " D
3  g 
0
> »  
'■5 cO 0  0 => 
X  5=
°  -Dk.
o£
T3
0u.
'0Q.
E
T3
0
‘0Q.
E
co
Q. 0 O => O
0 v- 
• >  0 ^ Q.
© O)
S> C 0 ■ ==> EO) (0 
0 C
T3
0
*0
Q.
E
0^ 0
o 0
E "" 
0
U
o£
.E d
^ 0 00 O OE c c. ^ 0 0  0 D) £
Q- —
E © *2
C  0
o >
0 2
©  ©  ■
ra g 0! 0  ® —
■ScD -  
0 JZlk_
0>
0 
0 
0 o
■o
0v.0
Q.
E
T3
0
‘0
Q.
E
"D
0k_
0
Q_
E
04—*
0i_
0
T3O
E
CM CO lO
0
0 ]□
© p■o tO
E
04—>
0k.
0■D ~0
1 I
CO
O  CO 
co 1-  1-
im
pa
ire
d 
.
.
.
 
_ 
- 
im
pa
ire
d 
(1
/3
)
158
Figure 6.1
T 2 weighted axial MRI in SLE patient showing periventricular 
high signal lesions
Figure 6.2
T-iweighted axial MRI in SLE 
patient showing enhancing  
lesion in the head of the right 
caudate nucleus.
Proton MRS SLE frontal lesion v frontal NAWM v control 
Volume Volume 6mls TR 2secs TE 10msecs
NAA
lipids
lesion
NAWM
control
3.0 2.0 01.0
ppm chemical shift
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Figure 6 .4
Proton MRS in SLE. lesion v NAWM v control 
Volume 6ml TR 2secs. TE135ms
NAA
Cho
control
NAWM
frontal lesion
3.0 0.0
ppm chemical shift
CHAPTER 7
1H MAGNETIC RESONANCE SPECTROSCOPY AND MAGNETISATION 
TRANSFER IN ADULT CASES OF PHENYLKETONURIA
7.1 SUMMARY
Proton MRS, magnetization transfer (MT) and MRI were carried out in 
five patients with PKU and in eight healthy controls. MRS and MT were 
collected from areas of signal abnormality in the posterior trigone and 
NAWM. Metabolite concentrations were calculated using the fully 
relaxed water spectrum as an internal standard of reference. There 
were no statistically significant differences in the metabolite 
concentrations of NAA, Cho and Cr from lesions or NAWM in the PKU 
patients compared to controls. Quantifiable levels of phenylalanine 
(phe) were not detected using MRS in the PKU patients. A modest 
reduction in the median MT ratio was observed from areas of high 
signal on MRI in the PKU group compared to NAWM in the same patients 
and white matter of healthy controls. These findings strongly suggest 
that the lesions visible on MRI in adults with PKU are due primarily to 
oedema rather than demyelination or axonal loss.
7.2 INTRODUCTION
It is now well established that some degree of intellectual impairment 
may occur in patients with PKU despite early treatment (Smith et al., 
1990; Thompson et al., 1990b). Neurological deterioration has also 
been documented recently in a number of patients in whom diagnosis 
was delayed or or who had relaxed or discontinued their diet (Thompson 
et al., 1993). These patients invariably have white matter 
abnormalities on MRI. Similar, though usually less marked changes on 
MRI may occur in patients who have no obvious neurological dysfunction
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(Thompson et al., 1993). There is also some evidence to suggest that 
the severity of MRI change in such patients correlates with the degree 
of hyper-phenylalaninaemia at the time of investigation and with the 
duration of exposure to high levels of phe (Bick et al., 1991a). It has 
been suggested on the basis of early pathological studies, carried out 
on patients with severe neurological involvement, that these MRI 
abnormalities may represent areas of dysmyelination and/or 
demyelination (Poser and van Bogaert 1959;) though more recently, a 
reversible component to the MRI abnormalities has been demonstrated 
suggesting that oedema may also be involved in lesion pathogenesis 
(Thompson et al., 1990; Bick et al., 1991b) or that remyelination 
occurs. At present conventional MRI is unable to provide specific 
information regarding the various pathological processes occurring 
within lesions and normal appearing white matter in PKU. The high 
signal areas visible on conventional MR images are the result of a non­
specific increase in water content and therefore may occur secondary 
to a number of processes including oedema, gliosis, demyelination and 
axonal loss.
As discussed in previous chapters, proton MRS provides information 
regarding the chemical pathology occurring within the brain. 
Magnetisation transfer (MT) is another NMR technique which relies on 
the transfer of energy between highly bound protons within structures 
such as myelin and the very mobile protons of free water. This effect 
can be quantitated as a magnetisation transfer ratio (MTR) - and shows 
promise in being able to differentiate between the MRI changes of 
demyelination (Dousset et al 1992; Gass et al., 1994) from that of 
oedema (Dousset et al., 1992).
These two NMR techniques, MRS and MT, have been used in the present 
study in five adult patients with PKU and abnormalities on MRI.
163
7.3 MATERIALS AND METHODS
7.3.1 Patients
The study was approved by the Joint Ethics Committee at the Institute 
of Neurology and the National Hospital for Neurology and Neurosurgery, 
London. Informed consent was obtained from all patients prior to each 
study.
Patient details are shown in Table 7.1. Two of the patients were 
diagnosed by routine neonatal screening and had no neurological signs 
or symptoms. Three patients were diagnosed in early childhood because 
of developmental delay and had evidence of late neurological 
deterioration including cognitive impairment and pyramidal signs. Eight 
healthy controls were also studied
7.3.2 NMR Techniques
MRI, MRS and MT were performed on a 1.5 T. G.E. signa whole body 
scanner using a standard quadrature head coil. The study commenced 
with a T 2 weighted fast spin echo imaging sequence (TR 5000 ms, TEf 
80 ms) (5mm slices with 2.5 mm gap, 256x256 matrix, echo train 
length 8 ). After imaging, a volume of interest localised to the 
posterior trigone was prescribed ranging in size from 3.5 to 8ml 
(Figure 1). The size and shape of each volume was adjusted to avoid 
inclusion of grey matter and cerebrospinal fluid. The region of interest 
included lesions and NAWM. An MRI of the voxel was then obtained to 
ensure accurate localisation. Water suppressed 1H spectra were 
obtained using a STEAM sequence. An MR image of the voxel was then 
obtained to ensure accurate localisation. Acquisition parameters were 
repetition time (TR) 2.135 ms, mixing time (TM) 12ms, TE 10 amd 135 
msecs. 256 averages were collected using an 8 step phase cycle in 
approximately 13 minutes. 1024 points were collected, with a spectral 
width of 750 Hz. Spectra were then collected from an area of normal
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appearing white matter in the centrum semi-ovale of the parietal lobe 
using the same parameters. Shimming to a line width of about 3Hz. and 
water suppression were re-optimised for each new location. After 
collection of the spectroscopic data, Gd-DTPA, 0.1 mM./kg. was
injected intravenously and T-i-weighted images were obtained (TR 500 
ms, TE 40ms). Spectroscopic data processing included 2Hz. line
broadening for filtering, Fourier transformation, and zero order phase 
correction. Data processing included 1 Hz. line broadening for filtering, 
Fourier transformation, and zero order phase correction. Peak areas 
were determined using a line-fitting programme (“SA / GE” , G.E.
Milwaukee W.I.). Peaks were fitted to a Gaussian line shape using a
Marquardt fitting procedure. Absolute concentrations for the 
metabolites were calculated using the fully relaxed water signal as an 
internal standard of reference as set out in chapter 2 and Appendix A.
Magnetization transfer
MT images were obtained in the PKU patients and in eight healthy age- 
matched controls. Eight axial slices through the the hemispheres were 
obtained which covered the regions of brain from which MRS had been 
performed.
Dual spin-echo images were obtained (SE = 1,500/32/80, 8 slices, 5mm 
thickness, 2.5mm gap, 256 x 128 matrix, scan time = 10 min), with and 
without the application of a saturation prepulse to saturate the broad 
resonance of immobile macromolecular protons. The applied pulse was a 
4-lobed, 64msec sine pulse, 2-kHz off-water resonance. The energy 
deposited by this pulse ensured a good signal-to-noise in the calculated 
MT image. To ensure exact coregistration of the saturated and 
unsaturated images, scans with and without saturation were 
interleaved for each phase encoding step. From the two images, i.e.,
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without (Mo) and with (Ms) saturation pulse , quantitative MT ratio 
images were derived pixel by pixel according to the equation: MT ratio = 
(Mo -Ms / Mo). Signal intensities in the calculated image represented 
the amount of MT between the free and bound water pool.
In the healthy controls and PKU patients, MT ratios were calculated 
from an area of white matter from the occipital trigones and from 
parietal white matter in the centrum semi-ovale. The areas from 
which MT were calculated approximated in size and location to the 
spectroscopic volumes of interest in the PKU patients.
In the patient group the total lesion area was calculated from the 
proton density-weighted images using a semi-automated lesion 
detection programme .
Statistical analysis was performed with a Mann-Whitney confidence 
interval and test. Results are expressed as a median value together 
with the range and p value.
7.4 RESULTS
7.4.1 MB!
MRI revealed diffuse high signal abnormalities on T2 weighted images 
in all five patients. In four of the patients these changes were of a 
moderate degree and seen predominantly around the trigones. One 
patient aged 34, who had been off a restricted diet since age 10 and had 
evidence of recent neurological deterioration with cognitive 
impairment and gait ataxia showed more widespread white matter 
changes (Figure 7.1). There was no evidence of Gd-DTPA enhancement 
on the Ti weighted images in any of the patients studied.
7.4.2 MRS
MRS showed a normal concentration of NAA in areas of MRI abnormality 
(median 11.54mM, range 10.56 - 11.75mM, p>0.09) and from areas of
normal appearing white matter (median 11.54mM, range 10.85 -
11.57mM, p>0.15) in the PKU patients compared to age matched controls 
(median 12.3mM, range 10.77- 13.7mM). The concentration of Cho in the 
MRI lesions (median 1.66mM, range 1.3 - 1.88 MM, p> 0.3) and NAWM 
(median 1.84mM, median 1.33 -2.31 mM, p>0.3) was also normal
compared to control white matter (median 1.83mM, range 1.48 - 
2.28mM). The Cr concentration was lower in the lesion areas ( median 
7.83mM, range 6.0 - 9.01 mM, p>0.065) and from NAWM (median 8.18mM, 
range 6.5mM - 9.33mM, p>0.07) in the PKU patients compared to the 
white matter in the healthy controls ( 9.98mM, range 7.73 - 11.83mM) 
though this did hot achieve statistical significance. No abnormal peaks
were.pbserved which could be attributed to phe or to myelin breakdown
> . * ,  •
products in the PKU patients?
7.4.3 M I  . '
The*evwas a modest reduction of the MT ratio from the area of high 
signal observed on MRI at the occipital trigones (median 28.1, range 
25.8 - 28.7) compared to ’ the occipital white matter from healthy 
controls (median 29.7, range 28.9 - 32.4, p <0.02) (Figure 4). There 
was no difference in the MT ratio from parietal NAWM in the PKU
patients ( median 30.1,range 28.6 - 31.1, p>0.09) and from parietal
white matter in the control group (median 31.3, range 330.5 - 31.55)
7.5 DISCUSSION
The findings of interest in this study are,
(1) the preservation of [NAA] and other brain metabolites in brain 
lesions and NAWM in adult patients with PKU and
(2) the modest reduction of MT in brain lesions in the same group
7.5.1 Normal [NAA1
The preservation of NAA in patients with PKU suggests that there is
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very little axonal loss occurring either within the MRI visible lesions 
or in the NAWM. Such a ‘non-destructive’ pathological process is also 
suggested by the resolution of MRI lesions which has been demonstrated 
with strict dietary control (Thompson et al., 1993).
7.5.2 Moderate reduction of MT in PKU
There is good experimental evidence to suggest that MT is able to 
differentiate between oedema and demyelination. Dousset and 
colleagues (1992) were able to show a modest reduction of the MT ratio 
from brain lesions in guinea pigs after the induction of EAE (a condtion 
in which there is inflammation and oedema in the absence of 
demyelination). In contrast, a significant reduction in the MT ratio was 
observed from lesions in patients with MS. A study by Gass et al 
(1994) has shown that the degree of MT reduction in patients with MS 
correlates with clinical disability indicating that a low MT ratio is 
indicative of a more more destructive pathological process.
In the present study, only a modest reduction in the MT ratio from
lesions in patients with PKU. This degree of change is consistent with
an increased water content of white matter which is known to be 
elevated in the post-mortem brains of patients with PKU compared to 
controls (Crome et al., 1962). Such a modest reduction of MT also 
suggests that there is little demyelination or axonal loss occurring 
within lesions or NAWM in the PKU patients.
7.5.3 Other findings
Quantifiable levels of phe which is assigned at 7.37 ppm in the proton 
spectrum were not detected in the brains of PKU patients in the present 
study. Recent work by Kreiss et al (1994b) has suggested that it is 
possible to detect and measure phe concentration in vivo. This was
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achieved by collecting spectra from large volumes of interest (18 - 
80ml), collating the spectra from a number of PKU patients and then 
producing a “difference spectrum” from the PKU patients against that 
of a control. The voxel size in the present study was rather small 
(ranging from 4-6ml) and may explain the inability to detect phe in the 
PKU group.
There was no spectroscopic evidence of myelin breakdown products in 
the form of increased lipid or macromolecule resonances such as those 
observed in acute multiple sclerosis lesions (Chapter 3) suggesting  
again that active myelin breakdown is not a prominent pathological 
feature in PKU lesions.
In this study a normal concentration of Cho was found in lesions and 
NAWM in the PKU patients. When this data was initially analysed (Davie 
et al., 1994b) using metabolite/Cr ratios an increase was observed in 
the Cho/Cr ratio within lesions and NAWM. This can now be attributed 
to an absolute reduction of Cr in the PKU patients (which did not quite 
achieve statistical significance) rather than an absolute increase in the 
concentration of Cho. The normal concentration of NAA, Cho and 
creatine in the present study is in keeping with the preliminary 
spectroscopic findings in PKU of Kreiss et al (1994b).
Proton MRS has shown no significant alteration in [NAA], [Cr] and [Cho] 
fom areas of signal abnormality and NAWM in five adults with PKU. MT 
has shown a moderate though significant reduction of the MT ratio from 
an area of signal abnormality in the same group. These findings suggest 
that the lesions occurring in patients with PKU are the result of 
oedema rather than demyelination or axonal loss.
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LEGENDS
Figure 7.1
Axial MRI (TR 5000msa TE 80ms) in patient with phenylketonuria 
showing predominant high signal lesions in the posterior trigones. A 
spectroscopic volume of interest over the posterior trigone is shown.
Figure 7.2
Magnetic resonance spectroscopy from lesion in posterior trigone in 
patient with phenylketonuria (upper spectrum) compared to control.
170
Figure 7.1
T 2 weighted axial MRI in a patient with phenylketonuria. There are 
areas of high signal in the white matter which is most marked at the 
posterior trigones. A localised volume of interest where spectroscopic 
data was collected from (Figure 7.2) is shown.
Figure 7.2
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MRS from phenylketonuria lesion v control 
Volume 6 mis TE 135 ms TR 2 secs
Cho
control
ppm chemical shift
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CHAPTER 8
CONCLUSIONS AND IMPLICATIONS FOR FUTURE RESEARCH
8 .1  CONCLUSIONS AND IMPLICATIONS FOR FUTURE RESEARCH
Over the last 10 years 1H MRS has become established as a reliable, non- 
invasive in-vivo technique which has advanced our understanding of 
many conditions affecting the central nervous system. One particular 
advantage that MRS has over other techniques is that it provides unique 
quantitative information regarding a variety of normal metabolites and 
macromolecules and the effects of disease on the brain at a biological 
level.
In this thesis I have demonstrated that 1H MRS is able to identify 
biological markers of myelin breakdown in the form of cytosolic 
proteins and lipids early on in the evolution of the acute MS lesion. 
Furthermore these changes can be observed over time until their 
resolution. This provides a great advantage over conventional MR 
imaging which is unable to visualise normal myelin or the products of 
myelin degradation. The ability to detect demyelination is clearly 
important for a number of reasons. First, it may permit the unravelling 
of the precise relationship between inflammation and demyelination 
and whether these two processes invariably occur in all lesions. 
Secondly, it potentially provides a means of monitoring the effect of 
drugs on the two aspects of the pathological process - demyelination 
and axonal loss - which are most likely to be responsible for the 
development of disability in MS.
MRS has also provided a means of assessing neuronal dysfunction and 
loss by the measurement of NAA- a neuronal marker. In the preceding
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chapters it has been shown that NAA falls within acute MS lesions and 
that at least in some lesions one can demonstrate a partial recovery of 
NAA. This observation is significant since it implies that neuronal 
dysfunction may occur in the acute phase of the MS lesion and that such 
neuronal dysfunction has the potential to recover. It seems likely 
however that this potential for recovery is limited at least in those 
patients who go on to develop disability. In the study of MS patients 
with persistent functional deficit described in Chapter 4 the 
concentration of NAA was reduced and remained low after followup for 
greater than six months. This suggests that at some stage in the 
development of clinical progression axonal loss occurs. The precise 
relationship between reversible neuronal dysfunction and the 
development of axonal loss is as yet unclear. A further spectroscopic 
study following patients with early relapsing remitting MS who 
subsequently enter the progressive phase of the disease would clearly 
be useful in addressing this issue. It is also evident from the studies 
described in this thesis (Chapters 4 and 5) that there is a strong 
relationship between the presence of disability and loss of axons 
within MS lesions and normal appearing white matter as evidenced by a 
persistent reduction of NAA. The mechanisms that produce such axonal 
loss are unclear.
MRI has suggested that an inflammatory process is the first detectable 
event in the development of the majority of acute MS lesions. However 
it is not yet known whether this inflammatory process may occur as an 
isolated event whithout the subsequent development of demyelination. 
It is also not known whether axonal loss or demyelination (either in 
lesions or in NAWM) may occur in the absence of any preceding 
inflammatory phase. Spectroscopy may be able to help in addressing 
these issues since this technique can provide specific evidence of
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demyelination and axonal loss and can thus be compared with various 
markers of inflammation such as the development of gadolinium 
enhancement on MRI, an increase in the production of circulating 
cytokines or using 1H MRS and the elevation of choline containing 
products which (from animal studies in experimental allergic 
encephalomyelitis) are known to be elevated during inflammation in the 
absence of demyelination.
One limitation of the studies described in this thesis is that they have 
provided information on relatively small areas of the brain. In a 
multifocal disease it would clearly be beneficial to have biological 
information from other lesions and areas of NAWM. The development of 
chemical shift imaging (CSI) now allows the acquisition of 
spectroscopic data from several brain slices simultaneously. Instead 
of information from one voxel it is now possible to collect data from a 
32 x 32 square providing over 900 spectra which can be examined 
individually and also collated to make a metabolite image. Each 
individual voxel has a volume of approximately 1ml. The accompanying 
chemical shift image shows the concentration of NAA through a slice of 
brain at the level of the ventricles. Further such studies using CSI and 
MRI should help unravel the precise relationship between inflammation, 
demyelination, axonal dysfunction and / or loss and the evolving 
clinical course.
The degree of spinal cord involvement in MS is also likely to be an 
important factor in the development of disability. As with studies of 
the brain however, there remains poor correlation between the presence 
of lesions visible on conventional MRI and persistent functional 
deficit. There does nevertheless seem to be a strong association 
between spinal cord atrophy and disability. It seems probable that such 
atrophy in the spinal cord is secondary to axonal loss. A spectroscopic
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study of the spinal cord may be useful in supporting this hypothesis. 
Spectroscopy is however technically far more demanding in the spinal 
cord than the brain. The voxel size has to be less due to the smaller 
area involved. The spinal cord is subject to greater mobility making
data acquisition less reliable and the surrounding epidural fat produces
large resonances which swamp the signal from cord metabolites. These 
problems are nevertheless surmountable (Figure 8.1.) A future
spectroscopic study of the spinal cord in MS would be of interest 
particularly in patients with primary progressive disease in whom a 
proportionately greater extent of the disease load is found in the spinal 
cord
Finally, MRS may have a role to play in the differential diagnosis of
MS. Distinct MRS abnormalities were found in the cerebellum in 
patients with autosomal dominant cerebellar ataxia and in the 
cerebrum in patients with phenylketonuria. This was not the case in the 
spectroscopic study of lesions in patients with neuropsychiatric 
manifestations of SLE described in chapter 6. One possible explanation 
for the lack of discriminatory findings with MRS in SLE is that only 
patients with chronic lesions were studied. A study of patients with 
acute enhancing SLE lesions would be worthwhile to determine whether 
there are any specific changes between the MR lesions seen with MS and 
and those occurring in SLE. Clearly there are many other conditions 
which may mimic MS either clinically or radiologically where 
spectroscopic information might be useful in diagnosis. A 
spectroscopic study in patients with small vessel microvascular 
disease visible on MRI would be particularly useful since coincidental 
(presumed ischaemic) lesions are frequently seen when scanning 
patients who are in their fifties or older. Similarly, an MRS study of 
patients with neurosarcoidosis and Behget’s disease might provide
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further information allowing greater diagnostic specificity. Whether a
pattern of spectral changes will emerge which is absolutely 
characteristic of multiple sclerosis remains to be seen.
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LEGEND
Figure 8.1
Magnetic resonance spectroscopy (TR 2000ms, IE  270ms) from a 
volume of cervical spinal cord in a healthy control.
Figure 8.1
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N AA
0.01.02.03.04.0
ppm
Proton magnetic resonance spectroscopy obtained from 
the cervical spinal cord of a healthy control.
(3mls, TR 3000ms, TE 144ms) using a PRESS sequence.
179
REFERENCES
Ackerman JJH, Grove TH, Wong GG, Gadian DG, Radda JK. Mapping of 
metabolites in whole animals by P-31 NMR using surface coils. Nature 
1980; 283:167-170.
Adams CWM, Poston RN, Buk SJ. Pathology, histochemistry and 
immunocytochemistry of lesions in acute multiple sclerosis lesions. J 
Neurol Sci 1989; 92: 291-306.
Allen IV. Pathology of multiple sclerosis. In: Matthews WB, Compston 
A, Allen IV, Martyn CM, editors. McAlpine’s multiple sclerosis. Second 
edition. Edinburgh: Churchill Livingstone, 1991: 341-378.
Arnold DL, Matthews PM, Radda GK. Metabolic recovery after exercise 
and the assessment of mitochondrial function in vivo in human skeletal 
muscle by means of 3 ip  NMR. Magn Reson Med 1984;1:307-315.
Arnold DL, Shoubridge EA, Villemure JG, Feindel W. Proton and 
phosphorus magnetic resonance spectroscopy of human astrocytomas in 
vivo: preliminary observations on tumour grading. NMR Biomed 
1990a;3 :184-189.
Arnold DL, Matthews PM, Francis G, Antel J. Proton magnetic resonance 
spectroscopy of human brain in vivo in the evaluation of multiple 
sclerosis:assessment of the load of disease. Magn Reson Med 
1990b;14:154-159.
180
Arnold DL. Reversible reduction of N-acetylaspartate after acute 
central nervous system damage. In: Proceedings of the eleventh annual 
meeting of the Society for Magnetic Reonance in Medicine (abstract) 
1992a;1:643.
Arnold DL, Matthews PM, Francis GS, O’Connor, Antel J. Proton magnetic 
resonance spectroscopic imaging for metabolic characterisation of 
demyelinating plaques. Ann Neurol 1992b; 31: 235-241.
Arnold DL, Riess GT, Matthews PM, Francis GS, Collins DL, Wolfson C., et 
al. Use of proton magnetic resonance spectroscopy for monitoring 
disease progression in multiple sclerosis. Ann Neurol 1994; 36: 76-82.
Baker M Psychopathology in systemic lupus erythematosus: 1. 
Psychiatric observations. Seminars in arthritis and rheumatism 1973; 
3: 95.
Barnes D, Munro PMG, Youl BD, Prineas JW, McDonald Wl. The 
longstanding MS lesion. A quantitative MRI and electron microscopic 
study. Brain 1991 ;114: 1271-1280.
Barratt HJ, Miller D, Rudge P. The site of the lesion causing deafness in 
multiple sclerosis. Scand Audiol 1988; 17: 67-71.
Beckmann N, Turkalj I, Seelig J, Keller U. 13-C NMR for the assessment 
of human brain glucose metabolism in vivo. Biochemistry 1991 ;30:6362- 
6366.
Behar KL, Ogino T. Assignment of resonances in the 1H spectrum of rat
181
brain by two-dimensional shift correlated and J-resolved NMR 
spectroscopy. Magn Reson Med 1991; 17: 285-303.
Behar KL, Rothman DL, Spencer DD, Petroff OAC. Direct measurement of 
macromolecule resonances in short-TE localized 1H NMR spectra of 
human brain in vivo at 2.1 Tesla [abstract]. In: Proceedings of the 
Society of Magnetic Resonance 1994; 1: 310.
Benton AL. Differential behavioral effects in frontal lobe disease. 
Neuropsychologia 1968; 6: 53-60.
Berry RG, Hodges JH. Nervous system involvement in systemic lupus 
erythematosus. Transactions of the American Neurological Association 
1965 90: 231-233.
Berry RG. Lupus erythematosus. In, Minckler J. Pathology of the Nervous 
System. 1971 McGraw-Hill, New York, pp 1482-88.
Bick U, Fahrendorf G, Ludolph AC, Vassallo P, Weglage J, Ullrich K. 
Disturbed myelination in patients with treated hyperphenylalaninaemia: 
evaluation with magnetic resonance imaging. Eur J Pediatr 1991a; 150: 
185-189 .
Bick U, Ullrich K, Stober U, Moller H, Fahrendorf G, Ludolph AC, et al. 
MRI white m atter abnorm alities in patients with treated  
hyperphenlalaninaemia: disturbed myelination or toxic oedema?
Neuropediatrics 1991b; 22: 174.
182
Birken DL and Oldendorf WH. N-acetyl-L-aspartic acid: A literature 
review of a compound prominent in 1H-NMR spectroscopic studies of 
brain. Neurosci Biobehav Rev 1989;13:23-31.
Blakely RD, Robinson MB, Thompson RC, Coyle JT. Hydrolysis of the brain 
dipeptide N-acetyl-L-aspartyl-L-glutamate :subcellular and regional 
distribution, ontogeny, and the effect of lesions on N-acetylated-alpha- 
linked acidic dipeptidase activity. J Neurochem 1988;50:1200-1209.
Brenner RE, Munro PMG, Williams SCR, Bell JD, Barker GJ, Hawkins CP, 
et al. The proton NMR spectrum in acute EAE: the significance of the 
change in the cho:cr ratio. Magn Reson Med 1993a; 29: 737-745.
Brenner RE, Munro PMG, Williams SCR, Barker GJ, Miller DH, Landon DN 
et al. Abnormal neuronal mitochondria: a cause of reduction in NA in 
demyelinating disease [abstract]. In: the 12th Proceedings of the 
society of magnetic resonance in medicine 1993b;1:281.
Bruhn H, Frahm J, Gyngell M, Merboldt KD, Hanicke W, Sauter R, et al. 
Cerebral metabolism in man after acute stroke: new observation using 
localized proton NMR spectroscopy. Magn Reson Med 1989; 9: 126-131.
Bruhn H, Frahm J, Merboldt KD, Hanicke W, Hanefield F, Christen HJ, et 
al. Multiple sclerosis in children:cerebral metabolic alterations 
monitored by localised proton magnetic resonance spectroscopy in vivo. 
Ann Neurol 1992; 32:140-150.
Burri R, Steffen C, Herschkowitz N. N-Acetyl-L-aspartate is a major 
source of acetate groups for lipid synthesis during rat brain
183
development. Dev Neurosci 1991; 13: 403-411.
Cady EB, Costello AMdeL, Dawson MJ, Delphy DT, Hope PL, Reynolds EOR, 
et al. Non-invasive investigation of cerebral metabolism in newborn 
infants by phosphorus nuclear magnetic resonance spectroscopy. Lancet 
1983; i: 1059-1062.
Callies R, Sri-Pathmanathan RM, Ferguson DYP, Brindle KM. The 
appearance of neutral lipid signals in the 1H-NMR spectra of a myeloma 
cell line correlates with the induced formation of cytoplasmic lipid 
droplets. Magn Reson Med 1993; 29: 546-552.
Casanova MF, Zito M, Weinberger DR, Kleinman JE. An 
iimmunocytochemical and autoradiographic study on the cellular 
localisation of cholinergic markers in the human cerebellum [abstract]. 
Soc Neurosci abstr 1990; 16: 535.
Chance B, Eleff S, Leigh JS. Non invasive, non destructive approaches to 
cell bioenergetics. Proc Natl Acad Sci 1980; 77: 7430-7434.
Chang L, Mehringer CM.Buchthal SD, Miller BL, Myer H, Satz P, et al. 
Decreased N-acetyl compounds and increased myo-inositol in cocaine 
and polysubstance abusers. In: Proceedings of the Society of Magnetic 
Resonance 1994; 2: 579.
Chong WK, Sweeney B, Wilkinson ID, Paley M, Hall-Craggs MA, Kendall 
BE, et al. Proton spectroscopy of the brain in HIV infection: correlation 
with clinical, immunologic and MR imaging findings. Radiology 1993; 
188: 119-124.
184
Christiansen P, Larsson HBW, Henriksen O. Time dependence of N- 
acetylaspartate and choline containing compounds in multiple sclerosis 
[abstract]. 12th meeting of The proceedings of the Society of magnetic 
resonance in medicine. 1993;1:279.
Christiansen P, Henriksen O, Stubgaard M, Gideon P, Larsson HBW. In 
vivo quantification ob brain metabolites by 1H-MRS using water as an 
internal standard. Magn Reson Imaging 1993; 11: 107-118.
Confavreux C, Aimard G, Devic M. Course and prognosis of multiple 
sclerosis assessed by the computerised data processing of 349 
patients. Brain 1980; 103: 281-300.
Crome L, Tymms V, Woolf LI. A chemical investigation of the defects of 
myelination in phenylketonuria. J. Neurol Neurosurg Psychiatry 1962; 
25: 143-148.
Curatolo A, D’Arcangelo P, Lino A, Brancati A. Distribution of N-acetyl- 
aspartic and N-acetyl-aspartyl-glutamic acids in nervous tissue. J 
Neurochem 1965; 12: 339-342.
D’Adamo AF and Yatsu FM. Acetate metabolism in the nervous system. N- 
acetyl-L-aspartic acid and the biosynthesis of brain lipids. J 
Neurochem 1966; 13: 961-965.
Davie CA, Hawkins CP, Barker GJ, Brennan A,Tofts PS, Miller DH, et al. 
Detection of lipid in the brain of healthy subjects by proton NMR 
spectroscopy [abtract]. In: Proceedings of the eleventh meeting of the 
Society of Magnetic Resonance in Medicine 1992; Works in
185
Progress:1724.
Davie CA, Barker GJ, Tofts PS, Quinn N, Miller DH. Proton MRS in 
Huntington’s disease. Lancet 1994; 343: 1580.
Davie CA, Hawkins CP, Barker GJ, Brennan A,Tofts PS, Miller DH, et al. 
Serial proton magnetic resonance spectroscopy in acute multiple 
sclerosis lesions. Brain 1994a; 117: 49-58.
Davie CA, Barker GJ, Brenton D, Miller DH, Thompson AJ. Proton 
magnetic resonance spectroscopy in adult cases of phenylketonuria 
[abstract]. J Neurol Neurosurg Psychiatry 1994b; 57: 1292.
Davie CA, Wenning GK, Barker GJ, Tofts PS, Quinn N, Marsden CD et al. 
Differentiation of multiple system atrophy from idiopathic 
Parkinson's disease using proton magnetic resonance spectroscopy. 
Ann Neurol 1995; 37: 204-210..
Dawson JW. The histology of disseminated sclerosis. Transac Royal Soc 
Edinb 1916; 50: 517-740.
Demaerel P, Faubert F, Wilms G, Casaer P, Piepgras U, Baert AL. MRI 
findings in leukodystrophy. Neuroradiology 1991a; 33: 368-371.
Demaerel P, Johannik K, Van Hecke PV, Van Ongeval C, Verellen S, 
Marchal G, et al. Localised h i NMR spectroscopy in fifty cases of newly 
diagnosed intracranial tumours. J Comput Assist Tomogr 1991b; 15: 67- 
76.
186
De Stefano N, Matthews PM, Antel JP, Preul M, Francis G, Arnold DL. 
Chemical pathology of acute demyelinating lesions and its correlation 
with disability. Ann Neurol 1995; 38: 901-909.
Doddrell DM, Galloway GJ, Brooks WM,et al. Water signal elimination in 
vivo using “suppression by mistimed echo and repetitive gradient 
episodes”. J Magn Reson 1986;70:176-180.
Dousset V, Grossman Rl, Ramer KN, et al. Experimental allergic 
encephalomyelitis and multiple sclerosis lesion characterisation with 
Gd - DTPA and magnetization transfer imaging. Radiology 1992; 182: 
4 8 3 -4 9 1 .
Fazekas F, Offenbacher H, Fuchs S, Schmidt R, Niederkorn K, Horner S, et 
al. Criteria for an increased specificity of MRI interpretation in elderly 
subjects with suspected multiple sclerosis. Neurology 1988;38:1822- 
1825.
Fazekas F. Magnetic resonance signal abnormalities in asymptomatic 
individuals: Their incidence and functional correlates. Eur Neurol 1989; 
29: 164-168.
Feinstein A, Ron M, Thompson AJ. A serial study of psychometric and 
MRI changes in multiple sclerosis. Brain 1993; 116: 569-602.
Filippi M, Miller DH, Paty DW, Kappos L, Barkhof F, Compston DAS, et al. 
Correlation between changes in disability and MRI activity in multiple 
sclerosis; a follow up study [abstract]. J Neurol 1994;241 (suppl): S89.
187
Fox PT et al. Nonoxidative glucose consumption during focal physiologic 
neural activity. Science 1988; 241: 462-464.
Frahm J, Merboldt KD, Hanicke W. Localised proton spectroscopy using 
stimulated echoes. J Magn Reson 1987; 72: 502-508.
Frahm J, Bruhn H, Gyngell ML, Merboldt KD, Hanicke W, Sauter R. 
Localised high-resolution proton NMR spectroscopy using stimulated 
echoes: Initial applications to human brain in vivo. Magn Reson Med 
1989a; 9: 79-93.
Frahm J, Bruhn H, Gyngell ML, Merboldt KD, Hanicke W, Sauter R. 
Localised proton NMR spectroscopy in different regions of the human 
brain in vivo. Relaxation times and concentrations of cerebral 
metabolites. Magn Reson Med 1989b; 11: 47-63.
Frahm J, Michaelis T, Bruhn H, Gyngell ML, Merboldt KD, Hanicke W. 
Improvements in localised proton NMR spectroscopy of human brain, 
water suppression, short echo times and 1ml resolution. J Magn Reson 
1990; 290: 464-473.
Frahm J, Bruhn H, Hanicke W, Merboldt KD, Mursch K, Markakis E. 
Localised proton NMR spectroscopy of brain tumours using short echo 
time STEAM sequences. J Comput Assist Tomogr 1992; 15: 915-922.
Gadian DG, Connelly A, Cross JH, lies RA, -»eonard JV. 1H spectroscopy 
in two children with ornithine transcarbamylase deficiency. In: The 
tenth Proceedings of the Society of Magnetic Resonance in Medicine 
1991; 1: 193.
188
Gass A, Barker GJ, Kidd D, Thorpe JW, MacManus D, Brennan A, et al.
Correlation of magnetization transfer ratio with clinical disability in
multiple sclerosis. Ann Neurol 1994; 36: 62-67.
Gerard G, Weisberg LA. MRI periventricular lesions in adults. Neurology 
1986; 36: 998-1001.
Gideon P, Henriksen 0, Sperling B, Permille C, Skyhoj Olsen T, Jorgensen 
HS, et al. Early time course of N acetylaspartate, creatine and 
phosphocreatine, and compounds containing choline in the brain after 
acute stroke. A proton magnetic resonance spectroscopy study. Stroke 
1992; 23: 1566-1572.
Ginsburg KS, Wright EA, Larson MG, et al . A controlled study of the 
prevalence of cognitive dysfunction in randomly selected patients with
SLE. Arthritis Rheum 1992 35: 76-82.
Giunti P, Sweeney MG, Spadaro, et al. The trinucleotide repeat 
expansion on chromosome 6p (SCA 1) in autosomal dominant cerebellar 
ataxias only in ADCA Type 1. Brain 1994;117: 645-649.
Granot J. Selected volume excitation using stimulated echoes (VEST). 
Applications to spatially localised spectroscopy and imaging. J Magn 
Reson 1986; 70: 488.
Grimaud J, Millar J, Thorpe JW, Moseley IF, McDonald Wl, Miller DH. 
Signal intensity on MRI of basal ganglia in multiple sclerosis. J Neurol 
Neurosurg, Psychiatry 1995; 59: 306-308.
189
Grossman Rl, Lenkinski RE, Ramer KN, Gonzalez-Scarano F, Cohen JA. 
MR proton spectroscopy in multiple sclerosis. AJNR 1992; 13: 1535- 
1543.
Haase A, Hanicke W, Frahm J, Matthaei D. Surface coil NMR in diagnosis 
Lancet 1983;ii: 1082-1083.
Haase A, Frahm J, Hanicke W. 1H NMR chemical shift selective (CHESS) 
imaging. Phys Med Biol 1985; 30: 341-344.
Halliday AM, McDonald Wl, Mushin J. Delayed visual evoked response in 
optic neuritis. Lancet 1972; I: 982-985.
Hanly JG, Fisk JD, Sherwood G, et al . Cognitive impairment in patients 
with SLE. J Rheum 1992; 19: 562-567
Harding AE. The clinical features and classification of the late onset 
autosomal dominant cerebellar ataxias. A study of 11 families 
including descendants of “the Drew family of Walworth.” Brain 1982; 
105: 1-28.
Harris EN, Hughes GRV. Cerebral disease in systemic lupus 
erythematosus. Semin Immunopathol 1985; 8: 251-266.
Haseler LJ,Griffey RH, Sibbitt Jr. WL, Sibbitt RR, Griffey BV, Matniyoff 
NA Evolution of neuropsychiatric systemic lupus erythematosus by 
volume localised proton nuclear magnetic resonance spectroscopy 
[abstract]. In: The tenth Proceedings of the Society of Magnetic 
Resonance in Medicine 1991; 1: 229.
190
Hawkins CP, Munro PMG, MacKenzie F, Kesselring J, Tofts PS, Du Boulay 
EPGH, et al. Duration and selectivity of blood-brain barrier breakdown 
in chronic relapsing experimental allergic encephalomyelitis studied by 
gadolinium-DTPA and protein markers. Brain 1990; 113: 365-378.
Hay EM, Black D, Huddy A, et al . Psychiatric disorder and cognitive 
impairment in systemic lupus erythematosus. Arthritis Rheum 1992; 
35: 411-416.
Hayes DJ, Hilton-Jones D, Arnold DL, Galloway G, Styles P, Duncan J, et 
al. A mitochondrial encephalomyopathy. A combined 31 p -m ag n etic  
resonance and biochemical investigation. J Neurol Sci 1985; 71: 105- 
118.
Hume Adams J and Duchen LW. 1992 Greenfield’s Neuropathology. 
Edward Arnold, Great Britain.
Hoffmann PM, Stuare WH, Earle KM, Brody JA. Hereditary late onset 
cerebellar degeneration. Neurology 1971; 21: 771-777.
Hume Adams J, Duchen LW. In: Greenfield’s Neuropathology 1992 
Edward Arnold, Great Britain.
Husted CA, Goodin S, Hugg JW, Maudsley A, Tsuruda JS, de Brie SH. 
Biochemical alterations in multiple sclerosis lesions and normal 
appearing white matter detected by in vivo 31P and 1H spectroscopic 
imaging. Ann Neurol 1994; 36: 157-165.
IFBN Multiple Sclerosis Study Group. Interferon beta-1 b is effective in 
relapsing remitting multiple sclerosis. I. Clinical results of a 
multicenter, randomized, double-blind, placebo-controlled trial [see
191
comments]. Neurology 1993; 43: 655-661. Comment in: Neurology
1993; 43: 641-643.
Inglis BA, Brenner RE, Munro PMG, Williams SCR, McDonald Wl, Sales KD. 
Measurement of proton NMR relaxation times for NAA, Cr and Cho in 
acute EAE. In: Proceeding of the eleventh Annual Meeting of the SMRM. 
Book of Abstracts 1992; Works in progress: 2162.
Jue T, Arias-Mendoza F, Connella NC, Shulman Gl, Shulman RG. A 1HNMR 
technique for observing metabolite signals in the spectrum of perfused 
liver. Proc Natl Acad Sci USA 1985; 82: 1633-1637.
Johnson RT, Richardson EP The neurological manifestations of 
systemic lupus erythematosus. Medicine (Baltimore) 1968; 47: 337- 
369.
Katz D, Taubenberger JK, Cannella B, McFarlin DE, Raine CS, McFarland 
HF, et al. Correlation between MRI and lesion development in chronic 
active multiple sclerosis. Ann Neurol 1993; 34: 661-669.
Kauppinen RA and Williams SR. Nondestructive detection of glutamate 
by 1H nuclear magnetic resonance specteroscopy in cortical brain slices 
from the guinea pig: evidence for change in detectability during severe 
anoxic insults. J Neurochem 1991; 57: 1136-1144.
Kauppinen RA, Nissinen T, Karkkainen A, Pirtila TRM, Palvimo J, Kokko 
H, et al. Detection of Thymosin I34 in situ in a guinea pig cerebral 
cortex preparation using 1H NMR spectroscopy. J Biol Chem 1992; 267: 
9 9 0 5 -9 9 1 0 .
192
Kauppinen RA, Williams SR, Busza AL, van Bruggen N. Applications of 
magnetic resonance spectroscopy and diffusion-weighted imaging to 
the study of brain biochemistry and pathology. TINS 1993; 16: 88-95.
Kawaguchi Y, Okamoto T, Taniwaki M, AizawaM, Inoue M, Katayama S., et 
al. CAG expansions in a novel gene for Machado Joseph disease at 
chromosome 14q32.1. Nat Genet 1994; 8: 213-215.
Kermode AG, Thompson AJ, Tofts P, MacManus DG, Kendall BE, Kingsley 
DPE, et al. Breakdown of the blood-brain barrier precedes symptoms 
and other MRI signs of new lesions in multiple sclerosis: pathogenetic 
and clinical implications. Brain 1990;113:1477-1489.
Kesselring J, Miller DH, Robb SA, Kendall BE, Moseley IF, Kingsley D, et 
al. Acute disseminated encephalomyelitis: MRI findings and the 
distinction from multiple sclerosis. Brain 1990; 113: 291-302.
Kidd D, Thorpe JW, Thompson AJ, Kendall BE, Moseley IF, MacMannus DG, 
et al. Spinal cord MRI using multi-array coils and fast spin echo. II. 
Findings in multiple sclerosis. Neurology 1993; 43: 2632-2637.
Kidd D, Thompson AJ, Kendall BE, Miller DH, McDonald Wl. The benign 
form of multiple sclerosis: MRI evidence for less frequent and less 
inflammatory disease activity. J Neurol Neurosurg Psychiatry 1994; 57: 
10 7 0 -1 0 72 .
Kish SJ, Currier RD, Schut L, Perry TL, Morito CL. Brain choline 
acetyltransferase activity in dominantly inherited olivopontocerebellar 
atrophy. Ann Neurol 1987; 22: 272-275.
Koopmans RA, Li DKB, Zhu G, Allen PS, Penn A, Paty DW. Magnetic 
resonance spectroscopy of multiple sclerosis: in-vivo detection of 
myelin breakdown product, [letter]. Lancet 1993;341:631-632.
Kreiss R, Ross BD, Farrow NA, Ross BD. Metabolic disorders of the brain 
in chronic hepatic encephalopathy detected with H-1 MR spectroscopy. 
Radiology 1992; 182: 19-27.
Kreiss R. Quantitation in localised proton MR spectroscopy [abstract]. 
In: Proceedings of the society of magnetic resonance 1994; 1: 3.
Kreiss R. Pietz J, Penzien J, Herschkowitz N, Boesch C. Unequivocal 
identification and quantitation of phenylalanine in the brain of patients 
with phenylketonuria by means of localised in vivo 1H MRS [abstract]. In: 
Proceedings of the second meeting of the Society of Magnetic 
Resonance 1994b; 1: 308.
Kriss A, Francis DA, Cuendet F, Halliday AM, Taylor DSI, Wilson J, et al. 
Recovery after optic neuritis in childhood. J Neurol Neurosurg 
Psychiatry. 1988; 51: 1253-1258.
Kurtzke JF. Rating neurological impairment in multiple sclerosis: an 
expanded disability status scale (EDSS). Neurology 1983; 33: 1444-52.
Kuwabara T, Watanabe H, Ohkubo M, Sakai K, Tsuji S, Yuasa T. Lactate 
increase in the basal ganglia accompanying finger movements. -A 
localized 1H-MRS study-[abstract]. In The Proceedings of the Society of 
Magnetic resonance 1994; 1: 565.
194
Larsson HBW, Frederiksen J, Kjaer L, Henriksen O, Oleson J. In vivo 
determination of T-i and T2 in the brain of patients with severe but 
stable multiple sclerosis. Magn Reson Med 1988; 7: 43-55.
Larsson HBW, Christiansen P, Jensen M, Frederiksen J, Heltberg A, 
Oleson J, et al. Localised in vivo spectroscopy in the brain of patients 
with multiple sclerosis. Magn Reson Med 1991; 22: 23-31.
Lassmann H, Suchanek G, Ozawa K. Histopathology and the blood- 
cerebrospinal fluid barrier in multiple sclerosis. Ann Neurol 1994; 36 
(Suppl): S42-S46.
Li DKB, Mayo J, Fache S, Robertson W, Kastrukoff LF, Oger J, et al. Lack 
of correlation between clinical manifestations and lesions of MS seen 
by NMR [abstract]. Neurology 1984; 34(Suppl 1): S136.
Lim L, Ron MA, Ormerod IEC, David J, Miller DH, Logsdail SJ, et al . 
Psychiatric and neurological manifestations in systemic lupus 
erythematosus. Quart J Med 1988; 66: 27-38.
Lukes SA, Crooks LE, Aminoff MJ, Kaufman L, Panitch HS, Mills C, et al. 
Nuclear magnetic resonance imaging in multiple sclerosis. Ann Neurol 
1983; 13: 592-601.
Lumsden CE. The neuropathology of multiple sclerosis. In: Vincken PJ, 
Bruyn GW, editors. Handbook of clinical neurology. Amsterdam: North 
Holland, 1970; 9: 217-309.
195
McAlpine D. The benign form of multiple sclerosis. A study based on 
241 cases within three years of onset and followed up until the tenth 
year or more of the diseas. Brain 1961; 84: 186-203.
McDonald Wl, Miller DH, Barnes D. The pathological evolution of 
multiple sclerosis. Neuropathol Appl Neurobiol 1992; 18: 319-334.
Mcllwain H, HS Bachelard. In, Biochemistry and the central nervous 
system. 5th ed. Edinburgh: Churchill Livingstone, 1985: 282-335.
Matthews PM, Andermann F, Arnold DL. A proton magnetic resonance 
spectroscopy study of focal epilepsy in humans. Neurology 1990;40:985- 
989.
Matthews PM, Francis G, Antel J, Arnold DL. Proton magnetic resonance 
spectroscopy for metabolic characterisation of plaques in Multiple 
Sclerosis. Neurology 1991a; 41:1251-1256.
Matthews PM, Berkovic SF, Shoubridge EA, Andermann F, Karpati G, 
Carpenter S, et al. In vivo spectroscopy of brain and muscle in a type of 
mitochondrial encephalomyopathy (MERRF). Ann Neurol 1991b; 29: 435- 
438.
Matthews PM, Andermann F, Silver K, Karpati G, Arnold DL. Proton MR 
spectroscopic characterization of differences in regional brain 
metabolic abnormalities in mitochondrial encephalomyopathies. 
Neurology 1993; 43: 2484-2490.
196
May Gl, Wright LC, Holmes KT, Williams PG, Smith ICP, Wright PE, et al. 
Assignment of methylene proton resonances in NMR spectra of of 
embryonic and transformed cells to plasma membrane triglyceride. J 
Biol Chem 1986; 261: 3048-3053.
Merboldt KD, Bruhn H, Hanicke W, Michaelis T, Frahm J. Decrease of 
glucose in the human visual cortex during photic stimulation. Magn 
Reson Med 1992; 25: 187-194.
Michaelis T, Merboldt KD, Bruhn H, Hanicke W, Frahm J. Absolute 
concentrations of metabolites in the adult human brain in vivo: 
quantification of localised proton MR spectra. Neuroradiology 1993; 
187: 219-227.
Miller BL. A review of chemical issues in 1H NMR spectroscopy:N-acetyl- 
L-aspartate, creatine and choline. NMR Biomed 1991; 4: 47-52.
Miller BL, Moats RA, Shonk T, Ernst T, Wooley S, Ross BD. Alzheimer 
disease: depiction of increased myo-inositol with proton MR
spectroscopy. Radiology 1993; 187: 433-437.
Miller DH, Rudge P, Johnson G, Kendall BE, MacManus DG, Moseley IF, et 
al. Serial gadolinium enhanced magnetic resonance imaging in multiple 
sclerosis. Brain 1988a; 111: 927-939.
Miller DH, Kendall BE, Barter S, Johnson G, MacManus DG, Logsdail SJ, et 
al. Magnetic resonance imaging in central nervous system sarcoidosis. 
Neurology 1988b; 38: 378-383.
Miller DH, Johnson G, Tofts PS, MacManus D, McDonald Wl. Precise 
relaxation time measurements of normal appearing white matter in 
inflammatory central nervous system disease. 1989; 11: 331-336. 
Magn Reson Med 1989;11:331-336.
Miller DH, Austin SJ, Connelly A, Youl BD, Gadian DG, McDonald Wl. 
Proton magnetic resonance spectroscopy of an acute and chronic lesion 
in Multiple Sclerosis [letter]. Lancet 1991; 337: 58-59.
Miller DH, Buchanan N, Barker G, Morrissey SP, Kendall BE, Rudge P, et 
al. Gadolinium-enhanced magnetic resonance imaging of the central 
nervous system in systemic lupus erythematosus. J Neurol 1992a; 239: 
4 6 0 -4 6 4 .
Miller DH, Thompson AJ, Morissey SP, MacManus DG, Moore SG, Kendall 
BE, et al. High dose steroids in acute relapses of multiple sclerosis. 
Mri evidence for a possible mechanism of therapeutic effect. J Neurol 
Neurosurg Psychiatry 1992b; 55: 450-453.
Minderhoud JM, Mooyaart EL, Kamman RL, Teelken AW, Hoogstraten MC, 
Vencken LM, et al. In vivo phosphorus magnetic resonance spectroscopy 
in multiple sclerosis. Arch Neurol 1992; 49: 161-165.
Moon RB and Richards JH. Determination of intracellular pH by 3ip 
magnetic resonance. J Biol Chem 1973; 248: 7276-7278.
Morrissey SP, Miller DH, Hermaszewski R, Rudge P, MacManus DG, 
Kendall BE, et al. Magnetic resonance of the central nervous system in 
Behget’s disease. Eur Neurol 1993; 33: 287-293.
198
Narayana PA, Wolinsky JS, Jackson EF, McCarthy M. Proton MR 
spectroscopy of gadolinium-enhanced multiple sclerosis plaques. J Mag 
Reson Imag 1992; 2: 263-270.
Nelson HE. National Adult Reading Test. 1971 NFER-Nelson. Windsor. 
Nelson HE. A modified card sorting test sensitive to frontal defects. 
Cortex 1976; 12: 313-324.
Norton WT, Poduslo SE, Suzuki K. Subacute sclerosing 
leukoencephalitis. II. Chemical studies including abnormal myelin and 
an abnormal ganglioside pattern. J Neuropat Exp Neurobiol 1966; 25: 
5 8 2 -5 9 7 .
Offenbacher H, Fazekas F, Schmidt R, Freidl W, Flooh E, Payer F., et al. 
Assessment of MRI criteria for a diagnosis of MS. Neurology 
1993;43:905-909.
Olsen WL, Longo FM, Mills CM, Norman D. White matter disease in AIDS: 
findings at MR imaging. Radiology 1988; 169: 445-448.
Ordidge RJ, Bendall MR, Gordon RE, Connelly A. Magnetic Resonance in 
Biology and Medicine. Eds, Govil, Khetrapal and Saran. McGraw-Hill, 
New Dehli 1985: pp 387.
Ordidge RJ, Connelly A, Lohman JAB. Image-Selected In vivo 
Spectroscopy (ISIS). A new technique for spatially selective NMR 
spectroscopy J Magn Reson 1986;66:283-294.
199
Ormerod IEC, Miller DH, McDonald Wl, Boulay EPGH du, Rudge P, Kendall 
BEW, et al. The role of NMR imaging in the assessment of multiple 
sclerosis and isolated neurological lesions. A quantitative study. Brain 
1987; 110: 1579-1616.
Papero PH, Bluestein HG, White P, Lipnick RN. Neuropsychologic 
deficits and anti-neuronal antibodies in paediatric systemic SLE. Clin 
Exp Rheum 1990; 8: 417-424.
Patel TB and Clark JB. Synthesis of N-acetyl-L-aspartate by rat brain 
mitochondria and its involvement in mitochondrial/cytosolic carbon 
transport. J Biochem 1979; 184: 539-546.
Patel TB and Clark JB. Lipogenesis in the brain of suckling rats. J 
Biochem 1980; 188: 163 -168.
Paty DW, Oger JJF, Kastrukoff LF, Hashimoto SA, Hooge JP, Eisen AA, et 
al. MRI in the diagnosis of MS: a prospective study and comparison of 
clinical evaluation, evoked potentials, oligoclonal banding and CT. 
Neurology 1988; 38: 180-184.
Paty DW, Li DKB. Interferon beta-1 b is effective in relapsing remitting 
multiple sclerosis. II. MRI analysis of a multicenter, randomized, 
double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the 
IFNB Multiple Sclerosis Study Group [see comments]. Comment in 
Neurology 1993; 3: 641-643. Neurology 1993; 43: 662-667.
Perry TL, Hansen S, Berry K, Mok C, Lesk D. Free aminoacids and related 
compounds in biopsies of human brain. J Neurochem 1971; 18: 521-528.
200
Petroff OAC, Ogino T, Alger JR. High resolution proton magnetic 
resonance spectroscopy of rabbit brain: regional metabolite levels and 
postmortem changes. J Neurochem 1988; 51: 163-171.
Petroff OAC, Graham GD, Blamire AM, Al Rayess M, Rothman DL, Fayad 
PB., et al. Spectroscopic imaging of stroke in humans: histopathology 
correlates of spectral changes. Neurology 1992; 42: 1349-1354.
Phadke JG and Best PV. Atypical and clinically silent multiple 
sclerosis: a report of 12 cases discovered unexpectedly at necropsy. J 
Neurol Neurosurg Psychiatry 1983; 46: 414-420.
Poser CM, van Bogaert L. Neuropathological observations in 
phenylketonuria. Brain 1959; 82: 1-9.
Poser CM, Paty DW, Scheinberg L, McDonald Wl, Davis FA, Ebers GC, et al. 
New diagnostic criteria for multiple sclerosis: guidelines for research 
protocols. Ann Neurol 1983; 13: 227-231.
Poser S, Luer W, Bruhn H, Frahm J, Bruck Y, Felgenhauer K. Acute 
demyelinating disease. Classification and non-invasive diagnosis. Acta 
Neurol Scand 1992; 86: 579-585.
Preece NE, Williams SR, Jackson G, Duncan JS, Houseman J, Gadian DG. 
1H NMR studies of vigabatrin induced increase in cerebral GABA. In: 
Proceedings of the tenth meeting of the Society of Magnetic Resonance 
in Medicine 1991; 2; 1000.
201
Prichard J, Rothman D, Novotny E, Petroff O, Kuwabara T, Avison M., et 
al. Lactate rise detected by 1H NMR in human visual cortex during 
physiological stimulation. Proc Natl Acad Sci USA 1991; 88: 5829- 
5831.
Prineas JW, Barnard RO, Revesz T, Kwon EE, Sharer L, Cho E-S. Multiple 
sclerosis: pathology of recurrent lesions. Brain 1993; 116: 681-693.
Rao SM, Leo GJ, Haughton VM, St Aubin-Faubert P, Bernardin L. 
Correlation of magnetic resonance imaging with neuropsychological 
testing in multiple sclerosis. Neurology 1989; 39: 161-166.
Rothman DL, Petroff OAC, Behar KL, Matson RH. Localized 1HNMR 
measurement of gamma-aminobutyric acid in human brain in vivo. Proc 
Natl Acad Sci USA 1993; 90: 5662-5666.
Rothman DL, Behar KL, Petroff AC. Improved quantitation of short TE 1H 
NMR human brain spectra by removal of short Ti macromolecule 
resonances. In: The Proceedings of the Society of Magnetic Resonance 
1994; 1: 47.
Schaefer J, Stejskal EO, Beard CF. Carbon-13 nuclear magnetic 
resonance analysis of metabolism in soyabeans labelled by 1 3CO 2 . Plant 
Physiol 1975; 55: 1048-1053.
Schonell FJ. In: Backwardness in the basic subjects. 1942 Oliver and 
Boyd, Edinburgh.
Schut JW and Haymaker W. Hereditary ataxia. A pathologic study of 
five cases of common ancestry. J Neuropath Clin Neurol 1951; 1: 183- 
213.
Scolding NJ, Sussman J, Compston DAS. In vitro studies of 
oligodendrocytes derived from adult human white matter. J Neurol 
1994;241 (suppl 1):S27.
Shiino A, Matsuda M, Morikawa S, Inubushi T, Akiguchi I, Handa J. 
Proton magnetic resonance spectroscopy with dementia. Surg Neurol 
1993; 39: 143-147.
Simmons ML, Frondoza CG, Coyle JT. Immunocytochemical localization 
of N-acetyl-aspartate with monoclonal antibodies. Neuroscience 1991; 
45: 37-45.
Smith I, Beasley MG, Ades AE. Intelligence and quality of dietary 
treatment in phenylketonuria. Arch Dis Child 1990; 65: 472-478.
Stehbens WE, Pathology of the cerebral blood vessels. St Louis: Mosby. 
1972.
Tallan HH, Moore S, Stein WH. N-acetyl-L-aspartic acid in brain. J Biol 
Chem 1956; 219: 257-264.
Tallan HH. Studies on the distribution of N-acetyl-L-aspartic acid in 
brain. J Biol Chem 1957; 224: 41-45.
203
Tan EM, Cohen ES, Fries JF, Masi AT, McShane DJ Rothfield NF, et al. 
The 1982 revised criteria for the classification of systemic lupus 
erythematosus. Arth Rheum 1982; 25: 1271.
Taylor-Robinson SD, Weeks RA, Sargentoni J, Marcus CD, Bryant DJ, 
Harding AE, et al. Evidence for glutamate excitotoxicity in Huntington’s 
disease with proton magnetic resonance spectroscopy [letter]. Lancet 
1994; 343: 1170.
Thompson AJ, Hutchinson M, Brazil J, Martin EA. A clinical and 
laboratort study of multiple sclerosis. Q J Med 1986; 58: 69-80.
Thompson AJ, Kermode AG, MacManus DG, Kendall BE, Kingsley DPE, 
Moseley IF, et al. Patterns of disease activity in multiple sclerosis: 
clinical and magnetic resonance imaging study. BMJ 1990a; 300: 631- 
634.
Thompson AJ, Smith I, Brenton D, Youl BD, Rylance G, Davidson DC, 
Kendall B., et al. Neurological deterioration in young adults with 
phenylketonuria. Lancet 1990b; 336: 602-05.
Thompson AJ, Kermode AG, Wicks D, MacManus Dg, KendAII BE, Kingsley 
DPE et al. Major differences in the dynamics of primary and secondary 
progressive multiple sclerosis. Ann Neurol 1991; 29: 53-62.
Thompson AJ, Miller D, Youl B, MacManus D, Moore S, Kingsley D, et al. 
Serial gadolinium-enhanced MRI in relapsing-remitting multiple 
sclerosis of varying disease duration. Neurology 1992; 42: 60-63.
i
i
i
204
Thompson AJ, Tillotson S, Smith I, Kendall BE, Moore SG, Brenton DP. 
Brain MRI changes in phenylketonuria. Associations with dietary 
status. Brain 1993; 116: 811-821.
Thorpe JW and Miller DH. MRI: its application and impact. International 
MS Journal 1994; 1: 7-16.
Tofts PS and Wray S. A critical assessment of methods of measuring 
metabolite concentrations by NMR spectroscopy. NMR Biomed 1988; 
1: 1-9.
Twieg DB, Meyerhoff DJ, Hubesch B, Roth K, Sappey-Marnier D, Boska MD, 
et al. Phosphorus-31 magnetic resonance spectroscopy in humans by 
spectroscopic imaging: localised spectroscopy and metabolite imaging.
Magn Reson Med 1989; 12: 291-305.
Urenjak J, Williams SR, Gadian DG, Noble M. Specific expression of N- 
acetylaspartate in neurons, O ligodendrocyte-type-2 astrocyte  
progenitors, and immature oligodendrocytes in vitro. J Neurochem 1992; 
59: 55-61.
Urenjak J, Williams SR, Gadian DG, Noble M. Proton nuclear magnetic 
resonance spectroscopy unambiguously identifies different neural cell 
types. J Neurosci 1993; 13(3): 981-989.
Van der knaap MS, Van der Grond J, Luyten PR, Hollander JA,Nauta JJP, 
Valk J. 1H and 31P magnetic resonance spectroscopy of brain 
degenerative cerebral disorders. Ann Neurol 1992; 31: 202-211.
205
Van Hecke P, Marchal G, Johannik K, Demaerel P, Wilms G, Carton H, et 
al. Human brain proton localized NMR spectroscopy in multiple 
sclerosis. Magn Reson Med 1991; 18: 199-206.
Van Rijen PC, Luyten PR, van der Sprenkel JWB, et aU H  and 31 PNMR
measurement of cerebral lactate, high energy phosphate levels, and pH 
in humans during voluntary hyperventilation: associated EEG,
capnographic, and Doppler findings. Magn Reson Med 1989;10:182-
Vion-Dury J, Meyerhoff DJ, Cozzone PJ, Weiner MW. What might be the
impact on neurology of the analysis of brain metabolism by in vivo 
magnetic resonance spectroscopy. J Neurol 1994; 241:354-371.
Wing JK, Cooper JE, Sartorius N. In: The measurement and
classification of psychiatric symptoms. An instruction manual for the 
Present State Examination and CATEGO program. 1974 Cambridge 
University Press: Cambridge.
Wolinsky JS, Narayana PA, Fenstermacher MJ. Proton magnetic 
resonance spectroscopy in multiple sclerosis. Neurology 1990; 40: 
1 76 4 -69 .
Young IR, Hall AS, Pallis CA, Legg NJ, Bydder GM, Steiner RE. Nuclear 
magnetic resonance imaging of the brain in multiple sclerosis. Lancet 
1981; ii: 1063-1066.
206
Appendix A 
MRS quantification: practical implementation
1. The concentration of a metabolite can be estimated from the peak area
[metabolite] = k * peak_area * 2 (R2(0) - R2) *  2 (R l(0 ) - R 1 )*1 0 (T G  - TG (0)/200
over vol_VOI * N_protons
wherek is the calibration constant of the scanner (in fact = 1/sensitivity). 
This can be determined using the spectrum from a compound of known 
concentration (see below section 2). It may vary with time, and should be 
measured periodically (ideally before and after each exam, until its stability 
has been established). Data must be collected in a consistent way (ie keeping 
spectral width fixed, from same part of coil).
NB k for all metabolites, and for water, should be identical.
peak_area must be measured in a consistent way. Ultimately this will be 
by curve fitting, to reduce intra- and inter-observer variability, and the 
time needed for analysis.
R1 gain must be recorded for each spectrum; R1(0) is a standard value, 
which can be chosen for convenience (eg. 7).
R2 gain must be recorded for each spectrum; R2(0) is a standard value, 
which can be chosen for convenience (eg. 20).
TG is the transmitter gain (in units of l/10dB); TG(0) is a standard value
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(e.g. 70). Note that if spectra are collected at several echo times (see 
comments on Ti and T2 below) TG will change by 60 units between short 
and long TEs, even if everything else (including the patient/phantom) 
remains constant. In this case a different value of TG(0) should be used 
for long and short echo spectra, eg 130 for short TEs and 70 for long TEs.
vol_VOI is the size of the volume of interest in ml.
N_protons is the number of protons that contribute to the peak. (See 
section 6).
At each acquisition the following parameters must be recorded: R l, R2, 
TG, voLVOI.
2. The calibration constant k can be determined in 2 ways:
2.1 This can be achieved most accurately, from a phantom of water or 
metabolites of known high concentration (eg lOOmM for good signal to 
noise ratio (SNR) and short acquisition time). A long TR (to avoid Ti
relaxation) and short TE (to avoid T2 losses)should be used; however there 
may be extra underlying peaks at short TE, and a plot of signal vs TE may 
be useful. To avoid standing wave effects, the phantom should be small 
(e.g. <10 cm in diameter), or made of oil.
2.2 This is most conveniently, from a water spectrum of the same VOI 
in the head: water spectra have been collected for nearly all metabolite 
spectra collected recently and can be used to retrospectively calculate the k
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values for the scanner, and hence approximate concentrations. Water 
concentration taken from control data (Norton et al., 1966) has been taken 
as 45.5M in grey matter and 39.75 M in white matter ) and is likely to vary 
in lesions, but it should be possible to use a PD weighted image to relate the 
unknown concentration to that in normal appearing white matter or grey 
matter, which is less likely to change.
For either calibration method R l, R2, TG and vol_VOI must be noted, as 
for the metabolite spectra.
3. Accuracy and assumptions
3.1 The dependence of peak area on TG, R l and R2 is as expected. This 
can be checked by varying the coil loading over the range of TG's normally 
found, and ensuring k does not alter. (This is true at least over the TG 
range 45-150). Altering NEX has no effect on peak area .
3.2 The spectra have no Ti or T2 losses. Ti and T2 determined in a 
phantom will, in general, be quite different from those in vivo. (See 
section 5, below).
3.3 Sensitivity k is independent of position in the coil (i.e. the 
non-uniformity in the head coil can be ignored). This can be checked over 
the normal range of VOI positions, and if necessary a different value of k 
used for each position.
3.4 There are no standing wave effects in the head or phantom
3.5 The VOI dimension are accurate. This can be checked by measuring 
k at several VOI sizes.
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3.6 Water suppression does not affect metabolite peak area. If  it does 
reduce some peaks (e.g.Cr) in a consistent way, then k can be determined 
for this particular peak.
4. Water content of the brain
In 2.2 we assumed it is 39.75M and 45.5M for white and grey matter 
respectively. However it can be measured using 1 and 2.1 (to determine k 
for water); this more accurate value would have 2 uses:
4.1 it could be used in place of the control values to calculate retrospective 
k values and metabolite concentrations. It may vary significantly between 
VOI's in NAWM and VOI's containing mostly lesion.
4.2 Proton Density (PD) might be interesting in its own right, as a further 
characteriser of lesions.
5. T i^  and T?:
Unless very long TRs and very short TEs were used to collect the spectra 
corrections must be made for Ti and T2 relaxation. Assuming that the
mixing time, TM, is negligible (which it should be for all our spectra), 
[metabolite] calculated from equationtl must be multiplied by:
1 /exp(TE / T2) * (1 - exp(TR / T i)
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For water spectra (TE=10ms, TR=6000ms) this factor will be very close to
1.0 for most tissue, and can be neglected. For phantom studies, however, it 
may be necessary to allow for Ti saturation in the water signal. For
metabolites Frahm (1989b) gives the following relaxation times:
Compound Group chem/
shift
Insula
r
grey
matter
Occip
ital
white
matter
Thala
mus
Cereb
ellum
T l t2 Ti t2 Ti t 2 Ti t2
Lac c h 3 1.3 1550 1200
NAA c h 3 2.0 1650 330 1450 450 1400 340 1700 300
Cr/PCr
n -c h 3 3.0 1750 250 1550 240 1750 200 1500 190
n -c h 2 3.9 1750 160 1050 190 120
Cho N-(CH3)3 3.2 1100 380 1150 330 1200 320 1500 410
Tau n -c h 2,
s -c h 2
3.3 1700 270
Ins -4H 3.5 1350 130 900 110 1100 150 1850 130
- 1H 4.0
Lipid
0.9
1.3
Note that we don't know how Ti and T2 change with pathology; it is 
possible to measure Ti and T2 in every patient, but the measurements are 
very time consuming and are not normally made. Any concentrations 
calculated using the 'standard' values above should therefore probably be 
referred to as 'apparent concentrations'.
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6. Examples
Note 1) that the term ( T G  >  3 0 ) is zero if TG <= 30 and one if TG > 30, 
so that an extra 60 is added to T G metabolite for long echo spectra, to match 
the 'extra' 60 in the short TE water spectrum.
2) that if an external standard other than water is used, the factor of 111M 
(the concentration of the standard) should be changed appropriately, 
where Intensity is the intensity measured from a proton density image.
PD weighted spin echo (SE) or (FSE) images can be used for the intensity 
measurement, but if for any reason measurements on lesion are to be made 
from one sequence and NAWM from the other, it should be noted that PD 
measured on FSE images must be multiplied by a calibration factor of
0.952 to be comparable with the SE values. No calibration factor is 
required if both measurements are made on images from the same 
sequence.
Note that if an area other than NAWM is used to calibrate the lesion PD, 
the factor of 39.75M (the water concentration of white matter) should be 
changed appropriately.
6.3 If  T i and T2 are assumed not to change with pathology, then A, B, C, 
and D are constants for a particular metabolite and pulse sequence. For 
the 'standard' sequences we typically use (TE=10, 135, 270, TR = 2000 
(pre-upgrade, 4.7 software), 2200 (4.8 software)) the relevant values of A, 
B, C and D for white matter are given below.
When using either calibration method it is important to include all the 
water signal in the area water measurement; even when well shimmed the
base of the water peak may be very wide so an integration range of 3.0 -
8.0 ppm is suggested. It is also vital to correct both the metabolite and the 
water spectrum for DC offsets before integration; a baseline correction 
may also be necessary for the metabolite spectrum.
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Compound Group N_protons A C(Te  
= ...)
D(TR  
= ...)
10 135 270 2000 2200
Lac c h 3 1.3 3 0.666
NAA c h 3 2.0 3 0.666 1.03 1.51 2.26 1.42 1.36
Cr/PCr
n -c h 3 3.0 3 0.666 1.04 1.72 2.94 1.47 1.40
n -c h 2 3.9 2 1.000 1.06 2.32 5.41 1.47 1.40
Cho N-(CH3)3 3.2 9 0.222 1.03 1.43 2.04 1.19 1.16
Tau n -c h 2,
s -c h 2
3.3 2
2
1.000
Ins ?? - 4H 3.5 4 0.500 1.08 2.83 7.98 1.29 1.24
??- 1H 4.0 1 2.000
Lipid
0.9
1.3
R l  metabolite " 
R l  water
R^metabolite ~ 
R 2 Water
B R l  metabolite “ 
R l water
R^metabolite “ 
R^water
B
0 0 1 1 0 2
0 1 2 1 1 4
0 2 4 1 2 8
0 3 8 1 3 16
0 4 16 1 4 32
0 5 32 1 5 64
0 6 64 1 6 to OO
0 7 128 1 7 256
A = 2/proton index 
B = 1/ (R1 - R 2)
C = T2 correction factor 
D = Ti correction factor
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